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Abstract 
Nuclear receptor activation, particularly that of the pregnane X receptor (PXR) and 
constitutive androstane receptor (CAR), is increasingly recognised as a key 
determinant in the development of drug-drug interactions (DDIs) as a result of 
their key role in the transcriptional regulation of numerous drug metabolizing 
enzymes and drug transporters. PXR and CAR involvement in the regulation of the 
cytochrome P450 enzymes is of greatest concern, since these enzymes metabolise 
the majority of currently available therapeutics.  Various methods are available to 
investigate the activation of these receptors in response to drug challenge, 
including reporter gene assays, primary human hepatocytes and transgenic mouse 
models.  However, these models lack the sophistication to effectively assess 
receptor cross-talk, a key regulatory mechanism in the control of drug metabolism 
with the potential to impact the development of DDIs.  Using a novel panel of PXR & 
CAR transgenic mouse models this study was designed to investigate the role of 
cross-talk between PXR and CAR in the metabolism and pharmacokinetics of 
commonly available pharmaceuticals, with particular emphasis on species-specific 
regulation. 
This study has identified potential interactions with PXR and CAR following 
treatment of wild-type mice with cyclophosphamide, gefitinib, anastrozole and 
letrozole.  Data from the PXR/CAR transgenic mouse panel has also provided 
evidence that the aromatase inhibitors, anastrozole and letrozole, interact with PXR 
and CAR in a species- and gender-specific manner.  Cross-talk between these 
receptors plays a key role in the regulation of P450 expression and drug 
pharmacokinetics following treatment by these agents, although the elimination of 
these drugs appears to be primarily renal, in contrast to data derived from humans.  
Of particular note is the aromatase inhibitor-induced up-regulation of Cyp2b10 
expression and activity observed in all models possessing a functional CAR moiety.  
A corresponding induction in CYP2B6 transcriptional activation has been 
confirmed in a novel reporter mouse model, indicating a potential DDI risk if co-
administered with a drug requiring CYP2B6 for its metabolism, i.e. 
cyclophosphamide.  These data therefore support the use of these models as a tool 
to dissect the regulatory cross-talk of these receptors in the control of drug 
metabolism, and thus to improve the assessment of DDI risk in the development of 
therapeutics. 
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1.1 XENOBIOTIC METABOLISM AND ITS ROLE IN THE 
DEVELOPMENT OF DRUG-DRUG INTERACTIONS 
1.1.1 DRUG-DRUG INTERACTIONS: INCIDENCE AND RISK FACTORS 
One of the key issues associated with drug development is the accurate 
identification of drug-drug interactions (DDIs), which occur when one drug 
interferes with the function of another co-administered therapeutic.  This 
interference can occur as a result of modulation of the pharmacokinetics, 
pharmacodynamics or pharmaceutical properties of an agent, resulting in 
altered drug disposition or activity (Riechelmann et al., 2005; Riechelmann and 
Krzyzanowska, 2006; Riechelmann and Saad, 2006; Riechelmann, 2007; 
Riechelmann and Krzyzanowska, 2007; Riechelmann et al., 2008; Riechelmann 
and Del Giglio, 2009).  Importantly, this phenomenon has several serious 
clinical implications, being capable of modulating clinical efficacy and having 
the potential to cause increased toxicity as a result.  Estimates of the frequency 
of DDIs in clinically relevant adverse drug reactions are limited, and 
significantly variable as a result of intra-population variation.  A UK-based study 
investigating DDI incidence in a population of 18,820 subjects estimates that of 
6.5% of the population admitted with adverse drug reactions (ADRs), 16.6% 
were as a direct result of drug-drug interactions (Pirmohamed et al., 2004), 
although other smaller studies indicate a large range of between 15-59% of 
ADRs being attributable to DDIs (Davies et al., 2009; Reis and Cassiani, 2011).  
Although this is a comparatively small proportion of the test population, when 
considering this result from a whole population perspective, it is clear that this 
issue will affect significant numbers of people, and therefore an understanding 
of the factors implicated in the development of DDIs is essential. 
Numerous studies have demonstrated that the risk of DDIs is increased by four 
factors: Age, gender, number of co-morbidities and number of concurrently 
administered drugs (Pirmohamed et al., 2004; Riechelmann et al., 2005; 
Riechelmann and Krzyzanowska, 2006; Riechelmann and Saad, 2006; 
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Riechelmann, 2007; Riechelmann and Krzyzanowska, 2007; Riechelmann et al., 
2008; Davies et al., 2009; Riechelmann and Del Giglio, 2009; Hu and Hayton, 
2011; Miranda et al., 2011; Bucşa et al., 2012; Obreli-Neto et al., 2012) The 
concurrent administration of various drugs, also known as polypharmacy, is of 
particular concern, with the risk of DDIs increasing from 13% with 2 drugs, to 
38% with 4 drugs, and exponentially increasing to 82% with 7 drugs (Goldberg 
et al., 1996; Buajordet et al., 2001).  This is a particular problem in the elderly, 
with estimates suggesting that 13-92% of this population receive multiple 
concurrent therapies as a result of the increasing co-morbidity burden observed 
with age (Lees and Chan, 2011; Obreli-Neto et al., 2012).  The elderly are 
therefore particularly vulnerable to the development of DDIs, with the effect 
being exacerbated by age-related decline in various physiological processes, 
including drug metabolism and renal elimination, which can themselves alter 
drug absorption and disposition (Obreli-Neto et al., 2012).  It is also of prime 
importance in the treatment of complex diseases, in which the use of co -
administration regimes is prevalent. 
A therapeutic area of particular concern is that of oncology, in which not only 
are combination regimes of anti-neoplastic agents prevalent, but also regularly 
combined with treatments to ameliorate drug toxicity, in addition to those 
already being administered to the patient to treat co-morbidities.  In addition to 
prescribed drugs, there is further potential for DDIs from over -the-counter 
remedies which are also commonly co-administered by the patient.  Median 
estimates of the number of drugs taken in oncology patients range from 5 -9 
prescribed medications per patient (Hanigan et al., 2008; Puts et al., 2009; 
Cashman et al., 2010; Lees and Chan, 2011; Prithviraj et al., 2012), with the only 
study isolating over-the-counter drug use estimating frequency at 1.7 over-the-
counter medicines per patient (Prithviraj et al., 2012).   According to the data 
presented by Goldberg et al. (1996), this puts this population at high risk of 
DDIs, and this escalates further when considering that cancer is more prevalent 
in the elderly population.  Various studies have indicated that approximately 
one third of ambulatory cancer patients are at risk of potential DDIs 
(Riechelmann, 2007; Riechelmann and Krzyzanowska, 2007; Riechelmann et al., 
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2008; Riechelmann and Del Giglio, 2009), although this figure appears to be 
higher in those populations with brain tumours/metastases as a result of 
prescribed anti-convulsant drugs (Riechelmann and Del Giglio, 2009).  Of these 
interactions, 87% are related to medications prescribed alongside anti-
neoplastic therapies, both to support chemotherapy and to treat co-morbidity.  
The most commonly interacting drugs include aspirin, warfarin, anti-
depressants and anti-convulsants (Riechelmann, 2007; Riechelmann et al., 
2008; Riechelmann and Del Giglio, 2009).  However, this information is 
theoretical, being based on computer simulation to identify potential 
interactions between prescribed drug pairs.  The clinical prevalence of these 
interactions is still poorly understood, although a Norwegian study has 
demonstrated that 4% of all deaths in a cancer population were as a direct 
result of fatal adverse drug interactions (Buajordet et al., 2001).  Clearly, the 
clinical evidence base must be increased before the full extent of the problem in 
oncology treatment can be understood.  However, given the narrow therapeutic 
indices of the majority of anti-neoplastic agents, an interaction could have 
potentially fatal consequences through a reduction in clinical efficacy or 
increase in toxicity. 
To this point, only traditional pharmaceuticals have been discussed with 
respect to the risk of DDIs.  However, a potentially more serious issue relates to 
the interaction of therapeutics with unregulated sources of interacting 
chemicals, primarily complementary therapies, such as herbal medicines, but 
also various chemicals found in food, including vitamins and flavonoids.  
Numerous pre-clinical studies have demonstrated the ability of a number of 
herbal and dietary constituents to cause drug interactions, frequently through 
modulation of drug pharmacokinetics (Williamson, 2003; Rockwell et al., 2005; 
Mandlekar et al., 2006; Meijerman et al., 2006; Tirona and Bailey, 2006; Izzo 
and Ernst, 2009; He et al., 2010; Kennedy and Seely, 2010; Mason, 2010; Tarirai 
et al., 2010; Izzo, 2012; Won et al., 2012).  However, published clinical evidence 
regarding their use and safety in oncology treatment remains comparatively 
scarce for the majority of herbal medicines, with the best evidence base being 
available for St. John’s Wort (Mannel, 2004; Zhou and Lai, 2008; Borrelli and 
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Izzo, 2009; Izzo and Ernst, 2009; Kennedy and Seely, 2010; Tarirai et al., 2010; 
Olaku and White, 2011; Izzo, 2012).  The lack of clinical evidence base makes it 
challenging for physicians to correctly advise on the use of these chemicals, as 
well as to identify potential herb-drug interactions when they present.  This 
burden is increased by the finding that 30-60% of herbal supplement users will 
not tell a health professional that they are taking herbal medicines (Werneke et 
al., 2004; Engdal et al., 2008; McLay et al., 2011).  Investigations into the cause 
of this under-reporting suggest that it is primarily due to a lack of 
understanding of the risks of herbal supplements, with a small scale random 
sample indicating that the common perception is that they are safer than 
conventional medicine because they are natural, and thus less likely to cause 
side effects, interact with other drugs or result in dependency (Lynch and Berry, 
2007; Dunne, 2009).  One study identified fewer than 50% of herbal 
supplement users that understood that herbal medicines could interact with 
conventional drugs (McLay et al., 2011).  This lack of education and under-
reporting is of particular concern in the cancer population, in which not only is 
there a high risk of polypharmacy, but also a higher probability of herbal 
medicine use.  Estimates of the frequency of herb and dietary supplement use in 
cancer populations are extremely variable, being affected by numer ous factors 
including the country the study is performed in, type of cancer and gender.  In a 
general UK cancer population, estimates of herbal medication use range 
between 3.1-21.8% in adults (Gratus et al., 2009a; Gratus et al., 2009b; Damery 
et al., 2011).  However, a study in a general cancer population in Norway 
assesses the frequency as 46%, possibly reflecting a greater acceptance of 
herbal therapy in Norwegian society (Engdal et al., 2008).  The incidence of 
herbal preparation use is highest in the female breast cancer population with 
frequency being reported as 22.7-38.4% in UK populations (Damery et al., 
2011; McLay et al., 2011).  In the majority of cases, herbal supplements were 
commenced without obtaining any professional advice, either from a physician 
or herbalist (Damery et al., 2011; McLay et al., 2011), and therefore it is evident 
that unexpected DDIs caused by un-reported herbal medicine therapy could be 
a significant problem in cancer populations.  The potential for DDIs is therefore 
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significant in this subset of the population, but urgently requires further study 
in large scale clinical trials before it can be effectively managed in the clinic.  
From these studies, it is evident that oncology patients are at a high risk of DDIs, 
primarily as a result of polypharmacy.  However, systematic analysis of DDI 
prevalence in clinical populations is limited.  More complete clinical analysis of 
this phenomenon is therefore essential to provide oncologists with the best 
information on which to base clinical decisions regarding treatment regimes 
and to aid in the recognition of adverse drug events.  In order to initiate well-
directed clinical trials, pre-clinical in vitro and in vivo data is required to identify 
the molecular determinants of drug interactions, and thus the relative 
likelihood of a clinically relevant DDI occurring.  The molecular basis of DDIs 
will now be considered. 
1.1.2 DRUG-DRUG INTERACTIONS: ROLE OF THE CYTOCHROME P450 SYSTEM 
DDIs can arise as a result of various factors, both related to the patient receiving 
the treatment, e.g. age and gender, and to the drug being administered (Hu and 
Hayton, 2011).  Variations in any process linked to the absorption and 
disposition of a drug can result in DDIs, including physicochemical changes, 
such as variations in gastric pH and emptying time, and changes in drug 
pharmacodynamics.  However, of particular concern are those interactions that 
occur as a result of pharmacokinetic interference, in which the metabolism of 
one drug is changed as a result of interactions between a co-administered agent 
and various proteins associated with drug metabolism.  DDIs can occur at any 
level of drug metabolism (Phase I, Phase II or drug transport).  However, of 
particular concern are interactions with the cytochrome P450 (P450) enzyme 
system which is responsible for the metabolism of the majority of 
pharmaceuticals (Lee et al., 2006; Zhang et al., 2010).   
Cytochrome P450s are the key constituents of Phase I metabolism, being 
involved with the metabolism of a range of endobiotic and xenobiotic 
substances (Plant, 2007; Omiecinski et al., 2011b; Singh et al., 2011).  This 
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enzyme group is able to catalyse numerous reactions, including N- and O-
dealkylation, aliphatic & aromatic hydroxylation, N- and S-oxidation, 
deamination, C-hydroxylation and epoxide formation (Lamb et al., 2007; 
Omiecinski et al., 2011b), with the primary aim being to generate a reactive 
side-group for downstream Phase II metabolism (Gibson and Skett, 2001).  All 
reactions are catalysed by the haem core (ferriprotoporphyrin-9), located 
within the hydrophobic substrate binding pocket of the enzyme, in the presence 
of cytochrome P450 oxidoreductase (POR) (Henderson et al., 2003; Lamb et al., 
2007; Coleman, 2010).  Although 102 functional- and 88 pseudo-genes have 
been identified in the mouse genome, the total number of P450 genes identified 
in humans is 57 (Nelson et al., 2004; Plant, 2007; Singh et al., 2011).  Of these 
genes, the most important from the perspective of xenobiotic metabolism are 
the members of the CYP1, CYP2 and CYP3 families, with the 7 major isoforms 
(CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) having 
been associated with the metabolism of more than 90% of currently available 
therapeutics (Zhang et al., 2010; Pinto and Dolan, 2011; Singh et al., 2011).  It is 
the prevalence of P450-mediated drug metabolism which results in the 
predisposition to DDIs caused by P450-interaction (Lee et al., 2006).  The 
importance of the P450 enzyme system is further highlighted by recent FDA 
draft guidance for industry regarding the design of DDI trials, which 
recommends that the assessment of a drug’s ability to induce P450s is the first 
priority in assessing the risk of pharmacokinetic interactions (Zhang et al., 
2010; FDA, 2012).  Importantly, they recommend that initial analysis should 
encompass the induction of CYP1A2, CYP2B6 and CYP3A in vitro prior to 
assessment of other P450s, including CYP2C8, CYP2C9, CYP2C19 and CYP2D6, 
progressing to in vivo analysis if positive results are identified.  Of particular 
concern to DDI studies is modulation of CYP3A4 activity and expression, and 
therefore this enzyme will be used to demonstrate risks caused by 
polypharmacy and the main causes of P450-mediated DDIs. 
CYP3A4 is the dominant member of the CYP3A gene family in the majority of 
humans, accounting for 30-50% of total liver P450 content, and being 
associated with the metabolism of up to 60% of current therapeutics (Plant, 
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2007).  It is also a key enzyme in first-pass drug metabolism, being expressed in 
the small intestine (van Herwaarden et al., 2009; Van Waterschoot et al., 2009).  
Any interference with this enzyme therefore has significant potential to cause 
DDIs through the modulation of the pharmacokinetic parameters of a co-
administered drug which also relies on metabolism by CYP3A4.  Substrates of 
CYP3A4 are wide ranging, and include commonly prescribed medications, such 
as statins (simvastatin, lovastatin, atorvastatin), over-the-counter medications, 
such as codeine, herbal medicines, such as St Johns’ Wort (specifically its 
constituent, hyperforin), and dietary constituents, such as theophyllines and 
caffeine (Manzi and Shannon, 2005; Hisaka et al., 2010; Hokkanen et al., 2011).  
Importantly, many commonly used anti-cancer agents are substrates of 
CYP3A4, including several tyrosine kinase inhibitors (imatinib, gefitinib, 
erlotinib, nilotinib, dasatanib), the vinca alkaloids (vincristine, vinblastine and 
vinorelbine), the topoisomerase I inhibitor, irinotecan, the mitotic inhibitor, 
paclitaxel, the aromatase inhibitors, anastrozole, letrozole and exemestane, and 
the oestrogen receptor antagonist, tamoxifen (Sioufi et al., 1997a; Desta et al., 
2004; Manzi and Shannon, 2005; Scripture et al., 2005; Sanford and Plosker, 
2008; Murai et al., 2009; Hisaka et al., 2010; Ingle et al., 2010; Kamdem et al., 
2010; Lazarus and Sun, 2010; Desta et al., 2011).  The potential for DDIs 
mediated by CYP3A4 during cancer therapy is therefore significant, especially 
when considering the prevalence of polypharmacy regimes, although the effects 
are dependent on the type of interaction and the mechanism of the drug in 
question.  For instance, a DDI which induces enzyme activity could either 
increase the toxicity or clinical effectiveness of a pro-drug which requires the 
P450 in question for activation, or substantially reduce the clinical effectiveness 
of an active drug through excessive metabolism.  Clearly the effects would be 
reversed if the DDI inhibits enzyme activity.  It is therefore vital that the 
mechanism of a potential DDI is known, together with the metabolic nature of 
the drug, so that potential clinical effects can be effectively assessed. 
Interactions between drugs can be considered as two distinct types - 1) those 
that rely on enzyme inhibition, and 2) those that are caused by modulation of 
enzyme expression.  DDIs caused by enzyme inhibition are the best 
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characterised, and are the result of direct interaction between the enzyme and 
an inhibitory substance, resulting in reduced enzyme activity, and thus reduced 
metabolism.  These DDIs are observed rapidly following drug administration as 
a result of this direct interaction, with their longevity being dependant on type 
of inhibition (competitive, non-competitive or mechanism-based).  Substances 
that are known to strongly inhibit CYP3A4 activity include azoles (ketoconazole, 
itraconazole, voriconazole), macrolide antibiotics (clarithromycin, 
telithromycin, erythromycin), anti-retroviral protease inhibitors (ritonavir, 
saquinavir, nelfinavir, indinavir, atazanavir) and grapefruit juice (constituent 
responsible not yet determined) (Manzi and Shannon, 2005; Hisaka et al., 
2010).  Extreme caution is therefore required before initiating combination 
treatment regimes involving any of these chemicals in combination with other 
drugs that are metabolised by CYP3A4.  Although this type of DDI is clearly of 
importance, it shall not be discussed further because it is outwith the remit of 
this study.  However, further information regarding inhibition-based 
interactions with P450s can be found in the following reviews (Fontana et al., 
2005; Bachmann, 2006; Ghanbari et al., 2006; Hisaka et al., 2010; Lutz and 
Isoherranen, 2012).   
The second mechanism underlying DDIs, and the one most relevant to this 
study, are those DDIs mediated by interference between xenobiotics and gene 
transcription.  Of particular concern are those that are mediated by interaction 
with the transcription factors and nuclear receptors regulating metabolic 
proteins, such as the aryl hydrocarbon receptor (AhR), constitutive androstane 
receptor (CAR) and pregnane X receptor (PXR).  Activation or repression of the 
activity of these regulators can have significant effects on downstream 
pharmacokinetics as a result of drug-induced modulation of target gene 
expression.  The indirect modulation of gene transcription means that this type 
of interaction is unlikely to be observed until several days following drug 
administration, once protein induction/repression has stabilized.  The 
importance of these regulators in the development of DDIs is highlighted by the 
recommendations made in the FDA draft guidance regarding DDIs (Zhang et al., 
2010; FDA, 2012).  The initial assessment of CYP1A2, CYP2B6 and CYP3A 
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induction recommended in the guidance provides two important indications.  
Firstly, it provides an assessment of the potential for DDIs mediated by these three 
isoforms, all of which have been implicated in the metabolism of numerous drugs.  
However, perhaps more importantly, they also give an indication of key 
interactions at a regulatory level, being prototypically induced by activation of AhR 
(CYP1A2), CAR (CYP2B6) and PXR (CYP3A4).  The modulation of PXR is of 
particular concern, being a key regulator of CYP3A4 (Moore and Kliewer, 2000; di 
Masi et al., 2009).  However, the role of CAR as a mediator of DDIs is also evolving, 
with the increasing identification of interacting chemicals (Küblbeck et al., 2011a; 
Küblbeck et al., 2011b; Omiecinski et al., 2011a; Lynch et al., 2012).  Both receptors 
are also known to operate in a co-operative manner to regulate target genes, 
providing robust control of numerous metabolic proteins, and making these 
nuclear receptors two of the key regulators of xenobiotic metabolism.  In order to 
understand the role of these nuclear receptors in the development of DDIs, the 
following section will therefore consider PXR and CAR, and their role in the 
regulation of xenobiotic metabolism, in detail. 
1.2 PXR AND CAR ARE KEY REGULATORS OF DRUG 
METABOLISM 
1.2.1 PXR 
The pregnane X receptor (PXR, also known as SXR, PAR and NR1I2), named for 
its activation by pregnenolone derivatives, is a highly promiscuous orphan 
nuclear receptor known to be a key regulator of xenobiotic metabolism.  Its 
identification was comparatively recent, with both mouse and human 
orthologues being discovered in 1998, although orthologues have now been 
identified in other mammalian species, in addition to chicken and zebrafish 
(Blumberg et al., 1998; Kliewer et al., 1998; Krasowski et al., 2011).  It is 
primarily expressed in liver and small intestine, although lower levels have also 
been detected in other tissues, including heart, colon, stomach and some brain 
regions (Lamba et al., 2004).  This reflects its primary role as a xenosensor, 
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controlling the expression of various genes involved with drug metabolism, and 
in particular CYP3A4 (Table 1.2.1).   
Phase Gene PXR CAR Reference 
P
ha
se
 I
 
CYP1A2 ↑   ↑* *(Yoshinari et al., 2010) 
CYP1B1 ↑ ↔ (Tirona et al., 2004) 
CYP2A6   ↑* ↑ *(Itoh et al., 2006) 
CYP2B6 ↑ ↑  
CYP2C8 ↑ ↑ (Ferguson et al., 2005) 
CYP2C9 ↑ ↔ (Sahi et al., 2009) 
CYP2C19 ↑ ↑  
CYP3A4 ↑ ↑  
CYP7A1   ↓*    ↓ † 
*(Rezen et al., 2010)†(Miao et al., 
2006) 
CYP8B1   ↓*  ↓P† 
*(Rezen et al., 2010); †(Beilke et al., 
2009) 
CYP24A1 ↑ ↑ (Moreau et al., 2007) 
P
ha
se
 II
 
UGT1A1 ↑ ↑ (Bock, 2010) 
UGT1A3 ↑  (MacKenzie et al., 2010; Bock, 2011) 
UGT1A4 ↑  (MacKenzie et al., 2010; Bock, 2011) 
UGT1A6 ↑  (MacKenzie et al., 2010; Bock, 2011) 
SULT2A1 ↑  
(Saini et al., 2004; Echchgadda et al., 
2007; Bock, 2010) 
P
ha
se
 II
I MDR1 ↑ ↑ 
(Klaassen and Aleksunes, 2010) MRP2 ↑  
MRP3 ↑  
Table 1.2.1: Example human target genes of PXR and CAR involved with 
xenobiotic metabolism 
Adapted from Fraser et al. (2012).  ↑=induced, ↓=repressed, ↔=no change/basal 
expression, p=putative interaction in humans.  Bold indicates strong induction.  Unless 
otherwise stated, data was extracted from di Masi et al. (2009) .  */† indicates relevant 
reference in final column. 
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Class Compound PXR CAR References 
Prototypical 
 
Drug 
 
 
 
 
 
 
 
 
 
Herb 
 
 
 
 
Dietary 
 
 
Endogenous 
 
 
 
Environmental/ 
Industrial 
Rifampicin 
CITCO 
Atorvastatin 
Simvastatin 
Camptothecin 
Omeprazole 
Paclitaxel 
Methadone 
Clotrimazole 
Ketoconazole 
Mifepristone 
Warfarin 
Hyperforin 
Cryptotanshinone 
Artemisinin 
Ginkgo biloba 
Schisandrin A-C 
Cafestol 
β-Carotene  
Flavonoids 
Androstenol 
Dehydroepiandrosterone 
17β-Estradiol 
Vitamin K2 
Phthalic acid (DHEP) 
Nonylphenol 
++ 
 
+ 
++ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
++ 
+ 
+ 
 
+ 
 
+ 
- 
- 
 
 
 
 
+ 
+ 
 
 
 
+ 
- 
+ 
+ 
 
+ 
+ 
(Kobayashi et al., 2005; 
Duret et al., 2006; Sinz 
et al., 2006; Stanley et 
al., 2006; Staudinger et 
al., 2006; Kőhalmy et 
al., 2007; Ricketts et al., 
2007; Satsu et al., 
2008; di Masi et al., 
2009; Hernandez et al., 
2009a; Tolson et al., 
2009; Chen et al., 2010; 
Dong et al., 2010; 
Rulcova et al., 2010; 
Yao et al., 2010; Hoffart 
et al., 2011; Howe et 
al., 2011; Küblbeck et 
al., 2011a; Küblbeck et 
al., 2011b; Marino et 
al., 2011; Fraser et al., 
2012) 
Table 1.2.2: Example modulators of human PXR and CAR 
Blank spaces indicate no data is available.  ++, very strong agonist; +, agonist; –, 
antagonist (or inverse agonist, CAR only).  
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However, it also has many physiological functions, including in inflammation, 
angiogenesis and control of energy, cholesterol and bile acid metabolism 
(Stanley et al., 2006; Staudinger et al., 2006; di Masi et al., 2009).  It therefore 
has an extremely wide substrate specificity, encompassing various endogenous 
and exogenous chemicals (Table 1.2.2).  It is this promiscuity, combined with 
the potential breadth of downstream target gene induction, which makes it such 
a significant concern in the design of novel therapeutics (Moore and Kliewer, 
2000; Stanley et al., 2006; Fraser et al., 2012).  Although not specifically 
recommended in the FDA draft guidance, the use of PXR reporter assays to 
assess PXR activation potential of a novel drug is commonly used by the 
pharmaceutical industry as part of early pre-clinical development to eliminate 
chemicals with an unacceptable risk of DDIs at an early stage (Lin, 2006; Sinz et 
al., 2006; FDA, 2012).  Common methodologies used to assess nuclear receptor 
activation and its effects will be discussed in Chapters 3 & 4. 
The wide substrate specificity of PXR is a result of the large, highly flexible 
ligand binding domain (LBD) (Figure 1.2.1).  It consists of a three-layered α-
helical sandwich and a five-stranded anti-parallel β sheet, unique to PXR 
(Watkins et al., 2001; Timsit and Negishi, 2007; di Masi et al., 2009). The 
activation function-2 helix (AF-2; helix 12), essential for transcriptional 
activation, is packed against the body of the receptor at the rear of the LBD 
(Watkins et al., 2001; di Masi et al., 2009).  Other critical features required for 
receptor promiscuity are a 4 amino acid turn, known as the 2 helix, which 
appears to be involved with ligand entry and exit from the binding pocket by 
opening an access pathway, and the replacement of the 6 helix with a 
conserved flexible loop (residues 309-321).  Together these features allow the 
binding pocket to expand from its resting 1150 Å3 to more than 1600 Å3 when 
ligand bound (Watkins et al., 2001; Watkins et al., 2003; Timsit and Negishi, 
2007).  This allows PXR to be activated by large molecules, such as the 
macrolide antibiotic rifampicin (RIF), using an induced fit mechanism, with 
ligands being able to “test” multiple binding orientations within the LBD to 
obtain maximal activation (Watkins et al., 2003; Chrencik et al., 2005; Orans et 
al., 2005).  Of the 28 amino acids that line the predominantly hydrophobic LBD,  
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Figure 1.2.1: Structural representations of hPXR 
Ribbon depicts domain structure of hPXR, highlighting activation function-1 (AF-1), DNA 
binding domain (DBD), hinge region, ligand binding domain (LBD) and activation 
function-2 (AF-2).  Crystal structure of the PXR LBD in complex with hyperforin (2.1Å 
resolution) adapted from PDB ID: 1M13 (Watkins et al., 2003).  Light blue helix = 2 helix, 
purple helix = conserved flexible loop replacing 6 helix, red helix = AF-2 (helix 12).  3D 
protein structure adapted using RCSB PDB Protein Workshop 4.1.0 (Moreland et al., 
2005). 
only Met243, Ser247, Gln285, Trp299, His407 and Phe420 commonly interact 
with ligands (Watkins et al., 2001; Ekins et al., 2007; Timsit and Negishi, 2007).  
The importance of these amino acids has been demonstrated by site-directed 
mutagenesis, with even minor changes in the LBD resulting in significant effects 
on ligand-mediated PXR activation (Watkins et al., 2001; Watkins et al., 2003).  
This is of particular importance when considering variations in PXR activation 
and downstream gene protein (CCRP) and HSP90 (Kawana et al., 2003; Squires 
et al., 2004).  Upon activation, PXR dissociates from this complex by an 
unknown mechanism and translocates to the nucleus as a result of the 
15 
 
 
recognition of nuclear localization signals by importin- proteins located at the 
nuclear membrane (Figure 1.2.2) (Kawana et al., 2003).   
 
Figure 1.2.2:  Activation protocol for PXR (a) and CAR (b)  
Adapted from Fraser et al. (2012) 
PXR possesses two nuclear localization signals (NLS), with the activity of each 
being dependent on the mechanism of PXR activation.  The first is a bipartite 
nuclear localisation signal with the sequence RRXXKR---RXXRR, and is vital for 
ligand-independent nuclear translocation (Kawana et al., 2003).  The second is 
known as the xenochemical response signal (XRS), with the sequence MXXLXXL, 
and is located in the C-terminus of the LBD (Kawana et al., 2003; Squires et al., 
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2004).  This signal has been associated with ligand-dependent nuclear 
translocation.  Following nuclear translocation, PXR heterodimerizes with its 
binding partner, the retinoid X receptor- (RXR), prior to binding response 
elements in its target genes.  The favoured binding sites for the PXR/RXR 
heterodimer in target genes are two AG(G/T)TCA half sites separated by 3 
nucleotides in a direct repeat formation (DR-3), and two everted repeats of this 
half site separated by 6 nucleotides (ER-6) (Stanley et al., 2006; di Masi et al., 
2009).  However, they are able to bind other recognition sites, such as DR-4, DR-
5 and ER-8 motifs, although with lower affinity (Kliewer et al., 2002; Fraser et 
al., 2012).  This capability is of key importance in transcriptional control, 
because it forms the basis of crosstalk between nuclear receptors, such as PXR 
and CAR. 
The recruitment of co-activators/co-repressors to the target gene is essential to 
nuclear receptor-mediated gene transcription.  The function of these proteins is 
to achieve structural changes in the conformation of the nuclear receptor which 
either promote or repress transcription.  Examples of co -activators/co-
repressors for PXR and CAR are given in Table 1.2.3.  Among the co-activators 
recruited by PXR are the p160/steroid receptor co-activator (SRC) family.  The 
function of these proteins is to recruit histone acetyltransferase complexes, 
such as cAMP response element binding-protein (CREBP)/p300, which modify 
DNA structure to permit RNA polymerase access, and thus initiate transcriptio n 
(Watkins et al., 2003).  The binding of SRC-1 functions co-operatively with 
ligand binding to PXR to stabilize the AF-2 helix in an active conformation, so 
that ligand binding is restricted to a single optimal orientation through the 
restriction of LBD flexibility (Watkins et al., 2003; Orans et al., 2005).  This is 
achieved by three LXXLL motifs present in the co-activator which stabilize the 
conformation of the AF-2 helix by means of a charge clamp formed through 
interaction with Lys259 and Glu427 on the surface of PXR (Orans et al., 2005).  
In contrast, the co-repressors, which include the nuclear receptor co-repressor 
(NCoR) and silencing mediator of retinoid and thyroid hormone receptor 
(SMRT), bind to PXR to retain the AF-2 helix in a non-active conformation both 
in the presence of antagonists and absence of ligand (Stanley et al., 2006).  A 
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Co-
regulator 
type 
Co-regulator PXR CAR References/Notes 
C
o
-a
ct
iv
at
o
rs
 
SRC-1 * * 
(Miao et al., 2006; 
Stanley et al., 
2006; di Masi et 
al., 2009; 
Hariparsad et al., 
2009; Xie et al., 
2009; Azuma et al., 
2011) 
NCOA2 (GRIP1, SRC-
2) 
* * 
p/CIP (SRC-3) *  
RIP 140 *  
PGC-1 * * 
PBP * * 
ASC-2  * 
SMC-1  * 
C
o
-r
ep
re
ss
o
rs
 SMRT *  
NCoR * * 
SHP *  
SMILE  * 
PROX1 *  
Table 1.2.3: Co-activators and co-repressors recruited by PXR and CAR 
study investigating SMRT has identified that binding to PXR occurs via the ID2 
domain of SMRT (sequence motif: LXXXIXXXI/L), through the interaction of 
Lys259, Gly270 and Pro423 of the PXR LBD with Arg2347, Lys2348 and 
Leu2350 of SMRT (Wang et al., 2006).  However, charged residues within the 
PXR LBD also appear to have a core role in the control of PXR activatio n, with 
site-directed mutagenesis of Arg410, Asp205, Glu321 and Arg413 indicating an 
increase in co-repressor binding affinity following mutation to a hydrophobic 
alanine residue (Wang et al., 2006).  This complex interplay between nuclear 
receptors, ligands, co-activators and co-repressors is therefore responsible for 
the transcriptional regulation of target genes in response to xenobiotic 
challenge. 
To this point, the PXR-mediated activation cascade for the ligand-induced 
transcriptional control of target genes has been described.  However, recent 
studies indicate that many of these processes are further regulated by the post-
translational modification of PXR (Ding and Staudinger, 2005b; Ding and 
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Staudinger, 2005a; Lichti-Kaiser et al., 2009a; Pondugula et al., 2009; Blomster 
et al., 2010; Hu et al., 2010; Biswas et al., 2011; Staudinger et al., 2011; Rana et 
al., 2012).  Staudinger et al. (2009) gives a full review of all evidence of post-
translational modification in PXR to date, with ubiquitination, SUMOylation, 
acetylation and phosphorylation having all been reported.  However, the 
evidence base defining the effects and underlying mechanisms of post-
translational modification in PXR is currently extremely limited.  
Phosphorylation is the best characterised modification regulating ligand-
induced PXR response.  A species-specific response to protein kinase-A (PKA) 
signalling has been described, with phosphorylation enhancing ligand-induced 
PXR activation in mice, but repressing PXR activation in rats and humans (Ding 
and Staudinger, 2005b; Ding and Staudinger, 2005a).  Protein kinase-C (PKC), 
protein phosphatase-1/2a and cyclin dependant kinase-2 (CDK-2) activity have 
also been implicated in the repression of PXR activity, with the mechanism of 
PKC-mediated repression being associated with increased NCoR binding affinity 
whilst concurrently blocking recruitment of SRC-1 (Ding and Staudinger, 
2005b; Pondugula et al., 2009).  The importance of phosphorylation in the 
regulation of PXR activity has been further highlighted by a recent systematic 
site-directed mutagenesis study of predicted phosphorylation sites in PXR, in 
which heterodimerization, DNA-binding activity, co-repressor recruitment and 
nuclear translocation have all been found to be dependent on the 
phosphorylation status of 6 key residues: Ser8, Thr57, Ser208, Ser305, Ser350 
and Thr408 (Lichti-Kaiser et al., 2009a).  Phosphorylation is therefore an 
important regulator of PXR activity, and should be carefully considered when 
administering any substance that activates protein kinases. 
PXR is therefore a key regulator of numerous proteins concerned with 
xenobiotic metabolism, in addition to a number of key physiological functions.  
Its regulation of target genes is complex, involving numerous accessory 
proteins in addition to control by post-translational modifications.  However, 
whilst this flexibility is a significant benefit in terms of xenobiotic metabolism, it 
also increases the potential severity of adverse drug reactions and DDIs, being 
able to interact with all levels of xenobiotic metabolism, in particular the highly 
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promiscuous enzyme, CYP3A4, and also potentially interfering with normal 
physiological function to yield a pathological phenotype (Moore and Kliewer, 
2000; Harmsen et al., 2007; Ma et al., 2008b; Harmsen et al., 2009).  Full 
analysis of the potential for drug interaction with PXR is therefore vital to the 
prediction of DDIs. 
1.2.2 CAR 
The constitutive androstane receptor (CAR; NR1I3; MB67) was discovered in 
humans in 1994, followed by mouse in 1997 (Baes et al., 1994; Choi et al., 
1997).  It is a key regulator of xenobiotic metabolism (Masahiko and 
Honkakoski, 2000; Maglich et al., 2002; Yamamoto et al., 2003; Dickins, 2004; 
Moore, 2005; Nakata et al., 2006; Stanley et al., 2006; Tien and Negishi, 2006; 
Plant, 2007; Tompkins and Wallace, 2007; Monostory and Pascussi, 2008; di 
Masi et al., 2009; Muntané, 2009; Plant and Aouabdi, 2009).  However, CAR also 
has a significant role in the control of various physiological processes, such as 
energy homeostasis, lipid metabolism, bilirubin metabolism and haem 
biosynthesis (Maglich et al., 2002; Maglich et al., 2004; Ding et al., 2006; Roth et 
al., 2008; di Masi et al., 2009; Finn et al., 2009; Hernandez et al., 2009a; Wada et 
al., 2009).  CAR regulates a wide range of target genes across all phases of 
xenobiotic metabolism (Table 1.2.1), although CYP2B6 and its non-human 
orthologues (e.g. Cyp2b10 in mice, CYP2B1/2) are considered to be 
prototypically induced, and thus of value as a marker of CAR activation (Wei et 
al., 2000; Wang and Tompkins, 2008).  It also displays several traits unusual to 
the nuclear receptor class of proteins, including an unusual protein structure 
and constitutive basal activity (Dussault et al., 2002).  As a result of this 
constitutive activity, the novel definition of inverse agonist has been derived to 
describe certain compounds, such as androstanol and androstenol, which 
actively repress basal CAR activity instead of antagonizing CAR activation in the 
classical sense (Kenakin, 2004).  The constitutive activity of this nuclear 
receptor also allows target gene transcription to be activated by CAR in the 
absence of ligand-binding, and thus although it is activated by numerous 
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endogenous and exogenous chemicals, few of them bind directly to the LBD 
(Table 1.2.2).  The major mechanism of CAR-mediated gene transcription is 
mediated by the indirect activation of CAR by other signalling pathways in 
response to xenobiotic exposure, with very few chemicals having been 
identified as direct activators (Moore, 2005; Rencurel et al., 2005; Hernandez et 
al., 2009a).  This constitutive activity is a direct result of the unusual protein 
structure of this nuclear receptor. 
The normal structure of a nuclear receptor consists of 5 domains: 1) N-terminal 
DNA binding domain, which is highly conserved within the family; 2) hinge 
region; 3) a highly variable C-terminal domain containing motifs required for 
transcriptional activation of target genes, including the AF-2 domain, required 
for ligand-mediated activation, and binding sites for heterodimerization with its 
binding partner, RXR; 4) the activation function-1 domain, required for ligand-
independent activation; 5) hypervariable F domain (Monostory and Pascussi, 
2008).  However, CAR is unusual in that it consists of the N-terminal domain, 
hinge region and C-terminal domain only (Figure 1.2.3)(Monostory and 
Pascussi, 2008).  The LBD is smaller than that of PXR at approximately 675Å3 in 
humans, and consists of eleven  helices, two 310 helices (H2 and H2’), and 
three   strands (Suino et al., 2004; Xu et al., 2004).  The ligand binding site itself 
is framed by helices H1-5, H10 and   strands 3-4, meaning that it closely 
resembles that of the Vitamin D receptor in conformation.  However, it is 
thought that the position of the AF-2 domain within the LBD is responsible for 
the constitutive activity exhibited by CAR, with disruption of this conformation 
having been associated with switching CAR to an inactive form, such as 
observed following treatment with an inverse agonist (Timsit and Negishi, 
2007).  The conformation of AF-2 is therefore vital to the correct functioning of 
CAR, and is maintained by the cooperative function of three key structural 
features (Suino et al., 2004; Xu et al., 2004).  Firstly, the rigid structure linking 
the AF-2 domain to helix 10 is maintained by a unique short Helix-X -helical 
turn (Leu336, Ser337, Ala338 and Met339 in humans) together with the single 
amino acid residue separating Helix-X from the AF-2 domain (M350 human, 
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T350 mouse), restricting the motion of AF-2 and locking it into its active 
conformation (Suino et al., 2004; Xu et al., 2004).  Secondly, hydrogen bonding   
 
Figure 1.2.3: Representations of hCAR structure 
Ribbon depicts domain structure of hCAR, highlighting DNA binding domain (DBD), hinge 
region, ligand binding domain (LBD) and activation function-2 (AF-2).  Crystal structure 
of hCAR (2.6Å resolution) adapted from PDB ID: 1XVP (Xu et al., 2004).  Green helices = 
310 helices, 2 and 2’, yellow helix = Helix-X (H-X), red helix = AF-2.  3D protein structure 
adapted using RCSB PDB Protein Workshop 4.1.0 (Moreland et al., 2005). 
between the C-terminal carboxylate group of the AF-2 domain and Lys195 from 
helix 5 in humans (Lys205 in mouse) further stabilizes this structure (Suino et 
al., 2004; Xu et al., 2004).  Finally, the N-terminal domain is stabilized by the H2 
helix, which packs tightly against H3, stabilizing the conformation of both H3 
and AF-2 (Suino et al., 2004).  Importantly, although the conformation of AF-2 is 
essential for constitutive activity, it is not available for ligand-binding, being 
protected by the side chains of a highly conserved group of amino acids: Phe161 
(also key in constitutive activity), Asn165, Phe234 and Tyr326 (Xu et al., 2004).  
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Although the structure of CAR results in constitutive activity, this nuclear 
receptor is not available for activation of downstream target genes in the 
absence of external stimulus, being normally sequestered in the cytoplasm as 
part of a complex of CCRP, HSP90 and other accessory proteins (Kobayashi et 
al., 2003; Kanno et al., 2005b).  In response to ligand binding or indirect 
activation, CAR dissociates from this complex as a result of NLS activation, and 
is translocated into the nucleus, where it binds to RXR- prior to activating gene 
transcription (Figure 1.2.2).  The evidence base regarding mechanisms 
involved in CAR nuclear translocation are better defined than those of PXR, 
although the molecular trigger is still unclear.  It is evident that cellular 
signalling pathways, and particularly phosphorylation, are an intrinsic 
component of CAR activation, being involved with its sequestration in the 
cytoplasm and subsequent nuclear translocation (Zelko et al., 2001)  Recent 
studies have indicated that it is the phosphorylation status of Thr38 in human 
CAR that is essential to the control of nuclear translocation (Mutoh et al., 2009; 
Osabe and Negishi, 2011).  In response to phosphorylation of Thr38 by PKC, 
DNA binding is ablated as a result of the disruption of the C-terminal region of 
the first zinc finger, thus rendering CAR inactive and sequestering it in the 
cytoplasm as part of the CCRP:HSP90 complex (Mutoh et al., 2009).    
Dephosphorylation of Thr38 restores CAR activity and promotes nuclear 
translocation (Mutoh et al., 2009).  The essential role of the recruitment of 
protein phosphatase 2a (PP2A) to the CCRP:HSP90 complex in eliciting nuclear 
translocation of CAR following phenobarbital treatment has previously been 
described in mouse hepatocytes (Kawamoto et al., 1999; Yoshinari et al., 2003), 
and therefore PP2A has been suggested as the mediator of Thr38 
dephosphorylation (Mutoh et al., 2009).  Another candidate to perform this 
function is a cell membrane-bound regulatory subunit of protein phosphatase-
1 , PPP1R16A, which has also demonstrated the capacity to induce nuclear 
translocation through interaction with CAR (Sueyoshi et al., 2008).  The 
involvement of this latter protein is further supported by the identification of 
CAR localization at the cell surface, in addition to the cytoplasm (Koike et al., 
2005).  However, given the limited evidence for the involvement of both protein 
phosphatases, further analysis is required to fully elucidate this mechanism. 
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In terms of regulation, recent studies have implicated the extracellular signal-
related kinase (ERK) 1/2 and AMP-activated protein kinase (AMPK) signalling 
pathways in the control of nuclear translocation.  Although it is clear that AMPK 
has a role in the regulation of nuclear translocation, literature reports of the 
effect of AMPK activation on nuclear translocation are conflicting (Rencurel et 
al., 2005; Rencurel et al., 2006; Blättler et al., 2007; Shindo et al., 2007; Kanno et 
al., 2010a).  However, the evidence base supporting the involvement of the 
growth factor-ERK1/2 pathway is growing, with studies demonstrating that the 
dephosphorylation of phosphorylated-ERK1/2 is sufficient to induce nuclear 
translocation (Koike et al., 2007; Mutoh et al., 2009).  A recent study has 
subsequently demonstrated that growth factor-activated phosphorylated-
ERK1/2 binds to the XRS located near the C-terminus of CAR, inhibiting 
dephosphorylation of Thr38, and thus nuclear translocation (Osabe and 
Negishi, 2011).  The XRS is one of three NLS sequences located in rodents, and 
one of two located in humans.  Early studies have identified this region as being 
associated with nuclear translocation following PB treatment, a hypothesis 
given some corroboration by the effects of its interaction with phosphorylated-
ERK1/2 (Kawamoto et al., 1999; Zelko et al., 2001; Osabe and Negishi, 2011).  
However, according to later studies, it does not contain a conventional NLS, and 
has been suggested as a binding site for proteins that mask another NLS, thus 
inhibiting nuclear translocation prior to ligand activation (Kanno et al., 2005b; 
Kanno et al., 2007; Xia and Kemper, 2007; Kanno and Inouye, 2008).  Further 
study is therefore needed to examine the precise role of the XRS in nuclear 
translocation.  In terms of the other identified NLS motifs, the first (NLS1) is a 
basic amino acid sequence, which is well conserved across the NR1I family, 
located within the hinge region of the protein (RRARQARRR; rCAR - amino acids 
100-108).  However, this region is unable to function as an NLS in hCAR as a 
result of sequence divergence (Kanno et al., 2007).  The second motif (NLS2) is 
functional in both rodents and humans, and is a non-contiguous group of amino 
acids located throughout the LBD (amino acids 111-320)(Kanno et al., 2005b; 
Kanno et al., 2007).  This is the NLS potentially masked by proteins bound to the 
XRS.  Once the nuclear receptor is ligand-activated and released from the 
cytoplasmic CAR retention complex, active CAR is translocated into the nucleus 
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via an importin/Ran-GTP mediated process in which IPO13 binds to NLS2 for 
nuclear translocation (Kanno et al., 2010b).   
Once in the nucleus and bound to RXR-, the heterodimer binds to recognition 
sequences in the target genes to initiate transcription.  CAR preferentially 
recognises 3 binding motifs: DR-4 (e.g. AGTTCAnnnnAGTTCA), DR-5 (e.g. 
AGTTCAnnnnnAGTTCA) and ER-8 (e.g. TGAACTnnnnnnnnAGTTCA), although it 
can also bind other motifs, such as ER-5 and ER-10, with lower affinity (Frank et 
al., 2003; di Masi et al., 2009).  There is also potential for CAR-mediated 
transcriptional activation as a result of binding of a CAR monomer to DR-4 
motifs, and particularly the sequence AGAGTTCA, although the frequency and 
efficiency of this mechanism has not been assessed (Frank et al., 2003).  
However, it does appear that the preference for monomeric binding is stronger 
in humans than mice (Frank et al., 2003).  Co-factors are recruited following 
CAR binding to target gene promoters to modulate gene expression (Table 
1.2.3). 
CAR-mediated regulation of xenobiotic metabolism is therefore highly complex, 
relying on structural changes, post-translational modification and interaction 
with other signalling pathways to modulate target gene transcription.  However, 
the numerous physiological roles regulated by CAR make this nuclear receptor 
particularly susceptible to influence from endogenous systems.  A key example 
is the impact of energy state on drug pharmacokinetics and pharmacodynamics 
as a result of the modulation of genes associated with xenobio tic metabolism 
(Hernandez et al., 2009a).  The consideration of functional cross-talk between 
CAR-regulated systems is therefore essential to the analysis of potential CAR-
mediated DDIs.  CAR is also subject to circadian control as a result of its 
regulation by the PAR-domain basic leucine zipper transcription factors 
albumin D-box binding protein (DBP), thyrotroph embryonic factor (TEF) and 
hepatic leukaemia factor (HLF) (Gachon et al., 2006).  It may therefore be 
necessary to consider the potential for DDIs as a result of variability in drug 
pharmacokinetics caused by CAR-mediated chronotherapeutic effects.  In 
summary, although CAR is less promiscuous than PXR, the analysis of CAR-
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mediated DDIs is complicated by functional cross-talk with endogenous 
systems, as well as elements involved with its own regulation. 
1.2.3 CONTROL OF KEY P450S: NUCLEAR RECEPTOR CROSS-TALK 
Xenobiotic metabolism encompasses a highly complex and robustly controlled 
network of interacting proteins essential to protect the body from xenobiotic 
challenge.  This is reflected in the complexity of its regulatory network, in which 
multiple nuclear receptors and transcription factors interact to provide robust, 
fine control of this system, a phenomenon commonly known as receptor cross -
talk (Pascussi et al., 2008).  In part, cross-talk describes the redundancy 
inherent in the system, with multiple receptors capable of being activated by 
the same ligand or signalling pathway, recruiting the same co-activators/co-
repressors, or interacting with the same recognition sequences in target gene 
promoters.  However, it is this cross-talk which is responsible for the robust 
response against xenobiotic challenge demonstrated by the system, as well as 
the control of interactions between endogenous and exogenous pathways.  It is 
imperative that potential cross-talk between regulatory elements should be 
assessed when considering the development of DDIs, with the analysis of one 
receptor only providing an unrealistic representation of the effects in an 
inherently complex system.  A full review of the regulatory control of various 
P450s can be found in Fraser et al. (2012).  However, only regulatory cross-talk 
relevant to the expression of CYP2B6 and CYP3A4, which are prototypically 
induced by hCAR and hPXR respectively, will be considered in this introduction. 
1.2.3.1 CYP2B6 
Although the role of CYP2B6 has been considered minor, accounting for only 
6% of total hepatic microsomal protein expression, it is responsible for the 
metabolism of a wide variety of drugs, including cyclophosphamide, valproic 
acid, ketamine, methadone, bupropion, nicotine, and 
methylenedioxymethamphetamine (MDMA) (Wang and Tompkins, 2008; Benet 
et al., 2010a; Lo et al., 2010).  Activated hCAR is a key regulator of this gene, 
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binding to a DR-4 motif located in the phenobarbital responsive element 
module (PBREM) and an imperfect DR-4 located in the distal xenobiotic 
response element (XREM) of the promoter (Monostory and Pascussi, 2008; 
Wang and Tompkins, 2008).  However, hPXR also demonstrates an affinity for 
these DR-4 binding sites, although with a lower activity than hCAR, and thus has 
been implicated in the regulation of CYP2B6 (Sueyoshi et al., 1999; Goodwin et 
al., 2001; Wang et al., 2003; Wang and Tompkins, 2008).  A recent study has 
identified hPXR-mediated induction of CYP2B6 in primary human hepatocytes 
in response to treatment with oltipraz (Piton et al., 2010).  Interestingly, hPXR 
has also been linked to an increase in CYP2B6 expression observed in 
populations possessing the -82 TC single nucleotide polymorphism (SNP) in 
the promoter region of CYP2B6 (Li et al., 2010).  This SNP introduces a 
CCAAT/enhancer binding protein- (CEBP) site into the promoter region, with 
which PBREM-bound hPXR is proposed to interact, synergistically inducing 
expression.   
Cross-talk between CAR and PXR are therefore of importance for the control of 
CYP2B6 expression.  However, numerous other receptors and liver-enriched 
transcription factors are implicated in the regulation of this protein, with the 
proposed regulatory network being shown in Figure 1.2.4.  Studies have 
indicated that the okadaic acid response element (OAREKI) is required for 
maximal activation of PBREM-mediated gene transcription (Inoue and Negishi, 
2008).  This region contains a HNF4DR-1 binding site, a CACCC motif, and an 
E-box motif to which early growth response protein-1 (EGR1) binds.  Co-
operative functioning of these motifs is essential to achieving maximal CAR-
mediated CYP2B6 expression, with EGR1 binding to the E-box motif inducing 
DNA looping and facilitating the synergistic interaction of HNF4 bound to the 
OAREKI and active CAR bound to the PBREM (Inoue and Negishi, 2009).  The 
position at which HNF4 is bound to the CYP2B6 promoter is also of importance 
when defining its regulatory interactions (Benet et al., 2010a).  When bound to 
the OAREKI binding site, HNF4 interacts as described above.  However, when 
bound to a distal DR-1 HNF4 binding element located at -1642bp upstream of 
the CYP2B6 gene, the favoured interaction is between HNF4 and C/EBP 
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bound to an element located at -1597bp, leading to CAR-independent CYP2B6 
upregulation (Benet et al., 2010a).   
It is therefore clear that cross-talk between CAR, EGR1, HNF4 and C/EBP is 
required for maximal induction of CYP2B6.  However, studies to date have 
examined a very limited set of potential interactors with respect to regulatory 
cross-talk.  Importantly, there has been no analysis at present regarding the 
interaction between the XREM and other regulatory elements to support 
expression of this gene.  The interaction between the pathway characterised 
above and other transcriptional regulators has not been assessed.  No specific  
 
Figure 1.2.4: Regulatory network controlling CYP2B6 expression.  
Source: Adapted from Fraser et al. (2012) 
interactions with PXR have been analysed at present, although there is evidence 
for PXR-mediated gene regulation.  The glucocorticoid receptor has been found 
to indirectly mediate CYP2B6 expression through the induction of hCAR and 
hPXR, although in rodents it is able to directly mediate the expression of 
CYP2B6 orthologues (Meehan et al., 1988; Schuetz et al., 2000; Wang and 
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Tompkins, 2008).  The oestrogen receptor- (ER) has also been implicated in 
the induction of CYP2B6, although currently the mechanism underlying this is 
unclear.  One study indicates induction mediated by ER interaction with an 
oestrogen responsive element located at -1669 to−1657bp upstream of the 
CYP2B6 gene (Lo et al., 2010), whilst another favours ER interaction with an 
AP-1 site located upstream of the CYP2B6 gene, with synergistic action between 
this motif and the CAR-bound PBREM in conditions of high oestradiol 
concentrations, such as are observed in pregnancy (Koh et al., 2012).  Although 
significant advances have been made in our understanding of CYP2B6 
transcriptional regulation, the complexity of the regulatory network means that 
further analysis is required.  However, the key role of CAR in CYP2B6 regulation 
is well established, together with the importance of regulatory cross-talk to 
modulate gene expression. 
1.2.3.2 CYP3A4 
The importance of CYP3A4 in xenobiotic metabolism has been discussed in 
Section 1.1.2.  In terms of regulation, CYP3A4, and its mouse orthologue 
Cyp3a11, are both prototypically induced by PXR following drug activation.  For 
maximal induction of CYP3A4, synergistic interaction of 3 regions is required 
(Liu et al., 2008): 1) An ER-6 PXR response element (PXRE) at -172bp upstream 
of the start codon in the proximal promoter (Barwick et al., 1996; Goodwin et 
al., 1999; Quattrochi and Guzelian, 2001); 2) the dNR1 imperfect DR-3 binding 
motif and dNR3 sites located in the distal XREM enhancer region at -7800bp 
(Goodwin et al., 1999); and 3) the constitutive liver enhancer module of CYP3A4 
(CLEM4) located at -11.4 kbp, which contains multiple enhancer binding sites, 
including hepatocyte nuclear factor-1 (HNF1), HNF4 and AP-1, as well as a 
perfect ER-6 PXR binding motif which appears specific to a PXR homodimer 
complex which is as yet unidentified in vivo (Matsumura et al., 2004; Liu et al., 
2008).  It is the binding motifs in the PXRE and XREM that are essential to 
CYP3A4 expression, with mutation in both reducing rifampicin-induced CYP3A4 
expression by 85% (Goodwin et al., 1999).  CLEM4 is also associated with the 
constitutive expression of this gene, although it is not essential, with disruption 
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of the CLEM4 ER-6 motif resulting in no change in basal expression, whereas 
disruption of the XREM DR-3 motif causes a reduction in expression 
(Matsumura et al., 2004; Liu et al., 2008).  All binding sites described above are 
also able to bind hCAR, thus implicating CAR in CYP3A4 regulation (Goodwin et 
al., 2002; Urquhart et al., 2007).  However, studies have shown that hCAR 
binding of the PXRE motif alone is not sufficient to induce transcription of this 
gene, suggesting that hCAR acts co-ordinately with hPXR (Goodwin et al., 2002; 
Urquhart et al., 2007).   
The role of interacting transcription factors in CYP3A4 regulation is not as well 
defined as those involved in the regulation of CYP2B6.  The role of HNF4 has 
been the best defined, being a key regulator of PXR- and CAR-induced CYP3A4 
transcriptional regulation, with its role being dependent on to which of its 
recognition sequences it binds (Tirona et al., 2003; Liu et al., 2008).  When 
bound to the DR1 recognition site located at -7783 bp in the distal XREM, 
HNF4 synergistically interacts with PXR/CAR to induce promoter activity in 
transactivation assays performed in HepG2, Caco-2 and HeLa cell lines (Tirona 
et al., 2003).  However, when bound to the two response elements located 
downstream of the PXRE located in CLEM4, HNF4 represses PXR/CAR-
mediated transactivation by disrupting nuclear receptor DNA binding (Liu et al., 
2008).  Interestingly, C/EBP has also been implicated in CYP3A4 regulation, 
with disruption of a putative recognition site located at -132 bp repressing 
basal expression by 60%, as well as maximal expression induced by rifampicin, 
phenobarbital and metyrapone (Bombail et al., 2004; Martínez-Jimínez et al., 
2007).  Two further C/EBP binding motifs associated with CYP3A4 activation 
have also been identified in the CYP3A4 promoter at -1402 and -1668 bp.  
However, the exact role of C/EBP in regulation of this gene has not yet been 
defined, although a synergistic interaction between C/EBP and HNF3 
(FOXA3; bound to a recognition site at -1730 bp) which results in increased 
transcription as a result of chromatin remodelling has been described 
(Rodríguez-Antona et al., 2003; Bombail et al., 2004).  A putative Sp1 site (-104 
to -97 bp) has also been suggested to be important for CYP3A4 expression, with 
disruption of this site being responsible for a 50% reduction in promoter 
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activity (Bombail et al., 2004).  Other regulators reported to be associated with 
CYP3A4 regulation include STAT1, HNF1 and HNF3  (FOXA2), although the 
mechanisms underlying their role have yet to be determined (Martínez-Jimínez 
et al., 2007). 
In addition to those entities that directly interact with the CYP3A4 promoter, 
there are also a number that regulate gene expression through interaction with 
PXR and CAR.  For instance, the glucocorticoid receptor is reported to modulate 
PXR expression, leading to induction of CYP3A4, rather than acting through a 
putative glucocorticoid response element identified in the CYP3A4 gene (Khan 
et al., 2009; Zimmermann et al., 2009)  Hypoxia inducible factor-1 (HIF-1) 
represses CYP3A4 in the HepaRG cell line in response to oxidative stress by an 
indirect mechanism, such as modulation of regulatory proteins including PXR 
and CAR (Legendre et al., 2009).  However, the mechanism underlying this 
repression has not yet been characterised.  A number of transcription factors 
are also able to bind the ER-6 and DR-3 motifs preferentially targeted by hPXR, 
and thus to regulate CYP3A4 through competition or synergism with hPXR 
(Matsumura et al., 2004; Istrate et al., 2010).  Thyroid receptor 1 (TR1) 
competes with hPXR to bind these elements, repressing basal and xenobiotic-
induced expression (Istrate et al., 2010).  This competition has been implicated 
in the basal regulation of CYP3A4 activity, with the TR1:PXR ratio being 
correlated with basal gene expression.  It has also been reported that the 
vitamin D receptor (VDR) can compete for ER-6, DR-3 and DR-4 motifs, 
inducing CYP3A4 expression with a lower activity than PXR (Drocourt et al., 
2002; Khan et al., 2009).  However, VDR has also been shown to synergize with 
hPXR in the control of this gene, through VDR binding to response elements in 
CLEM4 (Pavek et al., 2010).  Finally, PXR-mediated CYP3A4 expression will also 
be modulated by the interaction of endogenous signalling pathways with this 
nuclear receptor (See Chapter 1.2.1).  One example is the regulation of CYP3A4 
as part of the cell cycle as a result of PXR phosphorylation by cyclin-dependent 
kinase 2 (Lin et al., 2008).   
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CYP3A4 regulation is therefore far more complex than that of CYP2B6, probably 
reflecting the greater importance of this enzyme in defence against xenobiotic 
challenge.  Unfortunately the complexity of the regulatory network hinders 
specific analysis of interactions between regulatory elements.  Systematic 
analysis of the interaction between regulatory elements is therefore required to 
provide a more coherent mechanistic understanding of the key elements of 
CYP3A4 regulation, and thus specific elements that may increase the risk of 
DDIs. 
In conclusion, examining the regulation of CYP2B6 and CYP3A4 has 
demonstrated the key role of CAR and PXR in the transcriptional regulation of 
these genes.  Cross-talk between various regulatory elements involved with 
transcriptional control is obviously a highly complex system, encompassing 
elements of endogenous systems as well as those specifically related to 
xenobiotic metabolism.  Whilst recent studies have begun to elucidate 
functional connections between binding elements in promoter regions, in 
addition to regulatory networks that indirectly influence gene expression, there 
is still significant research required before gene transcription can be fully 
understood.  The importance of assessing the interplay between xenobiotic 
metabolism and endogenous systems is also highlighted by the capability of 
endogenous molecules to regulate xenobiotic metabolism.  However, care must 
be taken when dissecting receptor-specific effects from experimental models in 
which regulatory cross-talk is inevitable, both in vitro and in vivo.  Selecting 
models that reduce the risk of generating erroneous data in pre-clinical 
molecular pharmacology studies is therefore an essential step in 
methodological design. 
1.3 PROJECT AIMS 
The ability to correctly predict DDIs from preclinical studies is an essential part 
of drug design.  With a growing understanding of the role of nuclear receptors 
in the control of xenobiotic metabolism has come the recognition that drugs 
that interact with these nuclear receptors could cause significant adverse 
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effects, including altered drug metabolism and potential toxicity.  Any ligand 
interacting with a nuclear receptor controlling xenobiotic metabolism, such as 
PXR and CAR, is therefore at risk of causing DDIs.  Characterising novel 
therapeutics with respect to their potential to activate PXR and CAR is therefore 
an essential step towards the identification of DDIs.  However, the majority of 
experimental approaches are unable to effectively analyse the effects of 
activation in a meaningful manner, because they are unable to model and 
dissect mechanisms underlying the regulatory cross-talk between these two 
receptors (See Chapters 3 & 4). 
This study has been designed to allow regulatory cross-talk between PXR and 
CAR in response to xenobiotic challenge to be assessed.  Initially, a panel of 
commonly used anti-neoplastic agents shall be analysed in a wild-type 
C57BL/6J mouse model to identify drugs with the potential to activate PXR or 
CAR, with up-regulation of Cyp3a11 and Cyp2b10 being used as a marker.  
Those drugs that demonstrate probable interaction with these nuclear 
receptors will then be subjected to a systematic analysis of PXR and CAR 
activation potential using a novel panel of transgenic mice which allow cro ss-
talk between these two receptors to be fully assessed (Scheer et al., 2008; Ross 
et al., 2010; Scheer et al., 2010).  These studies will investigate the role of PXR 
and CAR in modulation of P450 protein expression, enzyme activity and drug 
pharmacokinetics, providing both regulatory and phenotypic data.  A novel 
reporter model will also be employed to investigate species-specific variations 
in CYP2B6 expression (model unpublished).  This data will provide a solid basis 
for future studies, in which the potential for DDIs following administration of 
these drugs can be assessed by means of co-administration studies. 
 
 
  
 
 
 
 
 
 
 
 
2 CHAPTER 2 
MATERIALS AND METHODS 
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2.1 GENERAL 
2.1.1 MATERIALS AND CHEMICALS 
All chemicals unless otherwise stated were purchased from Sigma-Aldrich (UK).  
All cell culture reagents were purchased from Life Technologies, Paisley, UK.  All 
anti-cancer drugs for in vivo studies, including Femara (letrozole, Novartis) and 
Arimidex (anastrozole, Astra-Zeneca) were obtained via Ninewells hospital 
pharmacy (Dundee, UK).  Euthatal anaesthetic was purchased from Meriel 
Animal Health (Harlow, Essex, UK).  Cell+ TC flasks, 75 cm2 were purchased 
from Sarstedt (Leicester, UK).  Phosphate buffered saline (PBS) was purchased 
from Oxoid (Cambridge, UK).  RQ1 RNase-free DNase, random primers, dNTPs 
and nuclease-free water were purchased from Promega (Southampton, UK).  All 
other cDNA and TaqMan® real-time PCR reagents were purchased from Life 
Technologies (Paisley, UK).  Bio-Rad protein assay, XT MOPS running buffer and 
all elements of the Criterion blotting system, including pre-cast gels, were 
purchased from Bio-Rad Laboratories Ltd (Hemel Hempstead, UK).  Polylysine 
microscope slides, Whatman® Protran® nitrocellulose membrane, Whatman® 
filter paper and methanol for Western blotting were purchased from VWR 
International Ltd (Lutterworth, UK).  Full-range rainbow molecular weight 
markers were purchased from GE Healthcare (Chalfont St. Giles, UK).  
Secondary antibodies were obtained from Dako UK Ltd (Ely, UK).  Immobilon 
chemiluminescent horseradish peroxidase substrate was purchased from 
Millipore (Watford, UK).  7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-
hydroxy-4-trifluoromethylcoumarin (HFC), 7-benzyloxyquinoline (BQ) and 7-
hydroxyquinoline (HQ) were purchased from Cypex Ltd. (Dundee, UK).  7-
methoxy-4-trifluoromethylcoumarin (MFC) and 7-ethoxy-4-
trifluoromethylcoumarin (EFC) were purchased from BD Gentest (Cowley, UK).  
NADPH was obtained from Melford Laboratories (Ipswich, UK).  Letrozole and 
anastrozole powders for standard curves were purchased from Tecoland (New 
Jersey, USA).  HPLC grade acetonitrile, methanol and dichloromethane were 
obtained from Rathburn Chemicals Ltd (Walkerburn, Scotland).  MS grade 
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water, methanol and diethylether were purchased from Fisher Scientific 
(Loughborough, UK).  Columns for HPLC and UPLC-MS-MS analysis were 
purchased from Acquity (U.S.A.).  Histoclear II was obtained from National 
Diagnotics U.S.A. (Georgia, U.S.A.).  Nuclear fast red dye was purchased from 
Vector Laboratories Ltd (Peterborough, UK).  
2.1.2 STATISTICAL ANALYSIS 
Statistical analysis was performed using SigmaPlot 12.0 (Systat Software, Inc.).  
One way analysis of variance (ANOVA) using the Holm-Sidak post-hoc test were 
performed.  P values are represented by asterisks, with * representing p ≤ 0.05, 
** representing p ≤ 0.01 and *** representing p ≤ 0.001. 
2.2 ANIMALS 
2.2.1 ANIMAL MAINTENANCE 
All animal procedures were carried out in accordance with the Animals 
(Scientific Procedures) Act (1986) and after local ethical review. Animals were 
maintained in standard animal house conditions with ad libitum access to 
standard rodent diet and water, and a 12 hour light/dark cycle.   
2.2.2 ANIMAL MODELS 
All mouse models used in these studies were based on a C57BL/6J genetic 
background.  Wild type mice were obtained from colonies bred in-house.  
Information regarding supply and construction of the transgenic mouse lines 
used are detailed in Table 4.2.1.  All models were bred and genotyped in-house 
following initial supply. 
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2.2.3 IN VIVO STUDIES 
In vivo methods for initial drug screening and transgenic studies are given in 
Section 3.2.1 and 4.2.1 respectively.   
2.2.3.1 E0771 SYNGENEIC MODEL PILOT STUDY 
E0771 murine breast adenocarcinoma cell culture 
The E0771 cell line, obtained from Dr Fengzhi Li (Roswell Park Cancer Institute, 
Buffalo), is a murine metastatic breast adenocarcinoma cell line derived from 
C57Bl/6J mice for use as a syngeneic tumour model (DeGraw et al., 1993; 
Sirotnak et al., 1993; Mihich and Ehrke, 2000; Ewens et al., 2005; Ewens et al., 
2006; Gu et al., 2009; Stagg et al., 2010; Young et al., 2010; Gu et al., 2011).  
Using aseptic techniques, E0771 cells were maintained in Cell+ TC flasks, 75 
cm2 (Sarstedt, UK) in an incubator at 37°C in 5% CO2 using RPMI 1640 (+25mM 
HEPES, +GlutaMAX™) supplemented with 10% foetal bovine serum (E.U. 
approved, South American origin) and penicillin-streptomycin (100x).  Cells 
were split 1:50 twice weekly when they had reached approximately 70-80% 
confluency.  The cell layer was washed twice with 10 ml sterile PBS, then 
covered with 1 ml TrypLE™ Express and incubated at 37°C for 3 minutes to 
allow cell dissociation.  9 ml growth medium was added to the flask and cells 
were finally dissociated from the flask using gentle pipetting.  The cell 
suspension was removed to a 15ml falcon tube and centrifuged at 1,000 rpm for 
3 minutes in a benchtop centrifuge.  The supernatant was removed by 
aspiration, ensuring the cell pellet was not disturbed.  The cell pellet was 
resuspended in 12.5ml growth medium, with 250l being transferred into 25ml 
growth medium in a fresh flask, rocking to evenly distribute cells.  Medium was 
changed 3 days after seeding, and daily thereafter.   
Prior to injection into mice, cells were tested in house for mycoplasma infection, 
and sent to Charles River Laboratories (Margate, UK) for mouse essential panel 
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pathogen analysis to ensure that they were free from common mouse and cell 
based pathogens.  To produce the cell suspension for injection, when the cells 
reached 80-90% confluency they were dissociated from the flask using the 
protocol above.  However, a cell count was performed on a sample of cell 
suspension before continuing to the centrifugation step.  After the supernatant 
was removed from the cell pellet, the pellet was washed by resuspending in 
10ml PBS followed by centrifugation at 95 x g for 3 minutes.  The supernatant 
was aspirated and the cells were washed once more.  The supernatant was 
aspirated from the cell pellet and the cells were resuspended at 2.5 x 10 6 and 
1.25 x 106 cells/ml in Hanks’ balanced salt solution (HBSS; Life Technologies, 
UK), then transferred on ice ready for injection. 
E0771 syngeneic tumour model 
Under Euthatal anaesthesia (Harlow, UK), female C57Bl/6J wild type (n=5) and 
HuPXR/HuCAR transgenic mice (n=4) were injected s.c. into both flanks with 
either 2.5 x 105 (right hand side) or 1.25 x 105 (left hand side) E0771 cells 
suspended in 100 l HBSS (Day 0). Mice were weighed 5 times a week to 
monitor potential distress, and checked for tumours 3 times a week.  Once large 
enough, tumours were measured in 3 dimensions, 3 times a week, and a 
geometric mean diameter (GMD) calculated using the formula √     
 .  Mice 
were euthanized by rising CO2 once GMD ≥ 12.5mm, or if the mouse showed 
signs of distress or other pathology, such as tumour ulceration. 
Following euthanasia, blood was harvested by cardiac puncture into 
heparinized tubes which were subsequently centrifuged at 16,000 x g for 10 
minutes.  Plasma supernatant was removed to a clean eppendorf which was 
snap frozen in liquid N2 and stored at -70°C prior to analysis.  Each mouse was 
assessed for internal metastases by eye, with any secondary tumours being 
harvested.  Liver was weighed and bisected, with one half being transferred to 
fixative, and the other half being transferred to a bijou, snap frozen in liquid N2 
and stored at -70°C prior to analysis.  Both lungs were harvested into fixative.  
Primary and secondary tumours were harvested and bisected to check for 
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necrosis.  Where large enough, 1/3 tumour was transferred to fixative with the 
remaining 2/3 being snap frozen in liquid N2 and stored at -70°C prior to 
analysis.  Where the tumour was too small, the entire tumour was fixed.  Where 
tumours had invaded skin or muscle, a portion of surrounding tissue was also 
harvested to fixative.  All fixative samples were fixed in GURR (formal saline).  
The GURR (formal saline) samples were left at 4°C overnight, then rinsed twice 
in PBS and transferred to 70% ethanol for storage at 4 °C prior to wax 
embedding 
2.3 CYTOCHROME P450 ANALYSIS 
2.3.1 GENE EXPRESSION ANALYSIS 
2.3.1.1 RNA EXTRACTION AND QUANTITATION 
RNA was extracted using the “TRIzol® reagent with Purelink™ Micro-to-Midi 
system” protocol as given by the manufacturers (Life Technologies, UK).  RNA 
concentration was assayed using a UV spectrophotometer measuring 
absorbance at 240nm.  Each sample was diluted 1:200 in nuclease-free water 
(Promega, UK) and was read together with a nuclease-free water blank.  Purity 
was assessed by measuring absorbance at 260nm.  After quantitation, dilutions 
were produced for each sample at 100ng/l in nuclease-free water in 
preparation for cDNA synthesis. 
2.3.1.2 CDNA SYNTHESIS 
Prior to cDNA synthesis, the RNA was DNase treated.  In a final reaction volume 
of 10l, 600ng of diluted RNA (100ng/l) was mixed with RT buffer (1x; Life 
Technologies, UK), RQ1 RNase-free DNase (Promega, UK) and DEPC treated 
water (Life Technologies, UK).  The reaction was heated to 37°C for 10 minutes, 
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after which 1l RQ1 Stop buffer (Promega, UK) was added to the reaction, 
mixed and incubated at 65°C for 5 minutes to stop the reaction. 
To start cDNA synthesis, 150ng random hexamers (Promega, UK) were added 
to the reaction, which was then heated to 70°C for 10 minutes before being 
chilled on ice and the contents being spun down.  A master mix was produced, 
with each reaction receiving 8 l in total, containing RT buffer (1x; Life 
Technologies, UK), DTT (100nmol; Life Technologies, UK), dNTPs (10nmol; 
Promega, UK) and DEPC treated water.  This was incubated at 25°C for 5 
minutes before the addition of 100U Superscript reverse transcriptase (Life 
Technologies, UK).  The reaction was then heated in a thermal cycler using the 
following settings: 25C for 10 minutes  42C for 50 minutes  70C for 10 
minutes  4C ∞.  The samples were diluted 1:10 to obtain a 3ng/l final 
concentration, based on input RNA and stored at -20C. 
2.3.1.3 TAQMAN REAL-TIME PCR 
Singleplex TaqMan® real-time PCR gene expression assays (Life Technologies, 
UK) were run in a 96 well plate format using a Life Technologies, UK 7700 Real-
Time PCR system.  Samples were run in triplicate using the following reaction 
mix: 2.5 l cDNA, TaqMan® Universal PCR Master Mix (1x), TaqMan® gene 
expression assay (1x) and nuclease-free water to a final volume of 12.5l.  The 
reactions were performed according to the manufacturer’s instructions.  Mouse 
cyp3a11 (Mm00731567_m1), cyp2b10 (Mm01972453_s1) and cyp2c29 
(Mm00725580_s1) genes were analysed alongside the eukaryotic 18s 
ribosomal RNA housekeeping gene (Hs99999901_s1).  The data was analysed to 
give a fold difference relative to saline control using the comparative Ct (Ct) 
method as described by the manufacturer. 
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2.3.2 PROTEIN ANALYSIS 
2.3.2.1 ISOLATION OF MICROSOMAL FRACTION 
Snap-frozen liver portions (1/3) were defrosted on ice in 2ml KCl-Phosphate 
buffer (KHPO4 [0.01M, pH7.4], di-sodium EDTA [0.1mM], KCl [1.15%]) prior to 
scissor mincing and mechanical homogenization.  The homogenate was 
centrifuged at 11,500 x g in a benchtop centrifuge at 4°C for 20 minutes.  The 
supernatant, avoiding the fatty upper layer, was transferred to ultracentrifuge 
tubes (maintained on ice) and balanced prior to centrifugation at 100,000 x g at 
4°C for 80 minutes.  The supernatant (cytosolic fraction) was transferred to a 
fresh eppendorf tube and stored at -70°C.  The pellet (microsomal fraction) was 
resuspended in 200-800l KCl-Phosphate/Sucrose storage buffer (KHPO4 
[0.01M, pH7.4], di-sodium EDTA [0.1mM], KCl [1.15%], 0.25M sucrose) by hand 
homogenization.  The homogenate was divided into 100l aliquots and 
maintained on ice prior to storage at -70°C. 
2.3.2.2 PROTEIN CONCENTRATION DETERMINATION 
Protein concentration was determined using the Bio-Rad protein assay (Bio-
Rad Laboratories Ltd, UK).  A standard curve was produced by spiking 1ml Bio -
Rad protein assay reagent (1x in PBS) with 0, 3, 6, 9 or 12 g bovine serum 
albumin protein standard (1 mg/ml).  Samples were assayed in duplicate, using 
a 1:1000 dilution in 1x Bio-Rad protein assay reagent to enable direct read-out 
of concentration.  Samples and standards were produced and mixed in visible 
cuvettes.  Absorbance was measured using a visible light spectrophotometer at 
595nm, and protein concentration calculated from the standard curve. 
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2.3.2.3 WESTERN BLOTTING 
Prior to western blotting, samples were mixed with NuPAGE® LDS Sample 
buffer (1x; Life Technologies, UK) and -mercaptoethanol (10%), to give a final 
protein concentration of 2 mg/ml.  They were then denatured by heating to 
100°C for 10 minutes. 
Proteins were separated by electophoresis using the Bio-Rad Criterion™ pre-
cast SDS-PAGE gel system (Bio-Rad Laboratories Ltd, UK).  Criterion™ XT Bis-
Tris pre-cast gels (26 wells, 4-12% [Cyp2c only]/10% [all other genes]; Bio-
Rad, UK) were set up as per the manufacturer’s instructions using XT MOPS 
running buffer (1x; Bio-Rad, UK).  Gels were loaded with protein marker (5l, 
GE Healthcare, UK), positive control (5g dexamethasone-induced male wild-
type liver microsomes [Cyp3a/POR]/ 10g phenobarbital-induced male wild-
type liver microsomes [all other genes]), and samples (20g).  All wells were 
loaded with a constant volume (10l), with those wells containing less than 
this volume being filled with NuPAGE® LDS Sample buffer (1x; Life 
Technologies, UK).  Electrophoresis was started at a voltage of 100V for 20 
minutes to allow better stacking of proteins, before being increased to 200V 
until the 31kDa marker had just run off the bottom of the gel. 
The proteins were transferred to nitrocellulose membrane (VWR International, 
UK) using the Criterion™ blotter.  Nitrocellulose membrane (1 per gel) and 
Whatman filter paper (4 per gel; VWR International, UK) were cut to the same 
dimensions as the blotting sponge pads (2 per gel) (13cm x 9cm).  These were 
pre-soaked in transfer buffer (Tris base [16mM], glycine [120mM], methanol 
[20% v/v; VWR International, UK]) prior to the end of SDS-PAGE 
electrophoresis.  Upon completion, the SDS-PAGE gel was removed from the 
cassette and the stacking gel was removed.  A sandwich was then produced as 
follows: One sponge pad was placed on the cathode side of the cassette and 
covered with 2 pieces of Whatman paper.  The gel was briefly equilibrated in 
transfer buffer before being placed on the filter paper and carefully covered 
with the nitrocellulose membrane.  A further 2 sheets of Whatman paper were 
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placed on top of the membrane, and the bubbles were carefully removed using a 
roller.  The final sponge pad was placed on top of the sandwich and the cassette 
was closed, ensuring that the layers do not move.  The cassette was transferred 
to the Criterion™ blotter, together with a cooling block, and was then filled with 
transfer buffer.  The tank was placed in a tray full of ice to ensure that the 
module did not overheat and damage the proteins.  Proteins were transferred to 
the nitrocellulose membrane using a voltage of 100V for 90 minutes.  Equal 
transfer and loading was confirmed following electrophoresis using Ponceau S 
stain.  The stain was rinsed from the membrane firstly using distilled water, and 
then Tris buffered saline-Tween (NaCl [154mM], Tris base [50mM], Tween 
[0.1% v/v]; TBST).  The membrane was blocked overnight in milk:TBST 
solution (10% w/v).  
Membranes were incubated in polyclonal antisera diluted in milk:TBST solution 
(5% w/v) for 4 hours (see Table 2.3.1 for dilutions; all antibodies generated in 
house).  They were then washed in TBST for 4x 5 minutes on a rocker set at 
high speed, and incubated for 1 hour in the relevant secondary polyclonal, 
horseradish-peroxidase linked antibody (1:10,000 in TBST) (Table 2.3.1; Dako 
UK Ltd., Ely, UK), before washing as previously described.  The blots were 
visualized on a Fujifilm LAS-3000 mini-imaging system (Fujifilm UK Ltd., 
Bedfordshire, UK) using Immobilon chemiluminescent horseradish peroxidase 
substrate (Millipore, Watford, UK). Densitometric analysis was performed using 
MultiGauge version 2.2 software (Fujifilm UK Ltd.).   
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Antibody 
Raised 
against 
Dilution 
Secondary 
Antibody 
Cyp1a Mouse 1:10000 
Goat anti-
mouse 
Cyp2a Sheep 1:5000 
Goat anti-
sheep 
Cyp2b 
Rabbit 
1:2000 
Goat anti-
rabbit 
Cyp2c 1:5000 
Cyp3a 1:2000 
POR 1:2000 
Table 2.3.1: Antibodies used for western blotting 
2.3.2.4 CYTOCHROME P450 ACTIVITY DETERMINATION 
Fluorigenic Cytochrome P450 activity assays were performed in 96 well white 
assay plates using a final reaction volume per well of 150l.  Each incubation 
was performed in triplicate in 50mM Hepes pH7.4, 30mM MgCl2 and contained 
30g liver microsomal protein together with one probe substrate at the 
concentration given in Table 2.3.2.  The incubation mix was then warmed to 
37°C before the reaction was started by the addition of 0.67mM NADPH 
(Melford Laboratories, Ipswich, UK).  The reaction was measured in real time 
for 3 minutes using the excitation and emission wavelengths given in table 2.3.2 
on a Fluroskan Ascent FL plate reading fluorimeter (Labsystems, UK).  Turnover 
rates were calculated using standard curves generated using metabolite 
standards (see table 2.3.2). 
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Substrate (S) 
[S] 
/M 
Enzyme 
detected 
Metabolite 
excitation 
/nm 
emission 
/nm 
7-benzyloxy-4-
trifluoromethyl-
coumarin (BFC) 
30 
CYP3A4 
CYP1A2 
CYP2C19 
CYP1B1 
CYP1A1 7-hydroxy-4-
trifluoromethyl-
coumarin (HFC) 405 530 
7-ethoxy-4-
trifluoromethyl-
coumarin (EFC) 
40 
CYP2B6 
CYP2C19 
CYP2E1 
7-methoxy-4-
trifluoromethyl-
coumarin (MFC) 
120 
CYP2C9 
CYP2B6 
CYP2E1 
7-benzyloxy-
quinoline (BQ) 
40 
CYP3A4 
CYP1A1/2 
7-hydroxy-
quinoline 
Methoxyresorufin 
(MR) 
0.001 
CYP1A2 
Resorufin 530 584 Ethoxyresorufin (ER) 
CYP1A1/2 
CYP1B1 
Benzoxyresorufin 
(BR) 
CYP2B6 
Table 2.3.2: Fluorigenic activity assay probe data (human/rat only) 
Isoform = Major isoforms.  Isoform = Minor isoform.  Isoforms listed in order of 
contribution to overall activity. 
2.3.3 PHARMACOKINETIC ANALYSIS 
2.3.3.1 SAMPLE PREPARATION 
All samples were extracted using a solvent extraction method with an 
associated standard curve to account for differences in extraction efficiency.  
Letrozole and anastrozole powders (Tecoland, New Jersey, USA) were both 
reconstituted in acetonitrile (Rathburn Chemicals Ltd, Scotland). For each 
standard curve, the relevant drug was spiked into untreated whole mouse 
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blood:heparin (15IU/ml; 50:50 v/v) to give the following concentrations in a 
final volume of 20l: 0, 0.03125, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32 g/ml. 
To both samples and standards, 100l internal standard was added (Letrozole – 
Carbamazepine [2.5g/ml in PBS]; Anastrozole – Tamoxifen [0.15g/ml in 
PBS]), followed by 500l diethylether (Fisher Scientific, UK): dichloromethane 
(Rathburn Chemicals Ltd, Scotland)(70:30).  Tubes were then vortexed for 5 
minutes, then centrifuged at 20,500 x g for 5 minutes in a benchtop centrifuge.  
The organic phase was carefully removed to a clean eppendorf and evaporated 
using the Eppendorf Concentrator Plus at 30°C for 30 minutes.  The extracted 
drug was reconstituted in HPLC grade water:methanol (Letrozole – 60:40; 
Anastrozole - 50:50; Fisher Scientific, UK) and stored at -20°C before use. 
2.3.3.2 HPLC DETERMINATION OF LETROZOLE CONCENTRATION 
Letrozole and carbamazepine (internal standard) were separated using an 
Agilent 1100 HPLC using a Hypersil ODS (5m, 4.6 x 50mm; Agilent, UK) 
column maintained at 25°C.  Initial chromatographic conditions were 
methanol:water (60:40)(methanol-Rathburn Chemicals Ltd, UK) at a flow rate 
of 1.0 ml/min.  Mobile phase varied with time according to the protocol in 
Table 2.3.3.  Letrozole and carbamazepine were determined by fluorescence 
(Excitation = 230nm, Emmission = 295nm) and UV ( = 234nm) detection.  Blood 
concentrations of letrozole were determined using the standard curve 
described in section 2.3.3.1. 
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Time 
/mins 
Water  
(%) 
Methanol  
(%) 
0 40 60 
4.90 40 60 
4.91 5 80 
6.00 5 80 
6.01 40 60 
Table 2.3.3: Elution profile for letrozole/carbamazepine chromatography 
2.3.3.3 UPLC-MS-MS DETERMINATION OF ANASTROZOLE CONCENTRATION 
UPLC-MS/MS analysis was performed using a Waters Acquity UPLC and 
Micromass Quattro Premier mass spectrometer (Micromass, Manchester, 
United Kingdom).  Multiple reaction monitoring (MRM) data were acquired.  
The capillary voltage was set at 2kV, the desolvation temperature was at 450°C 
and source temperature at 120°C.  Cone gas flow was 5 l/hr and desolvation gas 
flow was 800 l/hr.  The cone voltage and collision energy were optimised for 
each compound, and are given in Table 2.3.4.  A dwell time of 0.05 seconds 
between MRM transitions was used. 
Substrate 
MRM 
Transitions 
Cone Voltage 
V 
Collision 
Energy 
kV 
Ion Mode 
Anastrozole 286.2>217.2 25 15 ES +ve 
Tamoxifen (IS) 372.2>71.9 40 26 ES +ve 
Table 2.3.4: Modes of detection, machine parameters and chromatography 
used with UPLC-MS/MS 
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Samples and standards were diluted 1:10 prior to analysis in methanol:water 
(60:40).  Anastrozole and internal standard (tamoxifen) were separated on an 
Acquity UPLC BEH C18 (1.7 µm, 2.1 x 50 mm) column, with an injection volume 
of 5l and using a mobile phase of methanol:water (60:40 v/v).  Elution was 
performed at a temperature of 45°C using the elution protocol given in Table 
2.3.5, with eluent A being water + 0.1% formic acid (v/v) and eluent B being 
methanol + 0.1% formic acid (v/v).  Transitions were made using a linear 
gradient.  Blood concentrations of anastrozole were determined using the 
standard curve described in section 2.3.3.1. 
Time 
min 
Flow 
ml/min 
Eluent A 
% 
Eluent B 
% 
Initial 0.6 40 60 
0.30 0.6 10 90 
0.65 0.6 10 90 
0.70 0.6 40 60 
1.00 0.6 40 60 
Table 2.3.5: Elution profile for anastrozole/tamoxifen chromatography 
2.3.3.4 PHARMACOKINETIC PARAMETER ANALYSIS 
Area under the curve (AUC), terminal half-life (t½), maximum plasma 
concentration (Cmax) and clearance were calculated in WinNonLin, version 3.1 
(Pharsight) using a simple non-compartmental model.   
2.3.4 CYP2B6-LACZ REPORTER ANALYSIS 
Cryofixed livers generated in section 2.2.3.5 were sectioned using a Bright 
Cryostat OFT5000 refrigerated microtome (15m thickness), attached to 
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polysine microscope slides (VWR international, UK) and stored at -70°C prior to 
staining.  On the day of staining, the sections were defrosted and air dried for 10 
minutes, before being rehydrated in 2mM MgCl2/PBS for 5 minutes.  Sections 
were then covered in X-Gal (25mg/ml)/dimethylformamide solution and 
incubated at 37°C overnight.  The following morning the X-
Gal/dimethylformamide solution was discarded and the slides were washed for 
5 minutes in 2mM MgCl2/PBS.  They were then counter-stained with nuclear 
fast red dye (Vector Laboratories Ltd, UK) for 5 minutes and treated as follows: 
washed in distilled water, 4 minutes  washed in 70% ethanol, 4.5 minutes  
washed in 95% ethanol, 1 minute  incubated in Histoclear II (National 
Diagnostics U.S.A., Georgia, USA), 3 minutes.  The sections were then air dried 
for 5 minutes before the cover slip was attached using DPX mountant for 
histology.  They were left at room temperature to cure for 5 days prior to 
microscopy. 
Sections were visualized using a Zeiss Axio Scope.A1 microscope (Carl Zeiss Ltd, 
UK) at 10x, 40x and 100x magnification.  Images were collected using Zeiss 
Axiovision Release 4.8.2 software (Carl Zeiss Ltd, UK).  Densitometry analysis of 
LacZ staining was performed using the Axiovision Automeasure module (Carl 
Zeiss Ltd, UK). 
2.3.5 BLOOD BIOCHEMISTRY ANALYSIS 
Plasma supernatant generated in section 2.2.3.5 was sent to The Clinical 
Pathology Service Laboratory, MRC Harwell (UK) for analysis of a panel of blood 
biochemistry markers, notably Creatinine, alkaline phosphatase (ALP), alanine 
transaminase (ALT), low density lipoprotein (LDL), glucose, total bilirubin and 
lactate dehydrogenase (LDH).  Results were analysed for changes with respect 
to saline control. 
 
  
 
 
 
 
3 CHAPTER 3 
INITIAL SCREENING FOR PXR AND CAR 
INTERACTORS 
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3.1 INTRODUCTION 
As discussed in section 1.3, PXR and CAR both have numerous physiological 
roles.  Perhaps the most important is acting as co-ordinate regulators of drug 
metabolism, but others include the regulation of energy, cholesterol & bile acid 
metabolism, as well as inflammation.  When considering these roles 
individually, it is clear that any drug that modulates the expression or activity of 
these receptors could cause potentially harmful adverse effects.  When 
considering each receptor as part of an intricate network controlling multiple 
key physiological processes, the potential for, and severity of, adverse effects 
caused by PXR or CAR interaction must increase because of the range of 
disruptions that can occur.  As a result, the risk of DDIs is also increased by PXR 
and CAR modulation.  Identifying substances that modulate nuclear receptor 
function is therefore of key importance to drug development, and requires a 
variety of screening methodologies. 
3.1.1 A QUESTION OF METHODOLOGY 
Assessing the activation of nuclear receptors, in particular the modulation of 
PXR activity, in response to drug treatment is an important stage in early drug 
design.  Several methodological approaches are now available to study nuclear 
receptor activation, including cell-based assays and transgenic animal studies.  
It is the high throughput in vitro assays that are used most widely in early drug 
design, with the many variants providing quick, quantitative indications about 
receptor activation. 
3.1.1.1 TRANSACTIVATION ASSAYS 
Transactivation (or reporter gene) assays are perhaps the most popular assay 
used when investigating drug interaction with nuclear receptors, and are 
responsible for identifying most of the currently available data regarding PXR 
and CAR activation (Table 1.2.2).  Indeed, transactivation assays examining 
PXR activation are routinely used by pharmaceutical companies to assess a 
novel compound’s suitability for clinical development (Lin, 2006; Sinz et al., 
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2008).  These high-throughput assays are run in immortalized cell lines, such as 
the HepG2 hepatocellular carcinoma cell line, meaning that there is less 
variability in cell populations than is found in primary hepatocytes, another key 
model for the assessment of metabolic profiles.  They also rely on a direct 
reporter to give data regarding activation potential, meaning that the effect can 
be quantified.   
There are two main models employed when constructing transactivation assays 
(Figure 3.1.1).  Using the first method, the cells are transfected with the full-
length nuclear receptor and a suitable reporter plasmid.  The reporter plasmid 
commonly consists of a portion of target gene promoter (commonly CYP3A4 in 
the case of hPXR or CYP2B6 for hCAR) containing the DNA binding domain 
(DBD) of the nuclear receptor in question, linked to a measurable reporter gene, 
such as luciferase (Moore and Kliewer, 2000; Honkakoski et al., 2001; Luo et al., 
2002; Lemaire et al., 2004; Yueh et al., 2005; Sinz et al., 2006; Harmsen et al., 
2007; Cui et al., 2008; Yasuda et al., 2008; Harmsen et al., 2009; Shukla et al., 
2011).  This design provides good results regarding nuclear receptor activation 
potential caused by direct binding to the LBD.  However, models employing this 
methodology compete with any innate nuclear receptor expressed by the cell, 
and although this is usually very low in immortalized cell lines, it could still 
interfere with reporter expression.  The second method employs a chimeric 
plasmid containing the LBD of the nuclear receptor linked to the DBD of another 
protein, commonly the yeast transcription factor, GAL4.  The chimeric plasmid 
is co-transfected with a reporter plasmid containing one or more copies of the 
DBD contained in the chimera, linked to, and driving the expression of, a 
measurable reporter, such as luciferase (Moore and Kliewer, 2000; Vignati et al., 
2004; Mu et al., 2006; Shukla et al., 2011).  The advantage of this design is that it 
removes the background noise caused by activating the innate nuclear receptor 
since the reporter plasmid can only be activated by the chimera (Moore and 
Kliewer, 2000).   
 Although useful to provide initial activation data for individual receptors, both 
types of assay suffer from significant disadvantages.  A major shortcoming is the  
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Figure 3.1.1: Two common methodologies for nuclear receptor 
transactivation assays 
a) Full length nuclear receptor is transfected together with a reporter plasmid consisting 
of a fragment of target gene promoter containing nuclear receptor (NR) recognition site 
upstream of the luciferase reporter gene.  Ligand binding induces binding to the NR 
recognition site and upregulates luciferase expression.  b) A chimeric construct 
containing the NR ligand binding domain (LBD) linked to the GAL4 gene is transfected 
together with a reporter plasmid holding multiple repeats of the GAL4 DNA binding 
domain (DBD) upstream of the luciferase reporter.  Ligand binding to the NR LBD induces 
GAL4 expression, and subsequently luciferase expression. 
inability of either assay to model nuclear translocation, one of the key stages in 
the activation of target genes by PXR and CAR.   The weakness of the first model 
lies in the overexpression of the full-length nuclear receptor.  It is well 
documented that PXR and CAR have a propensity to automatically translocate 
to the nucleus, regardless of activation state, when overexpressed (Pascussi et 
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al., 2000; Zelko et al., 2001; Saradhi et al., 2005).  This could potentially yield 
false positive results, positively identifying compounds that bind to the LBD 
when they don’t activate gene transcription in vivo because they do not induce 
nuclear translocation.  The second assay design uses only a fragment of the 
nuclear receptor, again creating an abnormal system in which LBD binding is 
segregated from nuclear translocation.  This means that neither can model the 
full activation protocol of PXR and CAR.  These assays are also unable to 
examine the role of nuclear receptor crosstalk, ignoring the complex network of 
transcription factors required for the correct regulation of target genes.  This 
issue is exacerbated by the use of immortalized cell lines, in which expression 
levels of many transcription factors controlling drug metabolism are extremely 
low, removing any possibility of crosstalk between transcription factors.  
Experimental variation is significant in most assays of this type as a result of 
using transient transfection methods, with their associated differences in 
transfection efficiency (Plant et al., 2000).  However, some groups have 
overcome this variability by creating stably transfected cell lines (Honkakoski 
et al., 2001; Raucy et al., 2002; Lemaire et al., 2004).  Finally, cellular isolation 
from systemic cues, such as hormonal signalling and energy state, removes  a 
key level of transcriptional control with respect to PXR and CAR activation, with 
several endogenous compounds being identified as modulating their activity 
(Table 1.2.2). 
3.1.1.2 PRIMARY HUMAN HEPATOCYTE MODELS 
Primary human hepatocytes (PHH) are the gold standard for in vitro pre-clinical 
drug tests, displaying full metabolic functionality and having the closest 
relationship to clinical data.  They are therefore considered to be a good model 
for pre-clinical assessment of drug interactions by the FDA (Guguen-Guillouzo 
and Guillouzo, 2010), giving data including enzyme expression and activity, 
gene expression and pharmacokinetics.  However, when considering a model 
for nuclear receptor activation studies, there are significant disadvantages to 
the basic PHH methodology.  General issues associated with culturing PHH 
include being costly, difficult to maintain, unpredictable to source and having a 
limited shelf life before their metabolic profile starts to degrade (Brandon et al., 
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2003; Harmsen et al., 2007; Guguen-Guillouzo and Guillouzo, 2010).  Inter-
individual variation is also a problem, since it is extremely unlikely all 
experiments can be sourced from the same individual, and therefore 
hepatocytes from other donors are likely to be required (Brandon et al., 2003; 
Guguen-Guillouzo and Guillouzo, 2010; Kamiguchi et al., 2010).  Although the 
ability to select hepatocytes displaying a similar metabolic profile and the use of 
pooled hepatocyte populations does ameliorate this effect to a certain extent, it 
cannot entirely remove it (Brandon et al., 2003; Kamiguchi et al., 2010).   
An issue specific to nuclear receptor activation analysis is the lack of a 
convenient direct reporter innate to the PHH model.  Examining cytochrome 
P450 expression patterns can give a strong indication of which receptors are 
likely to have been activated, but they cannot quantify activation or specifically 
dissect which receptors are involved because of the complex crosstalk required 
for transcriptional regulation.  Another shortcoming of the PHH model is that 
the expression of hCAR is rapidly down-regulated following harvest, with levels 
being commensurate with those in human liver samples for up to four days 
before being very significantly reduced (Pascussi et al., 2000; Washio et al., 
2011).  The basic primary human hepatocyte model is therefore not necessarily 
the first choice when screening drugs for nuclear receptor interaction, and must 
be combined with other techniques, such as transactivation assays or 
transgenic in vivo models to give meaningful data.  However, technological 
advances have resulted in PHH models with greater utility for the analysis of 
nuclear receptor activation.  The use of siRNA technology to produce 
knockdown models for the nuclear receptors allows the complex transcriptional 
control circuitry to be dissected, and consequently gives greater confidence in 
data obtained from the basic PHH model (Sane et al., 2008a).  Another model 
which has recently emerged involves the adenoviral transduction of a 
functional enhanced yellow fluorescent protein linked hCAR (EYFP-hCAR) 
protein into PHH (Li et al., 2009a; Tolson et al., 2009).  This protein localises in 
the cytoplasm and subsequently translocates to the nucleus following direct 
activation.  It is therefore possible to examine the nuclear translocation of hCAR 
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following drug treatment in a real-time manner using a convenient reporter, 
and negates some of the limitations of the native PHH model. 
3.1.1.3 IN VIVO MODELS 
Whilst in vitro techniques are powerful tools that produce fast, high-throughput 
screening data regarding the nuclear receptor activation potential of a chemical, 
they all have limitations when trying to analyse systems level phenomena.  The 
inability of the majority of in vitro assays to model nuclear translocation, one of 
the key and characteristic stages in nuclear receptor activation, is a significant 
weakness.  Another key problem lies in the isolation of cultured cell populations 
from systems level modulators, including hormones and dietary factors, which 
are known to have an effect on the activation status of nuclear receptors.  
Although culture conditions can be modified to reflect specific changes in 
hormone levels, etc., they cannot reflect the full complexity of external cellular 
modulators.  If a more complete understanding of nuclear receptor behaviour in 
a system is required, more complex non-human in vivo models must be used. 
As with all methodologies, the in vivo models are not infallible, and suffer from 
their own limitations.  There are ethical and legal issues associated with their 
use, covered by The Animals (Scientific Procedures) Act 1986, which are avoided 
by using in vitro methods.  Experiments run in vivo are much slower than the 
high-throughput in vitro methods, although they are able to yield significantly 
more data from a single experiment with efficient method design.  Because of 
the cost of maintenance, these models are costly to run.  However, the most 
important drawback of using non-human in vivo models is that of species-
specificity.  This phenomenon will be further discussed in Chapter 4.1.2.1, but in 
brief describes the differences in activation potential between human and non-
human receptors, resulting in differing metabolic profiles.  It is a key 
consideration when using in vivo models, and requires careful experimental 
design to obtain meaningful data. 
Although there are several experimental considerations associated with the use 
of these models, with correct model selection inferences can be made that ar e of 
material advantage when progressing studies into clinical models.  These are 
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the only pre-clinical models that are able to fully consider the role of systems 
level modulators in receptor function, and as such provide benefits that can’t be 
achieved using a cell based methodology.  Although wild-type animals are 
commonly used for initial toxicity and pharmacokinetic screens, there are other, 
more sophisticated in vivo methodologies available to analyse specific aspects of 
drug metabolism.  One example is the use of xenograft models, in which a 
human cell line is implanted into an immunocompromised animal (commonly 
mouse), to analyse drug-induced tumour necrosis.  These models provide 
greater clinical relevance because of the use of human cell lines, and give initial 
data regarding drug efficacy.  However, these models still rely on innate mouse 
physiology and therefore any information regarding drug metabolism must be 
treated with care.  The advent of transgenic models has meant that in vivo 
experiments can now be designed to specifically dissect drug metabolism and 
its control.  They are of particular use for analysing receptor activation and 
inter-species variation, with models available in which various constituents of 
the drug metabolism network are removed or humanized, enabling drug-
induced transcriptional control to be assessed.  These will be discussed in more 
detail in Chapter 4.   
3.1.1.4 AIMS AND OBJECTIVES 
In order to study the role of PXR and CAR in drug-drug interactions, we selected 
an in vivo methodology using a panel of novel PXR and CAR transgenic mice 
(Scheer et al., 2008; Ross et al., 2010; Scheer et al., 2010).  These will allow us to 
dissect the control of drug metabolism in response to drug treatment with 
respect to the two nuclear receptors, and give us systems level information 
regarding gene expression, Cytochrome P450 enzyme activity and changes in 
drug pharmacokinetics.  Prior to testing in the transgenic models, preliminary 
investigations were performed in C57BL/6J wild-type mice, the background 
upon which the transgenic mice are based.  Firstly, in order to select an 
experimental drug, several currently available anti-cancer drugs were tested for 
cytochrome P450 modulation (Table 3.1.1), particularly induction or 
repression of Cyp3a11 and Cyp2b10 which are prototypically modulated by 
PXR and CAR respectively.  All of these drugs were selected as potential PXR  
 
 
 
5
7 
Drug Mechanism Indication Clinical Dose Cytochrome P450s metabolised by 
Anastrozole 
Aromatase 
Inhibitor 
(selective,  
non-
steroidal) 
ER-positive breast cancer (post-
menopausal women) 
 Early adjuvant therapy (sole) 
 Early adjuvant therapy (post 
Tamoxifen) 
 Advanced adjuvant therapy 
1mg p.o. daily 
for 5 years 
CYP3A4 
CYP3A5 (minor) 
*Kamdem et.al (2010) 
Cyclophosphamide 
Alkylating 
agent 
Wide range of malignancies, 
including: 
 Lymphomas/Leukaemias 
 Multiple myeloma 
 Ovarian Adenocarcinoma  
 Breast carcinoma  
3-50mg/kg I.V. 
OR 
1-5mg/kg/day 
p.o. 
CYP2A6 
CYP2B6 
CYP2C8 
CYP2C9 
CYP2C19 
CYP3A4 
CYP3A5 
 
http://www.pharmgkb.org/pathway/PA2034#PGG 
Gefitinib 
Tyrosine 
kinase 
inhibitor 
Locally advanced/metastatic non-
small cell lung carcinoma with 
epidermal growth factor receptor-
tyrosine kinase mutations 
250 mg p.o. 
daily 
CYP3A4 
CYP3A5 
CYP1A1 
CYP2D6 
*Duckett and Cameron (2010) 
Letrozole 
Aromatase 
Inhibitor 
(selective,  
non-
steroidal) 
ER-positive breast cancer (post-
menopausal women) 
 Early adjuvant therapy (sole) 
 Early adjuvant therapy (post-
Tamoxifen) 
 Locally advanced/ metastatic 
first-line therapy 
 Advanced with disease 
progression post-Tamoxifen 
2.5mg p.o. daily 
for 5 years 
CYP2A6 
CYP3A4 
*Murai et.al (2009) 
 
Table 3.1.1: Anti-cancer drugs used in initial drug screen
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inducers because of their reported induction of CYP3A4 (Scripture et al., 2005; 
Purnapatre et al., 2008).  Having chosen our experimental drugs, we 
thenperformed experiments to optimise the dose of drug required to give an 
acceptable level of gene expression prior to testing in the transgenic models. 
3.2 METHODS: IN VIVO 
3.2.1 ANTI-CANCER DRUG PANEL TREATMENT 
Mice were dosed with a panel of anti-cancer drugs reported to be associated 
with increased expression or activity of the Cyp3a or Cyp2b enzymes, which are 
known to be prototypically induced by PXR and CAR respectively.  C57 BL/6J 
wild type mice (n=3 per group; male and female) were dosed p.o. on a once 
daily basis for 3 days with anastrozole (0.3 mg/kg), cyclophosphamide (50 
mg/kg), gefitinib (100 mg/kg) letrozole (100 mg/kg), or an equivalent volume 
of 0.9% saline vehicle control.  Mice were euthanized using rising CO2 24 hours 
following final dose.   
Following euthanasia, blood was harvested by cardiac puncture into 
heparinized tubes which were subsequently centrifuged at 16,000 x g for 10 
minutes.  Plasma supernatant was removed to a clean eppendorf which was 
snap frozen in liquid N2 and stored at -70°C prior to analysis.  Liver was 
weighed, then one small piece of liver was harvested into an eppendorf tube, 
with the remainder being bisected and transferred into bijou tubes.  All liver 
samples were snap frozen in liquid N2 and stored at -70°C prior to analysis. 
3.2.2 AROMATASE INHIBITOR DOSE RESPONSE ANALYSIS AND 
PHARMACOKINETIC STUDY 
To allow dose selection for future studies by comparison with samples 
generated in the anti-cancer panel study, C57BL/6J wild type mice (n=3 per 
group; male and female) were dosed p.o. on a once daily basis for either 1 or 3 
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days with anastrozole (10 mg/kg or 20 mg/kg), letrozole (25 mg/kg or 50 
mg/kg), or an equivalent volume of 0.9% saline vehicle control.   
In the 24 hours following the final dose, the drug-treated animals were 
periodically restrained to enable serial blood sampling from the tail vein.  One 
incision only was made into the tail vein at the start of the procedure, with the 
wound being periodically reopened throughout the day by warming using 
water, taking care to stop the bleeding immediately following sampling using 
manual pressure.  Blood (10l) was sampled at 10, 30, 60, 180, 360, 480, 720 
and 1440 minutes after dosage using a Gilson pipette into a clean eppendorf 
tube containing an equivalent volume of heparin (15 IU/ml) and kept on ice 
over the day, prior to long term storage at -70°C.  For letrozole, 5l blood was 
collected because of the higher sensitivity of the downstream letrozole assay.  
Mice were euthanized using rising CO2 following the final 24 hour timepoint.   
Following euthanasia, blood was harvested by cardiac puncture into 
heparinized tubes which were subsequently centrifuged at 16,000 x g for 10 
minutes.  Plasma supernatant was removed to a clean eppendorf which was 
snap frozen in liquid N2 and stored at -70°C prior to analysis.  Liver was 
weighed, then one small piece of liver was harvested into an eppendorf tube, 
with the remainder being bisected and transferred into bijou tubes.  All liver 
samples were snap frozen in liquid N2 and stored at -70°C prior to analysis. 
3.2.3 SAMPLE PROCESSING AND ANALYSIS 
All liver samples generated by the in vivo experiments described below were 
processed and analysed as described in Sections 2.3.1 and 2.3.2. 
 
 
 
 
60 
 
 
3.3 RESULTS 
3.3.1 SCREENING THE ANTI-CANCER DRUG PANEL 
3.3.1.1 ANALYSING GENE EXPRESSION FOLLOWING DRUG TREATMENT 
As a first step to probing the potential for PXR and CAR interaction, whole liver 
mRNA from vehicle control and drug treated mice was analysed by TaqMan® 
real-time PCR for the expression of Cyp3a11, Cyp2b10 and Cyp2c29, all of which 
are targets of these nuclear receptors.  At the doses tested, anastrozole and 
gefitinib did not significantly affect the expression of any of the genes in males 
or females (Figure 3.3.1).  The oxazaphosphorine cyclophosphamide had no 
effect on Cyp3a11 or Cyp2c29 expression in either sex.  However, a trend 
towards higher Cyp2b10 expression following cyclophosphamide treatment was 
seen in male mice, although it was not significant.  This is in agreement with 
published data which indicates that cyclophosphamide auto-induces its own 
metabolism by CYP2B6 through interaction with CAR and PXR (Chang et al., 
1997; Lindley et al., 2002; Harmsen et al., 2009; Wang et al., 2011).  In both 
sexes, very significant increases in expression of Cyp3a11 were seen following 
treatment with letrozole, and extremely significant induction of Cyp2b10.  There 
was also induction of Cyp2c29, although this was only significant in the male 
population.  This suggests that letrozole is a promising candidate to interact 
with both nuclear receptors, and particularly with CAR, the receptor which 
prototypically induces Cyp2b10. 
3.3.1.2 LETROZOLE INDUCES NUMEROUS CYTOCHROME P450S 
Although gene expression data suggests that induction of cytochrome P450s is 
occurring in response to drug treatment, it is of importance to know if increases 
in mRNA are associated with a corresponding induction in functional protein.  
Western blots were performed using pooled microsomal fractions isolated from 
whole liver samples harvested from treated mice.  These were then probed with 
polyclonal antibodies raised against a variety of key cytochrome P450s together 
with cytochrome P450 oxidoreductase (POR).   
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Figure 3.3.1: Induction of Cytochrome P450 mRNA in wild type C57BL/6J 
mice following 3 day treatment with an anti-cancer drug panel 
C57BL/6J mice (n=3 per group) were treated daily with either 0.9% Saline, 0.3 mg/kg 
Anastrozole (A), 50 mg/kg Cyclophosphamide (B), 100 mg/kg Gefitinib (C) or 100 mg/kg 
Letrozole (D) for 3 days.  Cyp3a11, Cyp2b10 and Cyp2c29 mRNA expression relative to 
0.9% Saline vehicle control was measured by TaqMan gene expression analysis in male 
(a) and female (b) liver RNA, and is expressed as fold difference ± range incorporating 
S.D. as recommended by Applied Biosystems comparative Ct analysis method.  Statistics 
analysed gene expression following treatment vs vehicle control.  * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001. 
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Figure 3.3.2: Induction of Cytochrome P450s in wild type C57 BL/6J mice 
following 3 day treatment with an anti-cancer drug panel 
C57BL/6J mice (n=3 per group) were treated daily with either 0.9% Saline (A), 0.3 mg/kg 
Anastrozole (B), 50 mg/kg Cyclophosphamide (C), 100 mg/kg Gefitinib (D) or 100 mg/kg 
Letrozole (E) for 3 days.  a) Western blots of pooled liver microsomes (n = 3 per group; 
20g/well).  + = positive control - Liver microsomes from male C57 BL/6J mouse treated 
with either phenobarbital (80 mg/kg/day for 3 days; 7.5g/well; Cyp1a, 2a, 2b, and 2c) 
or dexamethasone (50 mg/kg/day for 3 days; 5g/well; Cyp3a and POR).  b) 
Densitometry analysis - Fold induction/repression following drug treatment relative to 
saline control.  Numbers in red indicate >2 fold induction, numbers in green indicate >2 
fold repression.  Figures for Cyp1a, Cyp2a and Cyp2c represent densitometry for all bands 
identified on blot.  Cyp2b and Cyp3a indicate densitometry for Cyp2b10 and Cyp3a11 
isoforms only. 
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At a glance, it can be seen that none of the drugs significantly affect Cyp3a 
expression in mice, a surprising finding since CYP3A4 is involved in the 
metabolism of all four (Figure 3.3.2).  It is of particular interest in the case of 
letrozole, because it suggests that the increased level of mRNA identified by 
TaqMan® analysis does not translate to a corresponding induction in protein.  It 
is also clear that anastrozole does not affect cytochrome P450 expression at the 
dose tested.  With respect to the other drugs, a clear increase in Cyp1a, Cyp2a 
and Cyp2b expression is seen in male mice following treatment with 
cyclophosphamide and gefitinib, although only gefitinib achieves a >2 fold 
increase.  However, the situation is more equivocal when considering 
expression in female mice, with the higher basal expression of cytochrome 
P450s in females negating equivalent inductions.  Unlike in males, there is no 
induction of Cyp1a or Cyp2a in females.  There is also a modest induction of 
Cyp2b10 (the mouse orthologue to CYP2B6, and the top band detected by the 
antibody) in females following treatment with cyclophosphamide, but not with 
gefitinib.  Unfortunately immunoblot resolution is insufficient to allow 
quantitation of the Cyp2b10 isoform, and therefore this induction is masked 
when assessing densitometric data from the whole cluster.  There are also 
gender discrepancies when analysing Cyp2c expression, with there being no 
expression following gefitinib or cyclophosphamide treatment in males, but 
significant inductions with the same treatment in females (2.6 and 2.1 fold 
respectively, relative to vehicle treated). 
To this point letrozole induction has not been discussed.  Looking at the 
Western blots, it is immediately evident that letrozole strongly induces the 
expression of Cyp1a, Cyp2a and Cyp2b enzymes in male mice, with 2.5-, 8.1- 
and 4.2-fold induction respectively being seen upon densitometric analysis.  A 
Cyp2c induction of 1.9 fold is also seen in males; there is no induction of Cyp3a 
or POR.  In females, modest inductions of Cyp1a, Cyp2a and Cyp2b can be see n, 
although none of these reach the >2 fold threshold.  The most significant 
induction in females following letrozole treatment was in Cyp2c protein, where 
a 6.1-fold induction was measured.  Interestingly, letrozole was also responsible 
for a female-specific 2-fold induction in POR, the enzyme required for all 
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cytochrome P450 reactions.  On the basis of these results, it is clear that 
letrozole provides the best protein induction of all drugs tested, and is a 
potential substrate for PXR and CAR.  It is also evident that sexual dimorphism 
in cytochrome P450 expression and induction is an issue that must be 
considered in further experimental design. 
3.3.1.3 LETROZOLE INDUCES CYTOCHROME P450 ACTIVITY 
Western blot analysis showed that cytochrome P450s were being induced in 
response to drug treatment.  However, the most crucial aspect of protein 
induction with respect to drug-drug interactions is that of enzyme activity.  As 
part of this preliminary investigation, a panel of coumarin probes were used to 
measure isoform activity (Table 2.3.2).   
Data indicated that there was no significant induction in enzyme activity 
following anastrozole, cyclophosphamide or gefitinib treatment in males or 
females, although there was a non-significant increase of approximately 2-fold 
in BFC and BQ activity after gefitinib treatment in males (Figure 3.3.3).  This 
primarily indicates an increase in Cyp3a activity, although Cyp1a activity is also 
likely to be involved.  An increase in Cyp1a activity coincides with the increased 
induction seen in the Western blots.  Once again, letrozole induced the most 
profound changes in enzyme activity.  In males, activity data from all four 
probes is significantly increased by between 6 and 7-fold, suggesting a broad 
spectrum induction of enzyme activity, including Cyp1a, Cyp2b, Cyp2c and 
Cyp3a.  Again, there is sexual dimorphism in the response to letrozole.  No 
induction was seen in females with BFC and BQ probes, indicating that Cyp3a 
and Cyp1a enzymes are not being induced, an observation which concurs  with 
the Western blots.  However, significant increases in EFC and MFC activity 
indicate that Cyp2b, Cyp2c and Cyp2e enzymes are being induced.  Once again, 
the activity induction profiles suggest a role for CAR and PXR in the control of 
letrozole-induced metabolism. 
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Figure 3.3.3: Cytochrome P450 activity in wild type C57 BL/6J mice 
following 3 day treatment with an anti-cancer drug panel 
C57 BL/6J mice (n=3 per group) were treated daily with either 0.9% Saline, 0.3 mg/kg 
Anastrozole (A), 50 mg/kg Cyclophosphamide (B), 100 mg/kg Gefitinib (C) or 100 mg/kg 
Letrozole (D) for 3 days.  Cytochrome P450 activity in male (a) and female (b) liver 
microsomes was assessed using a panel of coumarin probes (human specificity given in 
table).  Data is expressed as fold difference ± S.D.  Statistics analysed average specific 
activity following treatment vs vehicle control.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  
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3.3.2 OPTIMIZING THE DOSE OF AROMATASE INHIBITORS 
On the basis of gene expression, Western blot and enzyme activity data, it was 
decided that letrozole was a likely target of CAR and PXR.  However, the dose 
used in the initial screen was very high in comparison to doses used clinically 
(100mg/kg vs 2.5 mg/day (approx. 0.038mg/kg based on an average 65kg 
woman)), and therefore experiments were performed to identify a lower dose 
which would give acceptable expression of cytochrome P450s.  As a result of the 
strength of induction following letrozole treatment, it was also decided to re -
analyse induction caused by the aromatase inhibitor anastrozole.  In the initial 
study, the dose tested was very low (0.3mg/kg) because experience within the 
lab indicated that this dose gave good data in pharmacokinetic studies.  
However, the low dose may have contributed to the inability to identify any 
changes in cytochrome P450 expression, and therefore the dose was increased 
in the current cohort. 
3.3.2.1 GENE EXPRESSION IS INDUCED FOLLOWING AROMATASE INHIBITOR 
TREATMENT 
Following experiences in the initial study, two lower doses of letrozole were 
tested: 25mg/kg and 50mg/kg.  Anastrozole doses were increased to 10mg/kg 
and 20mg/kg.  Although these are significantly higher than the clinical dose, we 
decided that they were most appropriate for an initial “proof of process” study, 
and could be reduced at a later date.  TaqMan® data for the new doses was 
analysed alongside the data generated from the original test cohort, and is 
shown in Figure 3.3.4.   
As before, Cyp2b10 is strongly upregulated following letrozole treatment in 
both males and females, although there is no dose-dependent induction.  There 
is sexual dimorphism in the magnitude of induction relative to vehicle control, 
with induction in males ranging between 10 and 50-fold, whereas induction in 
females is more modest, at between 4 and 6.5-fold.  This is as a result of the 
higher basal expression of Cyp2b10 in the females.  However, the inductions are   
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Figure 3.3.4: Induction of Cytochrome P450 mRNA in wild type C57 BL/6J 
mice following 3 day treatment with various doses of Letrozole and 
Anastrozole 
C57 BL/6J mice (n=3 per group) were treated p.o for 3 days with either 0.9% Saline, 
Letrozole (25 (A), 50(B) or 100 (C) mg/kg/day) or Anastrozole (0.3 (D), 10 (E) or 20 (F) 
mg/kg/day).  Cyp3a11, Cyp2b10, and Cyp2c29 mRNA expression relative to 0.9% Saline 
vehicle control was measured by TaqMan gene expression analysis in male (a) and female 
(b) liver RNA, and is expressed as fold difference ± range incorporating S.D. as 
recommended by Applied Biosystems comparative Ct analysis method.  Statistics analysed 
gene expression following treatment vs vehicle control.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001. 
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considered to be highly significant (p≤0.001) in both males and females, with 
the exception of the 25mg/kg dose in males.   
Cyp3a11 is also significantly induced in all treatment groups except the 
25mg/kg dose in females.  Unlike Cyp2b10 the effect appears to be dose-
dependent in the female cohort, varying from 1.5-fold in the 25mg/kg group to 
2.8-fold in the 100mg/kg cohort.  In the males, all doses significantly 
upregulated Cyp3a11 expression, with an increase from 1.9-fold in the 25mg/kg 
group to 3.1-fold in the 50mg/kg group being seen.  Induction then plateaus 
between 50-100mg/kg, with the latter being induced 2.9-fold.  This suggests 
that maximal induction of Cyp3a11 is achieved between 25-50mg/kg treatment 
indices in males, but that further induction is possible in females. 
Although induction of Cyp2c29 is seen in the 25mg/kg dosing group in both 
sexes (1.6-fold in males, 1.5-fold in females), it is not considered significant.  
However, dose-dependent upregulation is observed in males, with induction 
increasing to 2.2-fold after 50mg/kg treatment, and then to 3-fold following 
100mg/kg.  In females, no dose-dependency is seen, with a significant induction 
to 2.2-fold being observed after 50mg/kg treatment, followed by a non-
significant induction of 1.8 fold after 100mg/kg treatment.  In contrast to 
findings with Cyp3a11, it appears that maximal Cyp2c29 induction is achieved 
between 25-50mg/kg treatment indices in females, but that further induction is 
still possible in males.  It also suggests that the induction mechanism for the 
Cyp3a11 and Cyp2c29 genes is sexually dimorphic, a finding that has been 
previously reported in the literature (Down et al., 2007; Hernandez et al., 
2009b). 
When analysing the data following anastrozole treatment, it can be seen that 
there is little induction at doses lower than 20mg/kg, with only Cyp2b10 (male) 
and Cyp2c29 (female) approaching significance (1.8- and 1.6-fold respectively).  
Using a 20mg/kg dosing regime, there is very significant induction of Cyp3a11 
in both males and females (2.4- and 1.9-fold respectively).  This correlates well 
with the identification of CYP3A4 as the key cytochrome P450 involved in the 
metabolism of anastrozole (Kamdem et al., 2010), and suggests that anastrozole 
69 
 
 
may auto-induce its own metabolism.  A significant upregulation of Cyp2b10 is 
observed in both males and females, although the magnitude of induction 
appears lower in females.  Again, this may be as a result of the higher basal 
expression of Cyp2b10 in females, with actual expression level being 
approximately twice that of the males (data not shown).  There is no significant 
induction of Cyp2c29 in either sex following treatment with 20mg/kg 
anastrozole. 
3.3.2.2 BOTH AROMATASE INHIBITORS INDUCE CYTOCHROME P450 PROTEIN 
EXPRESSION 
To assess protein expression, a series of Western blots were performed on 
pooled microsomal extracts isolated from whole liver samples harvested from 
treated mice.  These were probed using a panel of polyclonal cytochrome P450 
antibodies together with a polyclonal antibody for POR.  Only 100mg/kg 
letrozole induced Cyp1a in males and females, with the lower doses having little 
effect (Figure 3.3.5).  However, sexually dimorphic expression of Cyp1a was 
observed following anastrozole treatment, with no induction being seen in 
males and slight induction being seen in females at all doses.   
The expression of Cyp2b is also influenced by letrozole treatment, with 
induction being seen following 100mg/kg treatment in males, but after 
50mg/kg in females.  This indicates that Cyp2b expression is more sensitive to 
letrozole-induced upregulation in females than in males.  On the other hand, 
anastrozole induces Cyp2b expression in both the 10 and 20mg/kg treatment 
groups in both sexes.  However, the magnitude of induction is greater in males 
than in females (3- and 2.7-fold vs 1.7- and 1.9-fold respectively) as a result of 
the higher basal expression rate in females.   
Sexual dimorphism was seen in the expression of Cyp2a, with no induction in 
males with either drug, but induction being seen with both drugs at all doses in 
females (2.1- and 2.6-fold for letrozole, 2.7-3.1-fold for anastrozole).  The 
25mg/kg letrozole treatment group did not reach the 2-fold threshold, although 
it was induced by 1.8-fold.  It is also noteworthy that anastrozole at all doses 
induced Cyp2a more strongly than letrozole, even at the highest dose.  In  
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Figure 3.3.5: Dose dependent induction of Cytochrome P450s in wild type 
C57 BL/6J mice following 3 day treatment with Letrozole or Anastrozole 
C57 BL/6J mice (n=3 per group) were treated p.o for 3 days with either 0.9% Saline (V), 
Letrozole (25, 50 or 100 mg/kg/day) or Anastrozole (0.3, 10 or 20 mg/kg/day).  a) 
Western blots of pooled liver microsomes (n = 3 per group; 20g/well).  + = positive 
control - Liver microsomes from male C57 BL/6J mouse treated with either phenobarbital 
(80 mg/kg/day for 3 days; 7.5g/well; Cyp1a, 2a, 2b, and 2c) or dexamethasone (50 
mg/kg/day for 3 days; 5g/well; Cyp3a and POR).  b) Densitometry analysis - Fold 
induction/repression following drug treatment relative to saline control.  Numbers in red 
indicate > 2 fold induction.  Densitometry for Cyp1a, Cyp2a and Cyp2c represents 
expression of full gene cluster.  Densitometry for Cyp2b and Cyp3a represents expression 
of Cyp2b10 and Cyp3a11 isoforms only. 
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contrast, Cyp2c is induced following the two highest doses of letrozole and 
anastrozole in males (2.3- and 3-fold vs 2.9- and 2.8-fold respectively), but is 
essentially unchanged in females. 
With respect to Cyp3a, a key enzyme in the metabolism of both drugs, no 
induction is seen at any of the doses tested in both sexes.  However, a modest 
induction of less than the two fold threshold (1.5-1.7 fold) is seen following 
letrozole treatment in males and females.  The exception to this is observed at 
the lowest drug concentration in females, where no induction is recorded.  
These findings correlate well with the data obtained by TaqMan® analysis, and 
suggest that letrozole induced upregulation of Cyp3a gene expression is as a 
result of increased gene expression or mRNA stabilization. 
Slight increases in POR expression are observed following treatment with 
letrozole at the highest two doses in males (1.4-1.6-fold).  This would be 
commensurate with the increase in Cyp1a, Cyp2b, Cyp2c and Cyp3a expression, 
and indicates an increase in cytochrome P450-mediated metabolism.  However, 
these are very small inductions, and therefore the clinical relevance is 
questionable. 
3.3.2.3 SEXUAL DIMORPHISM IN THE INDUCTION OF CYTOCHROME P450 ENZYME 
ACTIVITY 
In order to dissect which cytochrome P450 activities are induced, a panel of 
fluorigenic coumarin probes was employed to assay the microsomal extracts 
previously tested by immunoblotting.  The enzyme activity profiles for males 
and females vary significantly, and there are marked differences in response to 
each drug (Figure 3.3.6).  A noteworthy observation is the increased intra-
population variability seen in the female cohort, which complicates analysis. 
Examining letrozole induced enzyme activity in males, a significant induction in 
BFC activity of approximately 2-fold is seen following all doses.  An extremely 
significant increase in BQ activity of 2.5-fold is also observed in response to the 
highest letrozole dose, indicating an induction of Cyp3a activity.  EFC and MFC  
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Figure 3.3.6: Cytochrome P450 activity in wild type C57 BL/6J mice 
following 3 day treatment with various doses of Letrozole or Anastrozole 
C57 BL/6J mice (n=3 per group) were treated p.o. daily with either 0.9% Saline, Letrozole 
(25 (A), 50(B) or 100 (C) mg/kg/day) or Anastrozole (0.3 (D), 10 (E) or 20 (F) 
mg/kg/day) for 3 days.  Cytochrome P450 activity in in male (a) and female (b) liver 
microsomes was assessed using a panel of coumarin probes (human P450 specificity 
indicated in table).  Data is expressed as fold difference ± S.D.  Statistics analysed average 
specific activity following treatment vs vehicle control.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001. 
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are also modestly induced in the two lowest dose treatment groups, altho ugh 
only EFC activity is significantly induced in the 50mg/kg cohort.  Both EFC and 
MFC activities are extremely significantly induced in response to treatment with 
100mg/kg letrozole, indicating an induction of Cyp2b, Cyp2c and Cyp2e 
enzymes.  In females, there is no induction in any coumarin activity as a result 
of 25mg/kg letrozole treatment.  However, in contrast to the males, significant 
inductions are seen in all four coumarin assays following 50mg/kg treatment, 
even when considering the greater inter-individual variation evident in the 
females.  Also in contrast to the observations in males, although enzyme activity 
is induced between 1.6- and 2.6-fold in all four assays following 100mg/kg 
letrozole treatment, none of these inductions are considered significant, and all 
appear to be repressed when considered against the data gathered from the 
50mg/kg cohort.  This indicates that letrozole-induced enzyme activity is dose-
limited in females. 
The enzyme activity profile in response to anastrozole inductio n yields very 
different observations.  Modest inductions in EFC and MFC activity of 2.1/2.2-
fold and 2.6/2.7-fold were identified in males following 10 and 20mg/kg 
treatment respectively, indicating some induction of Cyp2b, Cyp2c and Cyp2e 
enzymes.  However, at no dose tested in males does any enzyme activity 
increase significantly, with no notable induction at all in BFC or BQ activities.  In 
females a very different activity profile is apparent.  As in males, no induction is 
seen with any probe following treatment with 0.3mg/kg anastrozole.  However, 
modest to strong inductions with all probes are seen following treatment with 
10mg/kg anastrozole, although only MFC activity is induced significantly.  This 
is probably as a result of the higher inter-individual variation which seems 
characteristic of the female cohort.  This trend suggests that there is induction 
in a range of cytochrome P450s in response to anastrozole treatment.  This 
finding is given further credence by the data obtained from the 20mg/kg 
treatment population, in which activity readings for all probes are significantly 
induced, with inductions in BFC (6.7 ± 1 fold) and MFC (5.8 ± 1.3 fold) activity 
being extremely significant and induction in EFC (5.5 ± 0.8 fold) being very 
74 
 
 
significant.  The lowest induction in females was seen in the BQ assay (2.2 ± 0.2 
fold). 
3.4 DISCUSSION 
3.4.1 THE AROMATASE INHIBITOR LETROZOLE IS A LIKELY CANDIDATE TO 
INTERACT WITH PXR AND CAR 
To enable examination of the effects of a range of drugs on a system, we elected 
to use a methodology employing a panel of mice transgenic for PXR and CAR 
(Scheer et al., 2008; Ross et al., 2010; Scheer et al., 2010)  However, before 
testing in these models occurred it was essential to identify drugs which were 
likely to interact with these nuclear receptors to avoid unnecessary 
experimentation.  Initial analysis was performed in C57BL/6J wild-type mice, 
and used expression and activity of key cytochrome P450s to identify potential 
interactions.  The drugs were selected on the basis that they are all substrates of 
CYP3A4 (Scripture et al., 2005; Purnapatre et al., 2008), indicating a possible 
interaction with PXR which prototypically controls this enzyme. 
The data from all analyses was striking, with letrozole widely inducing 
cytochrome P450 expression and activity to significant levels in both males and 
females.  Examining the induction profile following letrozole treatment suggests 
that it is likely to interact with CAR, although whether directly or indirectly is 
unclear.  Cyp2b10, an enzyme prototypically induced by CAR, is upregulated at 
both the mRNA and protein levels.  Further evidence is provided by the 
upregulation of Cyp1a, Cyp2a and Cyp2c enzymes, all of which have been 
identified as downstream targets of this nuclear receptor (Ferguson et al., 2002; 
Wei et al., 2002; Pascussi et al., 2003; Wang and Negishi, 2003; Ferguson et al., 
2005; Gillberg et al., 2006; Hernandez et al., 2006; Jackson et al., 2006; 
Pustylnyak et al., 2007; Chen and Goldstein, 2009; Yoshinari et al., 2010).  This 
conclusion also correlates with the increased enzyme activity observed using 
the EFC and MFC fluorigenic assays, both of which detect increases in Cyp2b, 
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Cyp2c and Cyp2e isoforms.  On the basis of these data, the role of letrozole as a 
direct or indirect activator of CAR seems likely. 
Letrozole is reportedly metabolised by CYP3A4 and CYP2A6 (Haynes et al., 
2003; Tao et al., 2007; Murai et al., 2009), and therefore any modulation of 
Cyp3a enzyme activity is likely to increase the rate of drug disposal.  
Interestingly, although Cyp3a11 mRNA was induced in both sexes, in neither sex 
did this translate to an induction of Cyp3a protein.  However, in males a highly 
significant increase in activity was seen with those probes associated with 
Cyp3a, whilst no induction was observed in the females.  There could be two 
explanations for this phenomenon.  Firstly, letrozole does not induce Cyp3a 
activity, but instead increases Cyp1a activity, the minor enzyme detected by 
BFC and BQ.  This hypothesis is given some credence by the strong induction in 
Cyp1a protein seen on Western blot analysis.  However, another explanation is 
that although overall expression of Cyp3a is not changed, the proportion of 
active enzyme is increased as a result of increased protein turnover, a finding 
consistent with data obtained by TaqMan® analysis.  It is impossible to identify 
which hypothesis is correct on the basis of these data, but the use of the more 
specific resorufin probes in future experiments should provide clarity on this 
point.  It is also important to note that this observation is sexually dimorphic, 
and therefore any explanation is likely to incorporate gender -specific 
physiology.  Cyp2a is also upregulated at the protein level in males only, 
indicating that there could be a gender influence in the metabolism in letrozole 
as a result of the sexually dimorphic expression of Cyp2a and Cyp3a enzymes.  
This topic will be considered in detail in Chapter 4. 
Interestingly, both cyclophosphamide and gefitinib induced a similar response, 
with Cyp1a, Cyp2a and Cyp2b being induced in males on Western blot analysis, 
and Cyp1a, Cyp2b and Cyp2c being induced in females.  Again, the expression 
profile indicates that both drugs are potential targets of CAR.  
Cyclophosphamide is known to auto-induce its own metabolism by CYP2B6 and 
CYP3A4, with the effect being attributed to the agonism of PXR (Chang et al., 
1997; Lindley et al., 2002; Harmsen et al., 2009).  However, Lindley et al. (2002) 
also noted a more potent induction of CYP2B6 than CYP3A4, suggestive of a role 
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for CAR.  In agreement with these data and our observations, reporter gene 
assays have recently identified cyclophosphamide as a CAR activator, probably 
acting via an indirect mechanism, with both PXR and CAR having equal 
responsibility for auto-induction of cytochrome P450s (Wang et al., 2011).  This 
therefore gives greater confidence that the methodology selected for use in this 
thesis yields reproducible data.   
At this time, there are no reports regarding nuclear receptor activation 
potential of gefitinib.  However, it is known to be primarily metabolised by 
CYP3A4 in the liver (McKillop et al., 2005; Li et al., 2009a; Duckett and Cameron, 
2011) which suggests the possibility of interaction with PXR.  It is also 
metabolised by CYP1A1 in the lungs (Li et al., 2009a; Duckett and Cameron, 
2011), an important finding for a medicine recommended by NICE for the 
treatment of non-small cell lung cancer 
(http://publications.nice.org.uk/gefitinib-for-the-first-line-treatment-of-
locally-advanced-or-metastatic-non-small-cell-lung-cancer-ta192).  CYP1A1 is 
upregulated in the lungs of smokers as a result of activation of the aryl 
hydrocarbon receptor (AhR).  However, recent evidence has also identified CAR 
as a regulator of CYP1A1 and CYP1A2 in primary human hepatocytes (Yoshinari 
et al., 2010), and linked the induction of CYP2B6 following treatment with 
cigarette smoke extract to CAR activation in HepG2 cells adenovirally 
transduced with hCAR (Washio et al., 2011) although this latter finding needs 
further evidence from a more suitable model, such as the EYFP-hCAR PHH 
model discussed in Section 3.1.1.2.  The expression of CAR in lung tissue is 
equivocal, with lung specific splice variants located in rats (Kanno et al., 2005a), 
but no expression identified in humans (Thum et al., 2006).  However, the latter 
study does not analyse the presence of splice variants, and by analysing samples 
obtained by bronchoalveolar lavage and bronchial biopsy could miss low level 
expression in specific cell types.  If it transpires that CAR splice variants are 
expressed in the lung and that they are involved in the induction of CYP1A1 in 
this location, this could represent a novel transcriptional control circuit of key 
importance when considering drugs targeting smoking-induced lung tumours.  
Our data suggests that gefitinib is a CAR activator, although further study is 
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required to confirm this.  With CAR being implicated in the control of CYP3A4 
and CYP1A1 metabolism, there is potential for CAR-induced auto-induction of 
gefitinib metabolism.  There is also potential for drug interaction caused by 
activation of CAR by cigarette smoke, thus changing drug pharmacokinetics.   
Therefore, a full analysis of the role of nuclear receptors in the disposition of 
this drug could be of key importance to clinical practice. 
3.4.2 DOSE OPTIMIZATION OF THE AROMATASE INHIBITORS 
On the basis of the data from initial experiments, it was decided to progress 
letrozole for dose optimization in C57BL/6J wild-type mice prior to testing in 
the transgenic models.  The broad enzyme and activity inductions observed 
following letrozole treatment suggest that this drug could induce DDIs, and 
since it is taken on a daily basis over a number of years, it has a broader 
opportunity to interact with co-medications than many cancer treatments.  
However, the dose tested was extremely high, and therefore two lower doses, 
25 and 50 mg/kg, were analysed for their efficacy in inducing cytochrome 
P450s.  It was also decided to re-examine anastrozole, another aromatase 
inhibitor of the same class as letrozole.  At the dose initially tested, there was no 
induction in expression or enzyme activity.  This dose was selected on the basis 
of laboratory experience in previous pharmacokinetic experiments.  However, it 
could be too low to induce a response that can be observed by conventional 
protein analysis after that treatment period, and therefore anastrozole 
concentration was increased to 10 and 20 mg/kg to enable analysis of 
cytochrome P450 profile. 
It becomes immediately apparent that increasing the dose of anastrozole causes 
induction of cytochrome P450s, with the profile at higher doses imitating that of 
letrozole in terms of enzymes induced.  Cyp2b is particularly induced in both 
sexes, in concordance with data obtained by TaqMan® analysis which indicates 
that Cyp2b10 mRNA is induced in a dose-dependent manner, with significant 
increases being seen following treatment with 20mg/kg anastrozole.  Similar 
dose-dependent inductions in EFC and MFC activity are observed, although 
these only attain significance in the female 20mg/kg cohort.   Gender -specific 
78 
 
 
response is also seen in the induction of Cyp1a and Cyp2a in females and Cyp2c 
in males.  It can therefore be suggested that anastrozole also interacts with CAR, 
in a similar manner to letrozole.  Interestingly, the induction in Cyp3a11 mRNA 
in males and females at the highest dose does not translate into an induction in 
Cyp3a protein, as seen following letrozole treatment.  However, it does translate 
into a significant increase in BQ and BFC activity in the females only, indicating 
a sexually dimorphic variation in response.  An induction in Cyp1a protein is 
seen in females only, although this does not exceed the 2-fold threshold.  This is 
likely to have a bearing on BFC and BQ activity, being the minor enzyme 
responsible for metabolism of these probes.  As with initial letrozole analysis, 
whether this increased activity is as a result of Cyp1a induction or increased 
Cyp3a protein turnover cannot be determined on the basis of these data.  
However, all data clearly identifies the 20mg/kg anastrozole dose as that most 
appropriate for future studies. 
When examining data from the letrozole dose optimisation, it becomes clear 
that the 25mg/kg treatment group displays no induction in protein levels for 
the cytochrome P450s tested in the male cohort, although inductions do occur 
at the mRNA and enzyme activity levels.  Once again, TaqMan® data indicates a 
significant induction in Cyp3a11 mRNA, which appears to translate to a 
corresponding increase in BFC activity.  However, because BQ activity is not 
also induced it must be questioned whether this induction is Cyp3a-related or 
as a result of inducing another cytochrome P450.  Non-significant inductions 
can also be seen following EFC and MFC analysis, indicating that induction is 
occurring in those enzymes in terms of activity, although at very low levels that 
are below the limit of detection for immunoblotting.  However, when analysing 
the same dose in the female cohort, the expression profile varies greatly.  
Firstly, there is a highly significant induction in Cyp2b10 mRNA, although other 
probes are not significantly induced.  This is not translated to an equivalent 
induction in protein, and neither is this associated with an induction in any of 
the activity assays.  Ultimately, the induction levels in the 25mg/kg cohort are 
not sufficient when compared to the higher doses for use in further studies.  
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The 50mg/kg letrozole dose appears to give much better induction levels than 
observed following lower dose treatments.  All three genes examined by 
TaqMan® analysis are induced very significantly, with the greatest induction in 
Cyp2b10 being translated to an induction in Cyp2b protein levels in both sexes.  
Slight induction of Cyp3a protein is also seen in both males and females, 
although this does not reach the two-fold threshold, indicating that increased 
gene expression is being translated to enzyme induction.  Again, sexual 
dimorphism is observed in the expression of Cyp2a and Cyp2c, with the former 
being induced in females, and the latter in males.  The effects of protein 
induction translate through to an induction of enzyme activity which is 
especially marked in the females.  Certainly, induction of both protein and 
enzyme activity seems to be greater in the females than in the males, although 
similar inductions in gene expression were seen.  This suggests that letrozole 
has a more significant effect on the female population than the male, and this 
will require further investigation.  However, the levels of protein induction 
observed using the 50mg/kg dose indicate that this is sufficient to obtain 
meaningful data in future studies, and therefore should be used in preference to 
the 100mg/kg dose to obviate potential toxicity issues in the mice. 
3.5 CONCLUSIONS 
Of the drug panel tested, all drugs appear to be potential targets of CAR.  There 
is also likely to be some interaction with PXR, although the induction in Cyp3a11 
mRNA does not translate to an induction in protein expression on Western blot 
analysis.  This is in concordance with data published regarding 
cyclophosphamide and its role as an activator of both PXR and CAR (Chang et 
al., 1997; Lindley et al., 2002; Harmsen et al., 2009; Wang et al., 2011).  
However, the response to letrozole treatment was by far the most significant, 
and therefore this drug was selected for further study. 
Dose optimization studies identified the 50mg/kg letrozole dose as the most 
appropriate for further analysis.  However, technical issues in initial analysis 
falsely identified the 25mg/kg letrozole dose as sufficient to yield a good 
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cytochrome P450 induction on Western blot analysis, and therefore this was 
the dose used in further study.  Dosing levels were also analysed for the 
aromatase inhibitor anastrozole, with the highest 20mg/kg dose being selected 
for further analysis. 
Throughout this analysis it has become evident that there is significant sexual 
dimorphism in the expression profiles for both drugs.  This must be carefully 
considered in future studies, and therefore both sexes must continue to be used. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 CHAPTER 4 
CHARACTERIZING THE INTERACTION OF 
AROMATASE INHIBITORS WITH PXR AND 
CAR 
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4.1 INTRODUCTION 
4.1.1 AROMATASE AND ITS INHIBITORS 
As a result of the data discussed in Chapter 3, the drugs letrozole and 
anastrozole were selected for further investigation into their ability to activate 
PXR and CAR.  Both are third generation, non-steroidal aromatase (CYP19) 
inhibitors (AI), licensed for the treatment of oestrogen receptor (ER)-positive 
breast cancer in post-menopausal women (Table 3.1.1).  Mechanistically, these 
drugs competitively inhibit the aromatase enzyme by non-covalent binding to 
the haem element, thus blocking the substrate binding site (Miller and Dixon, 
2002; Miller et al., 2008; Lønning, 2011), although recent studies have also 
indicated AI-induced transcriptional repression of the CYP19 gene may occur 
via the micro-RNA Let-7f, providing longer term aromatase suppression 
(Mackay et al., 2007); (Miller et al., 2012).  Aromatase is a key component of the 
oestrogen biosynthesis pathway, catalysing three consecutive hydroxylation 
steps in the conversion of C-19 androgens to C-18 oestrogens (Hong et al., 
2011), and therefore its inhibition leads to a decrease in oestrogen 
concentrations.  It is primarily expressed in ovarian granulosa cells in pre -
menopausal women, but is also expressed in a number of other tissues 
throughout the body, including muscle, adipose tissue, skin and brain (Garcia-
Segura et al., 2003; Bulun et al., 2007; Biegon et al., 2010; Chumsri et al., 2011; 
Luchetti et al., 2011; Inoue et al., 2012).     
Aromatase is essential for the correct physiological functioning of many 
systems.  However, it can become problematic when dealing with oestrogen-
dependent cancers in which aromatase over-expression is associated with 
tumour pathology.  The role of aromatase in oestrogen-dependent breast cancer 
has been particularly well characterized, being over-expressed by 
undifferentiated adipose fibroblasts recruited to the tumour ball to maintain a 
localized high oestrogen environment and promote tumour growth  (Bulun et 
al., 2007; Bulun and Simpson, 2008; Ito et al., 2011), thus providing the 
rationale for the clinical efficacy of the AIs.  In addition to their licensed 
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application in the treatment of various breast cancers, the AIs are also being 
investigated for use in various off-license indications.  These include ovarian 
and endometrial cancers (Bulun et al., 2007; Ito et al., 2011), endometriosis 
(Nothnick, 2011; Polyzos et al., 2011; Seal et al., 2011) and selected male and 
female fertility treatments (Montville et al., 2010; Ben-Haroush et al., 2011; 
Papanikolaou et al., 2011; Pritts, 2011; Sönmezer et al., 2011); (Cavallini et al., 
2011; de Ronde and de Jong, 2011; Saylam et al., 2011; Gregoriou et al., 2012).  
However, although it is clear that AIs could have potential utility in an 
increasing number of indications, the evidence base for these off -license 
applications is not yet sufficient for AI therapy to become a clinical paradigm.   
4.1.1.1 LETROZOLE 
Pharmacology 
Letrozole (Femara®) is indicated for the widest variety of oestrogen-dependent 
breast cancers of the two AIs analysed in this study (see Table 3.1.1), with 
clinical data indicating that it is superior to tamoxifen as adjuvant treatment for 
early breast cancer (Crivellari et al., 2008; Colleoni et al., 2011; Regan et al., 
2011a; Regan et al., 2011b; Chirgwin et al., 2012), as well as in the treatment of 
locally advanced and metastatic breast cancer (Ellis and Ma, 2007; Goss, 2007; 
Mouridsen, 2007).  Letrozole is also being extensively tested for various off-
label applications, including ovarian and endometrial carcinomas, 
endometriosis, male and female fertility treatment, hormone-induced growth 
defects and medical abortion.  Pharmacologically, it profoundly suppresses 
oestrogen production whilst exerting no effect on serum levels of follicle 
stimulating hormone, luteinizing hormone, thyroid stimulating hormone, 
cortisol, 17-hydroxyprogesterone, androstenedione and aldosterone following 
standard therapeutic doses (Iveson et al., 1993; Lipton et al., 1995).   
Letrozole suppresses aromatization to a greater extent than anastrozole, 
achieving a 98.9% inhibition in activity (Dowsett et al., 1995; Dixon et al., 2008).  
This equates to a suppression of plasma oestradiol concentrations of 96.6%, 
oestrone of 99.1% and oestrone sulphate of 99.5% (Geisler et al., 2008).  
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Importantly, intra-tumoural oestradiol was also suppressed by 97.6%, oestrone 
by 90.7% and oestrone sulphate by 90.1%.  It also indicates that letrozole 
achieves significantly greater oestrogen suppression than anastrozole, both in 
the plasma and in tissue (Dixon et al., 2008; Geisler et al., 2008).  However, the 
comparative clinical efficacy of letrozole relative to anastrozole is still being 
investigated (Monnier, 2010). 
Letrozole is considered to be a comparatively safe treatment, with a lower risk 
of thromboembolic events than tamoxifen.  However, the extent of oestrogen 
suppression is directly responsible for the majority of adverse effects associated 
with this class of drug.  Common side effects of aromatase inhibitor therapy 
include arthralgia, hot flushes, fatigue, myalgia and gynaecological effects 
(Gonnelli and Petrioli, 2008; Monnier, 2009; Dent et al., 2011).  A higher rate of 
hypercholesterolaemia has also been associated with long term letrozole 
treatment, although the evidence base for this finding is conflicting (Pandya and 
Morris, 2006; Gonnelli and Petrioli, 2008; Monnier, 2009; Zidan et al., 2010).  
However, possibly the most serious adverse events are those that affect the 
skeleton, including bone resorption, osteoporosis, and bone pain.  Bone 
resorption is a major concern in aromatase inhibitor therapy, with an increased 
number of fractures being recorded whilst receiving this treatment as a result 
of the profound oestrogen suppression induced by these drugs (McCloskey et 
al., 2007; Eidtmann et al., 2010; Edwards et al., 2011; Nuzzo et al., 2012; Zaman 
et al., 2012).  This is commonly treated by co-administration of 
bisphosphonates, most notably zoledronic acid, which has itself been recently 
suggested to repress aromatase activity by inhibiting serine phosphorylation, a 
post-translational modification essential for aromatase activity, indicating a 
potential positive functional drug-drug interaction with letrozole (Schech et al., 
2012). 
Metabolism 
The primary excretion mechanism of letrozole in humans is hepatic, being 
metabolised to a pharmacologically inactive carbinol metabolite, 4,4’ -
(hydroxymethylene)-dibenzonitrile, by CYP2A6 and CYP3A4 in humans (Sioufi 
et al., 1997a; Murai et al., 2009; Desta et al., 2011; Precht et al., 2012).  This 
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carbinol metabolite is then glucuronidated prior to excretion, although the 
enzyme responsible for this reaction has not yet been identified (Figure 4.1.1).  
Recent studies employing human liver microsomal fractions and recombinant 
human P450s have yielded important information regarding enzyme kinetics 
for the formation of the carbinol metabolite (Murai et al., 2009; Desta et al., 
2011).   
 
Figure 4.1.1: Proposed metabolism of letrozole in humans (Sioufi, 1997a; 
Murai, 2009; Desta, 2011; Precht 2012) 
CYP2A6 has a greater affinity for letrozole than CYP3A4, with Km of 3.0 ± 1.4 M 
and 92 ± 15 M being calculated respectively (Murai et al., 2009).  However, the 
reaction rate in the CYP3A4 pathway is significantly faster than that of the 
CYP2A6, having a Vmax of 22 ± 3 and 4.3 ± 0.2 pmol/min/nmol P450 
respectively.  The implication of these data is that CYP2A6 is the primary 
enzyme involved in letrozole metabolism at low concentrations, such as are 
present during conventional letrozole therapy.  If higher doses of letrozole are 
given, the CYP2A6 pathway becomes saturated, resulting in CYP3A4 becoming 
the predominant clearance enzyme, and a consequent increase in reaction rate.  
This cooperative functioning is of particular importance in those individuals 
possessing CYP2A6 polymorphisms associated with low metabolism, including 
CYP2A6*4 (in which the CYP2A6 gene is absent), CYP2A6*7 and CYP2A6*9, all of 
which are particularly prevalent in Asian populations (≤20% population) 
(Raunio et al., 2001; Rautio, 2003; Murai et al., 2009; Han et al., 2012).   
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Pharmacokinetics 
Letrozole is absorbed rapidly when given orally, with a bioavailability of 99.9 ± 
16.3% being recorded (Sioufi et al., 1997a).  The bioavailability does not vary 
with fed or fasting state, although the rate of uptake is reduced (Sioufi et al., 
1997b).  However, as a result of the treatment algorithm employed in 
conventional letrozole therapy, this decrease in absorption rate is unlikely to 
result in any clinical abnormality and therefore letrozole can be administered 
regardless of food intake.  Plasma protein binding is approximately 60%, mainly 
to albumin (55.1 ± 1.4%), with concentration in erythrocytes being 
approximately 80% that of plasma (Colussi et al., 1998).   
Letrozole is rapidly distributed within tissues, having a high volume of 
distribution at steady state (1.87 ± 0.47 L/kg; (Sioufi et al., 1997a)).  
Interestingly, a recent report examining pharmacokinetics in healthy male 
subjects (n=52) using a two-compartment model has identified significant 
association between body fat mass/BMI and peripheral volume of distribution 
(Jin et al., 2012).  They have also found a strong link between body weight and 
central volume of distribution.  This finding concurs with those published by 
Desta et al. (2011), in which letrozole concentrations in postmenopausal 
women with stage 0-III hormone receptor positive breast cancer (n=284) were 
found to be negatively correlated with BMI, and positively correlated with age.  
These findings suggest that body fat composition has a significant impact on the 
volume of distribution, a hypothesis consistent with the highly lipophilic nature 
of letrozole.   
The pharmacokinetics of letrozole are marginally non-linear in nature at high 
concentrations, as seen following a high single dose of ≥30 mg or multiple daily 
doses of 2.5 mg (Pfister et al., 2001).  This has been attributed to the saturation 
of the CYP2A6 pathway at high concentrations, resulting in the CYP3A4 
pathway becoming dominant.  It is also well documented that letrozole is a 
strong inhibitor of CYP2A6 activity, thus further decreasing the capacity of this 
pathway and potentially exacerbating the effect (Pfister et al., 2001; Jeong et al., 
2009).  Steady-state pharmacokinetics are attained after 2-6 weeks of treatment 
with 2.5mg letrozole daily. 
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A summary of published PK parameters in a variety of human populations is 
shown in Table 4.1.1.  Although intra-population variation is relatively high as 
a result of the small scale of these studies, important trends can be dissected 
from this data.  Although there is no variation in Cmax between healthy male and 
post-menopausal female populations, there does appear to be a trend towards 
higher exposure and slower metabolism in the males, with a marginally 
increased t½ and AUC0-∞ than the females.  This is likely to be as a result of the 
higher CYP2A6 activity identified in females (Benowitz et al., 2006).  The impact 
of health status on the pharmacokinetics of letrozole is made clear when 
comparing the healthy postmenopausal female population with that of the 
breast cancer population (Sioufi et al., 1997a; Pfister et al., 2001).  Changes in 
pharmacokinetics are observed in all parameters listed in the breast cancer 
population.  Tmax and t½ are both strongly increased, with clearance being 
decreased.  AUC0-∞ is also increased.  These findings suggest that metabolism 
and systemic clearance are inhibited in this population, probably as a result of 
reduced metabolism, although variation in volume of distribution as a result of 
physiological changes associated with the disease is also a possibility.  It is also 
worth noting that the intra-population variability in the breast cancer 
population is much higher than that of the healthy population, most likely as a 
result of the heterogeneity of this disease. 
Another comparison of interest is that of the healthy postmenopausal 
population against the healthy Japanese population (Sioufi et al., 1997a; Tanii et 
al., 2011).  Although the differences in Cmax and tmax are marginal, it is clear that 
t½, clearance and AUC0-∞ are significantly affected by race.  T½ and AUC0-∞ are 
both are both strongly increased in the Japanese population, with clearance 
being decreased by 70% resulting in a profile that more closely resembles the 
postmenopausal breast cancer population than the healthy.  The enzyme with 
the highest affinity for letrozole is CYP2A6, and therefore anything that 
interferes with CYP2A6 activity is likely to have a deleterious effect on letrozole 
metabolism.  It is therefore likely that that higher rate of CYP2A6 genetic 
polymorphisms in the Japanese population is responsible for the increased 
systemic exposure observed (Tanii et al., 2011). 
 
 
 
8
8
 
Population 
D
o
se
 
Factors 
Cmax/ 
nmol/L 
tmax/ 
h 
t½/ 
h 
CL/ 
L/h 
AUC0-t/ 
nmol h/L 
AUC0-∞/ 
nmol h/L 
Reference 
Healthy 
postmenopausal 
women (n=12) 
1 Fasted 
130 
(approx.) 
1.0 
(median) 
42.0 ± 15.3 2.21 ± 0.65  4290 ± 1471 
Sioufi et al., 
1997a 
Healthy male (n=12) 
1 Fasted 129 ± 20.3 0.88 ± 0.38 50.2 ± 21.8  648 ± 73.6 5920 ± 2470 
Sioufi et al., 
1997b 1 Fed 98.7 ± 18.6 2.08 ± 1.10 49.7 ± 18.3  591 ± 71.0 5730 ± 2240 
Postmenopausal 
women with 
advanced/metastatic 
breast cancer 
1 n=27 107 ± 39.2 8.10 ± 19.0 82.2 ± 55.0 1.52 ± 0.73 1372 ± 541 7387 ± 4063 
Pfister et al., 
2001 
66 n=24 467 ± 244 3.20 ± 4.91 118 ± 67.4 1.2 ± 0.50 8926 ± 4865  
Healthy Japanese 
postmenopausal 
women (n=12) 
 
1 Fasted 151.4 ± 46.4 1.5 ± 0.6 68.6 ± 36.7 1.496 ± 0.702 1959 ± 669 7241 ± 4020 
Tanii et al., 
2011 
 
*Data 
published as 
ng/mL.  
Converted to 
nmol/L for 
table 
14  652.3 ± 207.1 4.3 ± 2.3 88.9 ± 56.2 0.741 ± 0.265 12999 ± 4143  
Healthy Japanese 
postmenopausal 
women (n=10) 
1  113.6 ± 19.2 2.7 ± 1.2   1629 ± 308  
28  532.4 ± 185.0 5.5 ± 6.6  0.868 ± 0.334 11555 ± 4444  
Table 4.1.1: Summary of pharmacokinetic data published following 2.5 mg letrozole daily p.o.   
Dose indicates length of treatment course in days.  Data expressed as mean ± S.D.  Source data expressed as CV%, S.D. was calculated using 
the equation S.D. = mean x CV%.  Data from Tanii et al. (2011) converted to nmol/L for ease of  comparison. 
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The effect of these polymorphisms is more pronounced when comparing 
parameters calculated from the multiple dosing studies (Pfister et al., 2001; 
Tanii et al., 2011).  At steady state, exposure is significantly higher and systemic 
clearance slower than observed following a single dose in both populations. 
Systemic exposure at steady-state is much higher in the healthy Japanese 
population than in the postmenopausal breast cancer group, with Cmax being 
increased by 140%, clearance reduced by 62% and AUC0-t increased by 150% 
(Pfister et al., 2001; Tanii et al., 2011).  However, when investigating tmax and t½ 
we see that the Japanese population attains the former marginally later, but that 
t½ is 75% faster than in the breast cancer population.  It is clear that CYP2A6 
genotype is of key importance to letrozole metabolism, and that metabolism in 
the breast cancer population shares many similarities with a population high in 
CYP2A6 genetic polymorphisms.  However, as reported by Desta et al. (2011), 
CYP2A6 polymorphism alone does not fully account for inter-individual 
variation in letrozole metabolism, and therefore further investigation of the role 
of other factors, such as UDP-glucuronosyltransferases and drug transporters, 
would be of importance for a full analysis of population pharmacokinetics.  
Drug interactions 
At present, few drug interactions with letrozole have been identified.  The most 
well-documented of these is that of letrozole and tamoxifen.  The first study 
(Dowsett et al., 1999) investigated the impact of tamoxifen on letrozole 
pharmacokinetics in a postmenopausal locally advanced/locoregional 
recurrent/metastatic, hormone receptor positive breast cancer population 
(n=12) after a treatment regime of 6 weeks of letrozole monotherapy (2.5 mg 
p.o. daily) followed by 6 weeks of letrozole (2.5 mg p.o. daily) + tamoxifen (20 
mg p.o. daily).  It found that letrozole plasma concentrations and AUC were both 
significantly reduced following combination therapy, with the latter being 
reduced by an average of 38%.  Unfortunately, the sample size of this study was 
insufficient to assess the effect on drug efficacy, although the reduction in 
concentrations and AUC indicates that letrozole dose is effectively decreased to 
1.5-2 mg.  The changes in pharmacokinetics following combination therapy 
have been attributed to induction of CYP3A4 by tamoxifen, resulting in 
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increased letrozole metabolism (Dowsett et al., 1999; Desai et al., 2002; Sane et 
al., 2008b).  A concomitant trial using the same methodology in a 
postmenopausal progressive metastatic breast cancer population, but in which 
tamoxifen monotherapy was given for 6 weeks prior to tamoxifen + letrozole 
combination therapy, indicated that this finding was not reciprocal, with no 
changes being recorded in the pharmacokinetics of tamoxifen or its metabolites, 
N-desmethyl-tamoxifen or 4-hydroxy-tamoxifen, following combination therapy 
(Ingle et al., 1999). 
Letrozole to date has predominantly been administered as monotherapy in an 
oncology setting.  However, recently there has been increasing interest in novel 
combination regimes in which letrozole is combined with drugs that target 
other pathological characteristics of breast cancers, thus increasing the 
opportunity for adverse drug-drug interactions.  These trials are particularly 
targeted towards the treatment of HER2+ metastatic breast cancer in post-
menopausal women, and include the combination of letrozole with 
trastuzumab, lapatinib and gonadotrophin releasing hormone analogues.  The 
combination of concurrent letrozole + trastuzumab has been found to be more 
effective than letrozole monotherapy in the treatment of early stage HER2+ 
metastatic breast cancer (Fleeman et al., 2011; Koeberle et al., 2011; Huober et 
al., 2012).  Lapatinib + letrozole has also been shown to be more effective than 
letrozole monotherapy in this population (Chu et al., 2008; Sherrill et al., 2010; 
Fleeman et al., 2011).  One study of particular interest combines letrozole with a 
commonly used neoadjuvant chemotherapy regime (5-fluorouracil 600mg/m2/ 
doxorubicin 60mg/m2/cyclophosphamide 600mg/m2 administered every 3 
weeks) in the treatment of locally advanced breast cancer 
(Mohammadianpanah et al., 2012).  Although this was a relatively small study 
(n=50 per study arm) and ER status was not known at the time of treatment 
starting, both clinical and pathological response rates were notably, although 
not significantly, affected.  This was especially prominent once ER status was 
included in analysis, with a significant increase in overall clinical response of 
26% over those women receiving neoadjuvant chemotherapy alone in an ER-
positive population (92.74% vs 66.66%).  However, no pharmacokinetic 
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analysis was included in the study design, and this is of key importance when 
considering the metabolic pathways concerned with metabolising these drugs, 
and in particular cyclophosphamide which relies on CYP2A6 and CYP2B6 
among others. 
Although few adverse interactions have been identified when co-administering 
other drugs alongside letrozole, it is increasingly likely that letrozole will be 
taken concurrently with various other pharmaceuticals and herbal medicines 
during breast cancer treatment, as a result of the population age commonly 
associated with this disease.  The novel therapeutic areas and new therapeutic 
regimes being investigated are also of concern with respect to drug-drug 
interactions, because of the potential for variability in pharmacokinetics and 
pharmacodynamics as a result of the altered treatment demographic and 
increased doses employed.  In addition to the lower age of the test populations 
being investigated for these new applications, the subjects are also in different 
developmental stages (pre-puberty  post-menopausal) and of different 
genders, all of which can have significant effects on drug pharmacokinetics.  
There is also a paucity of good quality pharmacokinetic data associated with 
these clinical trials, making prediction of potential DDIs problematic.  To date 
there has not been a systematic pharmacokinetic analysis of letrozole with 
commonly co-prescribed medications, and this becomes increasingly 
concerning with the higher concentrations employed in areas such as fertility 
treatment, as well as the increasing role of letrozole as part of a co -
administration regime, particularly in the field of oncology in which the 
therapeutic indices of many drugs are very narrow.  In addition, the potential 
role of letrozole as a PXR or CAR ligand/interactor has not been well defined in 
the literature, a factor that could significantly impact its potential for DDIs.  A 
full consideration of pharmacology and pharmacokinetics is therefore essential 
for the continuing assessment of DDI potential. 
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4.1.1.2 ANASTROZOLE 
Pharmacology 
Anastrozole (Arimidex®) is a third generation, competitive aromatase inhibitor 
licensed for use in a number of oestrogen-dependent breast cancers, although it 
was initially approved for use in advanced breast cancer (see Table 3.1.1) 
(Plourde et al., 1994; Plourde et al., 1995; Buzdar et al., 1997).  It has been 
found to be superior to tamoxifen as adjuvant therapy in early ER-positive 
breast cancer, giving improved disease free survival, time to recurrence and 
time to contralateral breast cancer, although overall survival was equivalent 
between the two drugs (Cuzick et al., 2010; Kelly and Buzdar, 2010).  
Combination therapies of anastrozole with drugs including goserelin and 
leuprolide acetate are also showing promise in the treatment of pre-
menopausal breast cancer and male breast cancer respectively (Carlson et al., 
2010; Cheung et al., 2010).  Although not as prominent as letrozole, it is also 
being investigated for a number of novel indications including endometriosis 
(Bilotas et al., 2010; Ngô et al., 2010; Nothnick, 2011; Polyzos et al., 2011), 
gynaecomastia in pubertal boys (Mauras et al., 2009) and functional follicular 
ovarian cysts in girls with peripheral precocious puberty (Engiz et al., 2009).  It 
has also been assessed for use in fertility treatment, although it was shown to 
be less effective than clomiphene citrate (Tredway et al., 2011; Tredway and 
Schertz, 2011). 
As previously stated, anastrozole does not suppress oestrogen levels as strongly 
as letrozole (Dixon et al., 2008).  Aromatization has been found to be inhibited 
by 97% following a 1 mg/day dose of anastrozole (Geisler et al., 1996; Lønning, 
1998; Geisler et al., 2002; Geisler and Lonning, 2005), with it being suggested 
that anastrozole does not fit as tightly in the active site of the enzyme as 
letrozole (Furet et al., 1993; Mouridsen and Bhatnagar, 2005; Monnier, 2010).  
Plasma oestrone concentrations were suppressed by 96.3%, oestradiol by 89.9-
92.8% and oestrone sulphate by 95.3% (Dixon et al., 2008; Geisler et al., 2008).  
Oestrogen suppression is less marked in tissue, although still significant, with 
oestrone being suppressed by 83.4%, oestradiol by 89.0% and oestrone 
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sulphate by 72.9%.  At present, the clinical effect of the differential oestrogen 
suppression between letrozole and anastrozole has not been fully 
characterised, although data from the ATAC and BIG 1-98 trials suggests that 
letrozole has the greater clinical potency (Monnier, 2010; Geisler, 2011).   
Although effective at suppressing oestrogens, a recent study has highlighted the 
high inter-individual variability in the pharmacodynamics of anastrozole, with 
the range of anastrozole-induced oestrogen modulations encompassing modest 
but detectable suppression, profound suppression, and also an increase in at 
least one of the oestrogenic compounds in 4% of subjects (Ingle et al., 2010).  
This inter-individual variability in pharmacodynamics has been largely 
attributed to inter-individual variations in drug metabolism.  Clearly this 
variability in pharmacodynamics is likely to have a significant effect on drug 
efficacy and tolerability, and therefore it must be carefully considered when 
prescribing anastrozole.     
The clinical safety profile of anastrozole is similar to that of letrozole, with the 
majority of side effects being mild/moderate in intensity and associated with 
oestrogen suppression.  The most commonly reported adverse effects in the 
ATAC trial were hot flushes (35.7%) and arthraligia (35.6%), the latter of which 
could be as a result of anastrozole-induced increases in pro-inflammatory 
cytokines (Jingxuan et al., 2009; Kelly and Buzdar, 2010).  There were also more 
reports of hypercholesterolaemia in the anastrozole treated population than in 
the tamoxifen population, although there was a similar incidence of 
cardiovascular effects.  Once again, one of the most serious adverse effects 
following anastrozole treatment was that of bone resorption and osteoporosis, 
with an incidence of both fractures and osteoporosis of 11% in the anastrozole 
treated population of the ATAC trial (Cuzick et al., 2010; Eastell et al., 2010; 
Kelly and Buzdar, 2010).  Treatment with oral bisphosphonates, such as 
ibandronate and risedronate, have been shown to result in an approximately 
3% increase in bone mineral density (Markopoulos, 2010; Markopoulos et al., 
2010).  However, at present there is no evidence of improved cancer-related 
clinical benefit when combining bisphosphonates, such as is reported for 
letrozole + zoledronic acid (Markopoulos, 2010; Markopoulos et al., 2010).  
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Metabolism 
Although anastrozole has been clinically available for many years, only recently 
has its metabolism been characterized in the literature.  Hepatic metabolism is 
the primary route of clearance in humans, with 10% being cleared renally as 
unchanged parent drug (Sanford and Plosker, 2008).  The main metabolites of 
anastrozole were thought to be triazole (major), anastrozole N-glucuronide, 
hydroxyanastrozole and glucuronidated hydroxyanastrozole, (Sanford and 
Plosker, 2008; Ingle et al., 2010; Kamdem et al., 2010; Lazarus and Sun, 2010).  
However, a recent study by Kamdem et al. (2010) was unable to detect triazole 
both in vitro and in vivo, and therefore, in common with Sanford et al. (2008), 
they identified hydroxyanastrozole as the major metabolite for this drug.  
However, in vivo free hydroxyanastrozole appears to be short lived, with the 
majority being detected as the glucuronidated form.  The proposed metabolic 
pathway is shown in Figure 4.1.2. 
Hydroxyanastrozole is the predominant metabolite of CYP3A4 catalysed 
anastrozole metabolism, although a minor role is suggested for CYP3A5 
(Kamdem et al., 2010).  Interestingly, specific inhibition of CYP2C8 and CYP2A6 
in human liver microsomes indicated strong repression in anastrozole 
hydroxylation activity.  However, this was not confirmed in expressed P450s, 
with little or no activity detected in either.  Glucuronidation of anastrozole is 
predominantly catalysed by UGT1A4, with minor activity also detected for 
UGT2B7 and UGT1A3 (Kamdem et al., 2010; Lazarus and Sun, 2010).  To date 
there is no evidence regarding the specific UGTs associated with 
hydroxyanastrozole conjugation. 
Anastrozole has been shown to inhibit CYP1A2, CYP3A and CYP2C9 in vitro 
(Grimm and Dyroff, 1997).  Interestingly, the inhibition profile for both CYP1A2 
and CYP3A was biphasic, indicating the presence of 2 linear phases.  The result 
is two apparent Ki values for each enzyme: 8 and 80 M for CYP1A2, and 10 and 
55 M for CYP3A, with Cornish-Bowden plots indicating that anastrozole 
inhibition of CYP1A2 is competitive, whilst that of CYP3A is mixed 
(competitive/non-competitive).  The apparent Ki of CYP2C9 was also 10 M,  
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Figure 4.1.2: Proposed metabolism of anastrozole in humans (adapted 
from Kamdem et al. (2010)) 
with the inhibition being demonstrated to be competitive.  Given that the 
average steady-state Cmax of anastrozole is 0.3 M, it is unlikely that any 
inhibition will occur at standard doses. 
There is significant inter-individual variability in the concentrations of 
anastrozole N-glucuronide, hydroxyanastrozole and hydroxyanastrozole 
glucuronide (Ingle et al., 2010; Kamdem et al., 2010).  An example given in Ingle 
et al. (2010) demonstrates steady state anastrozole concentrations ranging 
from 0 ng/mL in 2 patients, both of whom possessed measurable anastrozole 
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metabolite concentrations, to 98.8 ng/mL.  Understanding the specific effect a 
patient’s individual enzyme activity profile has on anastrozole 
pharmacokinetics could significantly improve inter-individual variability in the 
efficacy and tolerability of anastrozole.  It is also important to note that 
although all anastrozole metabolites are assumed to be inactive, no systematic 
analysis has been performed to assess the potential activity of these chemicals.   
Pharmacokinetics 
Analysis of the pharmacokinetics of anastrozole in the literature is problematic 
as a result of variability and relative paucity of data published.  Many early 
papers do not give detailed PK parameter data, preferring to discuss C min at 
steady state pharmacokinetics together with changes in oestrogen levels as a 
measure of drug effectiveness and pharmacokinetic interactions (Plourde et al., 
1994; Plourde et al., 1995; Buzdar et al., 1997; Lønning, 1998; Dowsett et al., 
2001).  It is therefore difficult to obtain a full understanding of anastrozo le 
pharmacokinetics from these initial studies, although basic information is 
available.  Pre-clinical data indicates that anastrozole is rapidly and almost 
completely absorbed, although these studies have not been published and no 
quantitative estimate of bioavailability is available (Plourde et al., 1994).  
However, an early study in healthy Chinese males calculates bioavailability to 
be 100 ± 9%, confirming this finding (Yuan et al., 2001).  Once absorbed, 
anastrozole is extensively tissue distributed, with a volume of distribution of 
98.4 ± 41.9 L (Mauras et al., 2009).  Protein binding of anastrozole at 
therapeutic concentrations is reported to be 40% (Lønning, 1998).  Anastrozole 
pharmacokinetics are linear up to doses of 20 mg/day (Tredway et al., 2004).  
However, large inter-individual variation in the concentrations of anastrozole 
and its metabolites has recently been reported, indicating variability in 
pharmacokinetics (Ingle et al., 2010).  Also, a recent study suggests lower 
efficacy with higher BMI and postulates that this could be a result of an 
insufficient dose in this population (Sestak et al., 2010).  If this is found to be the 
case, it is likely to be a result of a greater volume of distribution as a result of 
the higher abundance of adipose tissue. 
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The most complete pharmacokinetic analysis of early trial data indicates a Cmax 
of 13.7 ng/ml, median tmax of 2 hours and t½ of 40.6 hours following dosing of 
healthy postmenopausal women (n=7) with 1 mg/day anastrozole (Yates et al., 
1996).  Steady-state pharmacokinetics are attained following 10 doses of 1 
mg/day anastrozole in 90-95% of subjects, with Cmin of 25.1 ng/ml being 
recorded at steady state (Plourde et al., 1994; Yates et al., 1996).  This is 
approximately 3.5 fold higher than is recorded after a single dose.  
Unfortunately no further pharmacokinetic information has been published from 
the early trials.  However, several recent studies have performed full 
pharmacokinetic analysis in order to validate novel generic formulations of 
anastrozole in various populations, although none of these allow an analysis of 
the effect of disease on pharmacokinetics.  This data is summarized in Table 
4.1.2.  Certain characteristics can be extracted from this data, although firm 
conclusions cannot be drawn as a result of the low sample sizes, changes in 
assay technology and relative paucity of data.  Firstly, with the exception of the 
data generated by Micheal et al. (2011), data regarding Cmax and t½ are 
concordant across populations (Yates et al., 1996; Yuan et al., 2001; Mauras et 
al., 2009; Noh et al., 2012).  The marginally higher concentrations seen in the 
later studies are most likely as a result of a change in assay technology, with a 
move from gas chromatography separation with electron capture detection 
methods (Yates et al., 1996; Yuan et al., 2001) to an HPLC-MS/MS method 
(Mauras et al., 2009; Micheal et al., 2011; Noh et al., 2012).  Although the use of 
median values precludes the drawing of conclusions with respect to tmax, the 
data does suggest some sexual dimorphism in anastrozole metabolism, with the 
male populations achieving Cmax faster than the females.  However, within sexes 
the median tmax shows little variation.  There also appears to be a potential 
racial variation in anastrozole pharmacokinetics when examining the data from 
Micheal et al. (2011).   
In summary, pharmacokinetic data from anastrozole studies is extremely 
variable in content, with no systematic analysis of the effects of disease, BMI, 
race or genetic polymorphisms currently available.   
 
 
 
9
8
 
Population 
Dosing 
schedule/ 
drug 
Cmax/ 
ng/mL 
tmax/ 
h 
t½/ 
h 
CL/ 
L/h 
AUC0-t/ 
nmol h/L 
AUC0-∞/ 
nmol h/L 
Reference 
Healthy 
postmenopausal 
women (n=7) 
Single 
Arimidex 
13.1 
2 
(median) 
40.6    
Yates et al. 
(1996) 
Healthy Chinese 
men 
(n=20) 
Fasted 
Single 
Arimidex 
10.2 ± 2.5 1.3 ± 0.4 41 ± 26  385 ± 117 429 ± 121 
Yuan et al. 
(2001) Single 
Generic 
10 ± 3 1.2 ± 0.5 42 ± 14  386 ± 117 443 ± 141 
Healthy 
postmenopausal/ 
surgically sterile 
Indian women 
(n=14) 
Fasted 
Single 
Arimidex 
16.02 ± 1.59 
1.75 
(median) 
57.06 
(median) 
 800.57 ± 1.66 866.11 ± 1.70 
Micheal  et al. 
(2011) Single 
Generic 
16.24 ± 1.50 
1.75 
(median) 
53.29  
(median) 
 780.11 ± 1.61 834.49 ± 1.64 
Healthy Korean men 
(n=24) 
Fasted 
Single 
Arimidex 
14.8 ± 2.6 
1.0 
(median) 
42.1 ± 8.4 5.93 ± 5.0%†  681.5 ± 160.5 707.1 ± 177.6 
Noh et al. 
(2012) Single 
Generic 
15.0 ± 2.3 
1.3 
(median) 
41.6 ± 7.8 3.21 ± 3.8%† 647.8 ± 118.0 669.4 ± 130.0 
Pubertal boys with 
gynaecomastia  
(n=42) 
14 days 
Arimidex 
39.3 ± 13.5 
1.0 
(median) 
46.8 1.54 ± 0.57 648 ± 240  
Mauras et al. 
(2009 
Table 4.1.2: Summary of pharmacokinetic data published following 1 mg anastrozole daily p.o.   
Dose indicates daily oral dose in mg.  Data expressed as mean ± S.D.  † = expressed as mean ± relative standard error (standard error as a 
percentage of mean parameter).  
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Drug interactions 
As in the case of letrozole, information regarding drug-drug interactions with 
anastrozole is limited, mainly as a result of its primary use as monotherapy.  
Given the metabolic pathways responsible for anastrozole clearance, any drug 
that changes the expression and activity of CYP3A4 is likely to result in altered 
anastrozole pharmacokinetics.  This is of particular concern because CYP3A4 is 
known to be responsible for the metabolism of approximately 60% of currently 
available drugs, meaning that opportunities for drug-drug interactions are 
likely to be high (Plant, 2007).  However, systematic analysis of potential drug-
drug interactions has not been performed.  Those interactions that have been 
analysed are detailed below. 
Once again, co-administration of anastrozole with tamoxifen yields a significant 
decrease in anastrozole concentrations of 27% relative to monotherapy, 
although there is no effect on those of tamoxifen (Dowsett et al., 2001).  Again, it 
is likely to be as a result of tamoxifen-induced upregulation of CYP3A4 
expression via PXR induction (Dowsett et al., 2001; Desai et al., 2002; Sane et al., 
2008b), thus increasing metabolism of anastrozole.  Although this interaction is 
unlikely to be of clinical relevance, with oestradiol suppression still reaching the 
assay limit of detection, it could be of importance in a patient treated with more 
than one therapeutic that increases the expression and activity of CYP3A4.  A 
recent study has also investigated a possible drug interaction between 
anastrozole and simvastatin (Bao et al., 2012).  Although the group concluded 
that there was no clinically relevant drug interaction between these two 
entities, they do report that in 3/9 subjects, a ≥30% change in anastrozole 
concentrations (2 increased and 1 decreased) was recorded following 
anastrozole + simvastatin treatment, suggesting that these drugs do interact, 
probably as a result of simvastatin-induced CYP3A4 expression via PXR 
induction (Howe et al., 2011).  There are no data available regarding the effect 
of anastrozole on simvastatin pharmacokinetics.   
Unfortunately, neither of these studies fully assessed changes in 
pharmacokinetics, relying instead on the analysis of changes in Cmin.  Although 
performing the studies once steady state pharmacokinetics are reached does 
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minimize variation in the PK parameters, it is possible that co-administration 
alters the pharmacokinetics more substantially than will be evident when 
purely considering concentration.  This means that these studies are likely to 
miss more subtle changes, such as variations in absorption, AUC and t½.  Small 
sample size is also an issue with the study published by Bao et al. (2012), in 
which 1/3 of all subjects demonstrate a ≥30% change and yet pharmacokinetic 
interactions are dismissed.  A larger scale study must be conducted in order to 
draw any conclusions regarding this interaction.  One study that did use a full 
pharmacokinetic analysis has suggested that anastrozole does not interact with 
warfarin, although anastrozole pharmacokinetics have not been considered. 
Reported drug-drug interactions with anastrozole are therefore rare as a result 
of the current clinical paradigm.  However, as a result of the metabolic 
pathways involved with anastrozole clearance, together with the growing 
interest in combination therapies and the prevalent risk of interactions with 
other prescription and over the counter drugs, it is likely that this could 
increase in the future.  Thorough pharmacokinetic analysis of these 
combinations, such as are seen in letrozole studies, together with the 
publication of full pharmacokinetic data from clinical trials are urgently needed 
in order to assess the risk of clinically relevant drug-drug interactions.  It is also 
of importance to assess the role of anastrozole as a PXR/CAR ligand since this 
could impact on its own pharmacokinetics as well as on those of other drugs.  
4.1.2 THE SPECIES-SPECIFICITY PROBLEM AND TRANSGENIC MODELS 
4.1.2.1 SPECIES SPECIFICITY 
As discussed in Chapter 3.1.1.3, the use of pre-clinical animal models to study 
pharmacodynamics and pharmacokinetics is common in the pharmaceutical 
industry because it allows metabolic control and systemic effects to be analysed 
in a physiologically relevant manner.  However, the divergent metabolic control 
systems present in different animal models limit the potential for extrapolating 
data to the clinical setting, because they are unable to accurately predict P450 
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induction in humans (Collins, 2001).  With the understanding of the role of 
nuclear receptors in the control of P450 metabolism has come the realisation 
that there is also species specificity in their ligand activation, and consequently 
in the induced expression profile.  It is therefore vital to have an understanding 
of these issues so that the best methodology can be selected for an in vivo study. 
Species specificity is a complex concept which encompasses all inter-species 
variations that could affect drug pharmacokinetics and pharmacodynamics, 
including metabolism, metabolic control, endocrine and neuroendocrine 
profiles, and body composition.  There are many potential causes of species 
specificity.  These include differences in the activity of nucleocytoplasmic 
shuttling sequences, resulting in aberrant gene expression (Kanno et al., 2005b; 
Kanno et al., 2007; Kanno and Inouye, 2008), changes in co-factor recruitment, 
such as SRC-1 interactions (Dau et al., 2012), as well as variations in nuclear 
receptor response to other signalling pathways (Lichti-Kaiser et al., 2009b).    
However, a major subset of inter-species variations in drug metabolism occur as 
a result of differences in the ligand binding domain of the controlling nuclear 
receptors, such as PXR and CAR, leading to species differential induction of 
P450s (Jones et al., 2000; LeCluyse, 2001; Östberg et al., 2002; Tirona et al., 
2004; Jyrkkärinne et al., 2005; Poso and Honkakoski, 2006; Graham and Lake, 
2008; Repo et al., 2008).  These receptors show significant species divergence in 
the amino acid sequence of their ligand binding domains.  An examination of 
variations in amino acid sequence between cloned PXR sequences for rabbit, rat 
and mouse indicates an amino acid identity of 82.0%, 75.9% and 77.3% 
respectively in the ligand binding domain relative to human PXR (Jones et al., 
2000).  This is in contrast to approximately 95% similarity in the DNA binding 
domain of these species.  Other groups have further characterized this variation 
by identifying the amino acids associated with species specific responses in 
various species (Östberg et al., 2002; Tirona et al., 2004).  Similar divergence is 
seen in the LBD of CAR, with amino acid identity between mouse and human 
CAR being reported at approximately 70% in this region (Baes et al., 1994; Choi 
et al., 1997; Moore et al., 2000; di Masi et al., 2009).  The significant divergence 
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in sequence in the ligand binding domain across species results in variations in 
ligand binding and activation potential of  
Drug 
Interacts 
with 
Species 
Mouse Human 
EC50 (nM) Action EC50 (nM) Action 
PCN* 
PXR 
200-700 + >10,000 N/A 
Rifampicin* NR  200-3000 + 
SR12813 4100 + 120-200 + 
Hyperforin NR  23 + 
Schisandrin 1250 + 2000 + 
5-Cholestan-
3,7,12-triol 
2500 + 5000 + 
TCPOBOP* 
CAR 
20-100 + No effect N/A 
CITCO* NR  25-304 + 
5-Androstan-3-ol 250-1500 - 
1000-
>10000 
- 
Meclizine 25 + 500-1000 - 
Clotrimazole No effect  50-1000 - 
5-Pregnane-3,20-dione 670-3000 +  
>10,000 
>>10,000 
Weak 
+ 
- 
Table 4.1.3: PXR/CAR ligands which demonstrate species specific activity 
NR = not reported.  + = agonist, - = antagonist (inverse agonist, CAR only).  Table 
adapted from Fraser et al. (2012).  PXR and CAR data adapted from di Masi et al. 
(2009), Stanley et al. (2006) and Moore et al. (2000).  * indicates prototypical 
inducer. 
various chemicals with respect to PXR and CAR, and is a major cause of 
interspecies variation in drug metabolism (Moore et al., 2000; di Masi et al., 
2009).  The importance of species specific nuclear receptor activation to pre-
clinical research is highlighted by a number of drugs which demonstrate 
differential activation of PXR and CAR between species, a selection of which are 
described in Table 4.1.3.   
In addition to providing a useful selection of tools for nuclear receptor studies, 
the identification of inter-species variation also highlights a potentially serious 
limitation of the use of animal models for pre-clinical studies, namely that of 
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species specific nuclear receptor activation.  As demonstrated in Table 4.1.3, 
the nuclear receptor activation potential of a chemical can vary widely between 
homologues.  Failure to fully consider these variations prior to clinical trials 
could therefore result in the clinical failure of a drug, serious adverse events 
and severe toxicity as a direct result of differential nuclear receptor activation 
and incorrect inter-species extrapolation.  A number of transgenic in vivo 
models have therefore been specifically engineered to address this problem.   
4.1.2.2 TRANSGENIC MODELS 
The use of transgenic models, commonly mouse models in which a gene of 
interest is modified, is a cornerstone of in vivo analysis.  With correct design and 
selection, these models allow the role of selected genes to be characterized in a 
physiologically relevant setting in which data regarding the downstream effects 
of gene modification, such as target gene expression and pharmacokinetics, can 
also be analysed.  One setting in which these models have demonstrated 
particular efficacy is in the analysis of nuclear receptor activation.  In order to 
allow a more physiologically relevant analysis of PXR/CAR activation profiles, 
numerous transgenic mouse models have been derived in which one or both 
genes are knocked-out (KO) or replaced with the human gene (humanized) (Xie 
et al., 2000; Staudinger et al., 2001; Wei et al., 2002; Zhang et al., 2002; Saini et 
al., 2004; Huang et al., 2005; Hernandez et al., 2007; Ma et al., 2007; Cheung and 
Gonzalez, 2008; Lichti-Kaiser and Staudinger, 2008; Ma et al., 2008a; Scheer et 
al., 2008; Ross et al., 2010; Scheer et al., 2010; Cheng et al., 2011; Hasegawa et 
al., 2011).  Collectively, these models allow ligand interactions with the 
PXR/CAR signalling pathways to be dissected at the same time as providing 
meaningful data regarding the downstream effects of activation.  They also have 
the advantage that mouse lines carrying the modification of interest can be 
continuously bred without the loss of the transgenic genes, as well as the 
potential for deriving more complex multiple transgenic models through 
selective cross-breeding.   
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There are various approaches to the construction of these transgenic models 
(Xie et al., 2000; Zhang et al., 2002; Saini et al., 2004; Huang et al., 2005; 
Hernandez et al., 2007; Lichti-Kaiser and Staudinger, 2008; Mota et al., 2011).  
However, the construction of the models selected for this study, developed and 
provided by CXR Biosciences Ltd. and TaconicArtemis, employed a targeted 
knock-in strategy, described in Figure 4.1.3 & 4.1.4, in which human PXR/CAR 
are inserted into the corresponding mouse locus under the control of the innate 
murine promoter, and in such a way as to disrupt the murine gene (Scheer et al., 
2008; Ross et al., 2010; Scheer et al., 2010).  The advantage of this method is 
that by employing the innate murine promoter all necessary transcription co -
factors, enhancers, etc. are available.  This ensures that the global expression 
pattern and magnitude in this model are comparable to those of wild-type mice, 
as well as showing equivalence to those found in human liver samples (Scheer 
et al., 2008).   
This model panel not only allows the analysis of ligand interactions with PXR 
and CAR, but also in depth analysis of the regulatory crosstalk between these 
two nuclear receptors in target gene regulation and of the implications of 
species specific interactions on downstream gene expression.  However, 
transcriptional regulation of human PXR/CAR themselves cannot be assessed in 
this model because the transgene is under the control of the murine promoter .  
The design of these models also allows the production of PXR/CAR splice 
variants, an increasingly important factor in assessing inter-individual variation 
and response to therapies.   Three hCAR splice variants (hCAR.1, hCAR.2 and 
hCAR.3) have been identified in the HuCAR models, in which the full sequence 
of introns and exons from exons 2-9 of the hCAR gene was inserted (Scheer et 
al., 2008).  Three PXR splice variants (hPXR.1, hPXR.2 and hPXR.3) have been 
identified in the HuPXR models, in which the transgene comprises a fusion of 
hPXR exons 2-4, full genomic sequence between exons 4-8 and a fusion of exon 
8-9 (Scheer et al., 2008; Scheer et al., 2010).  Subsequent analysis of a derived 
PXR/CAR double humanized model has identified detectable levels of all splice 
variants, with proportionate expression being comparable to that of human  
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Figure 4.1.3: Construction strategy of HuPXR (a) and PXR KO (b) mice 
(Adapted from Scheer et al. (2008) & Scheer et al. (2010)) 
a) HuPXR model (Scheer et al.(2010)): hPXR minigene consisting of a fusion of human 
exons 2-4, full genomic sequence from exons 4-8 and a fusion of exons 8-9 was knocked 
into the murine wild-type ATG transcriptional start site, disrupting the native mPXR gene.  
Mice were crossed onto a strain expressing FLPe recombinase to excise the hygromycin 
selection cassette through FLP-mediated recombination at FRT sites.  b) PXR KO model 
(Scheer et al. (2008)):  Derived from old PXR model in which hPXR minigene containing a 
fusion of exons 2-4, genomic sequence from exons 4-6 and a fusion of exons 6-9. Mice were 
crossed onto a C31 deleter strain to generate PXR KO model.  Black exons + lower case 
label = murine, white exons + upper case label = human.   
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Figure 4.1.4: Construction strategy of HuCAR and CAR KO mice (Adapted 
from Scheer et al. (2008)) 
Murine CAR coding region (exons 2-9) replaced with the human CAR coding region (exons 
2-9).  Mice were crossed onto an FLPe-recombinase expressing strain to generate the 
HuCAR model through FLP-mediated recombination at the FRT sites, removing the 
neomycin selection cassette.  CAR KO models were derived by crossing mice onto a C31 
deleter strain.  Black exons + lower case label = murine, white exons + upper case label = 
human. 
liver tissue, with the exception of hPXR.2 which was four-fold greater in the 
transgenic model (Ross et al., 2010). 
Another useful class of transgenic models for the analysis of drug metabolism 
are those in which certain drug metabolising enzymes are humanized.  The 
advantage of these models is that species-specificity with respect to enzyme 
function can be analysed, thus potentially yielding more clinically relevant data.  
These models can also provide important information regarding differential 
gene regulation between species.  Numerous models are available which 
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express human P450s, notably CYP1A1/1A2, CYP2D6, CYP2E1 and CYP3A4 
(Van Herwaarden et al., 2007; Cheung and Gonzalez, 2008; Scheer et al., 2010; 
Boverhof et al., 2011; Cheng et al., 2011; Hasegawa et al., 2011; Levova et al., 
2012; Scheer et al., 2012).  Many of these have been selectively bred onto a 
humanized PXR/CAR background in order to provide models which give a more 
relevant analysis of human P450 transcriptional regulation (Ma et al., 2008a; 
Hasegawa et al., 2011).  However, alongside the development of these models, a 
number of reporter lines in which a section of the 5’ upstream regulatory region 
of a P450 gene is linked to the start codon of a reporter gene, such as lacZ 
(Robertson et al., 2003; Stedman et al., 2004; Campbell et al., 2005; Charles et 
al., 2006) or luciferase (Zhang et al., 2003), have been developed.  These models 
provide a simple method of analysing cell- and tissue-specific expression of the 
human gene, and are also useful tools for assessing transcriptional regulation of 
the reporter-linked gene.     
One such model is the novel rCYP2B6-lacZ reporter mouse used in this study, in 
which approximately 70kb of the 5’ regulatory region is linked to a lacZ 
reporter gene, and randomly inserted into the murine host (develo ped by 
TaconicArtemis/CXR Biosciences Ltd., unpublished).  The large 5’ regulatory 
region inserted into this model is of sufficient size to incorporate the known key 
regulatory elements associated with CYP2B6 expression, including the PBREM 
and distal XREM (Wang and Tompkins, 2008; Inoue and Negishi, 2009; Benet et 
al., 2010b; Fraser et al., 2012).  This construct is available on both mPXR/mCAR 
and hPXR/hCAR backgrounds, and therefore allows the analysis of differential 
regulation of the CYP2B6 gene by the murine and human receptors.  In Chapter 
3, one of the features of aromatase inhibitor-induced P450 expression was 
induction of Cyp2b10, the mouse orthologue of human CYP2B6 which shares 
many of its regulatory motifs (See Section 1.2.3.1).  The ability of these drugs to 
induce this enzyme is of clinical concern, because it has a key role in the 
metabolism of many clinically important drugs, including drugs used in 
oncological treatment regimes, such as ifosfamide and tamoxifen (Wang and 
Tompkins, 2008).  Of particular concern is the pro-drug cyclophosphamide, 
which requires CYP2B6 metabolism to produce its active moiety, and which is a 
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key component of many chemotherapeutic regimes employed in the treatment 
of breast cancer (Wang and Tompkins, 2008).  Any modulation of CYP2B6 
induced by the aromatase inhibitors could therefore have significant 
downstream effects on the efficacy and toxicity of subsequent treatments.  The 
rCYP2B6-lacZ models are therefore a useful tool for the analysis of PXR/CAR 
mediated induction of CYP2B6 in response the aromatase inhibitors. 
4.1.3 AIMS AND OBJECTIVES 
In chapter 3, it was demonstrated that the AIs letrozole and anastrozole 
induced P450 metabolism in a manner suggestive of PXR and CAR activation.  In 
this chapter, the role of PXR and CAR in the P450-mediated metabolism and 
pharmacokinetics of these drugs will be further characterized using a panel of 
novel transgenic mouse models (Figure 4.1.3 & 4.1.4; Table 4.2.1) (Scheer et 
al., 2008; Ross et al., 2010; Scheer et al., 2010).  Pharmacokinetic, protein 
expression and activity data will be analysed across all genotypes.  Temporal 
changes in pharmacokinetics will also be investigated.  Both drugs will be 
analysed in males and females to provide data regarding gender-specific 
variation in nuclear receptor activation, drug metabolism and 
pharmacokinetics.  This methodology will allow the role of nuclear receptor 
crosstalk to be dissected, as well as an analysis of the impact of species and 
gender specificity on the metabolism of the aromatase inhibitors.  Finally, the 
impact of the aromatase inhibitors on the expression of CYP2B6 will be 
assessed in males and females using the rCYP2B6-lacZ reporter line on both the 
mouse and human PXR/CAR backgrounds.  This will allow species-differential 
induction to be assessed and provide evidence for any potential drug-drug 
interactions mediated by CYP2B6 in both species.  The null hypothesis is that 
the AIs interact with PXR/CAR in a species- and gender-specific manner to 
promote drug metabolism via the P450 enzyme system.   
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4.2 METHODS 
4.2.1 PXR AND CAR TRANSGENIC MODEL PHARMACOKINETIC STUDIES 
A panel of novel PXR and CAR transgenic mouse models (see Table 4.2.1) and a 
C57 BL/6J wild-type control model (n=3 per group; male and female) were 
treated p.o. on a daily basis for either 1 or 3 days with anastrozole (20 mg/kg), 
letrozole (25 mg/kg) or an equivalent volume of 0.9% saline vehicle (control).  
All drug treated animals underwent a pharmacokinetic study following the final 
drug dose as described in Section 2.2.3.2.  Following the final timepoint at 24 
hours, mice were euthanized using rising CO2. 
Model Name Notes Supplied by Reference 
PXR KO 
 All models produced by 
disrupting murine genes.   
 mPXR exon 2 removed in 
HuPXR and PXR KO models. 
 mCAR exons 2-9 removed in 
HuCAR and CAR KO models. 
 HuPXR/HuCAR are under 
control of the mouse 
promoter 
TaconicArtemis/ 
CXR Biosciences 
Ltd 
Scheer et al. 
(2008) 
CAR KO 
HuPXR 
HuCAR 
HuPXR/CAR KO 
PXR KO/HuCAR 
PXR/CAR DKO 
PXR/CAR DHu 
rCYP2B6_lacZ 
(mPXR/CAR) 
 Random insertion of lacZ 
under the control of ≈ 70kb 
of the human CYP2B6 
promoter. 
 Model designed on mouse 
and human PXR/CAR 
background 
CXR 
Biosciences 
(unpublished) rCYP2B6_lacZ 
(hPXR/CAR) 
Table 4.2.1: Transgenic mouse models used in in vivo studies 
Following euthanasia, blood was harvested by cardiac puncture into 
heparinized tubes which were subsequently centrifuged at 16,000 x g for 10 
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minutes.  Plasma supernatant was removed to a clean eppendorf which was 
snap frozen in liquid N2 and stored at -70°C prior to analysis.  Liver was 
weighed, then one small piece of liver was harvested into an eppendorf tube, 
with the remainder being bisected and transferred into bijou tubes.  All liver 
samples were snap frozen in liquid N2 and stored at -70°C prior to analysis. 
4.2.2 CYP2B6_LACZ TRANSGENIC REPORTER MODEL STUDIES 
rCYP2B6_lacZ (mPXR/mCAR background; male and female) and rCYP2B6_lacZ 
(HuPXR/HuCAR background; male only) transgenic models (see Table 2.1; n=3 
per group) were treated p.o. on a daily basis for 3 days with anastrozole (20 
mg/kg), letrozole (25 mg/kg) or an equivalent volume of 0.9% saline vehicle 
control.  Mice were euthanized using rising CO2 24 hours following final dose. 
Following euthanasia, blood was harvested by cardiac puncture into 
heparinized tubes which were subsequently centrifuged at 16,000 x g for 10 
minutes.  Plasma supernatant was removed to a clean eppendorf which was 
snap frozen in liquid N2 and stored at -70°C prior to analysis.  Liver was 
weighed, then lobe 1 was bisected, with one half being fixed in 1% PFA (for 
cryofixing) and the other half being fixed in GURR (formal saline) (for wax 
embedding) at 4°C.  After 4 hours, the 1% PFA fixed samples were rinsed twice 
with PBS (Oxoid, UK) before transferring to 30% sucrose solution at 4°C 
overnight, prior to cryofixing the following day and storage at -70°C.  The GURR 
(formal saline) samples were left at 4°C overnight, then rinsed twice in PBS and 
transferred to 70% ethanol for storage at 4°C prior to wax embedding.  Of the 
remaining liver, one small piece of liver was harvested into an eppendorf tube, 
with the remainder being bisected and transferred to bijou tubes.  All remaining 
liver samples were snap frozen in liquid N2 and stored at -70°C prior to analysis. 
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4.3 RESULTS 
4.3.1 CYTOCHROME P450 INDUCTION IS MEDIATED BY PXR AND CAR 
4.3.1.1 LETROZOLE 
Western blot analysis indicates that PXR/CAR status is an important factor in 
the control of expression of certain cytochrome P450s following letrozole 
treatment.  Sexual dimorphism in the expression of certain cytochrome P450s is 
also a feature, particularly when analysing Cyp2b10 expression.  No induction 
in Cyp1a is seen in any of the genotypes following letrozole treatment in males 
(Figure 4.3.1), with a similar pattern observed in females (Figure 4.3.2).  With 
respect to Cyp2a, no induction is seen in males or females.  No significant 
induction in Cyp2c is observed in both sexes.     
Unsurprisingly, the greatest inductions are seen in Cyp2b and Cyp3a protein, 
the two enzymes prototypically induced by CAR and PXR activation 
respectively.  Interestingly, there is obvious sexual dimorphism in the 
expression of Cyp2b10, with no expression seen in males, but basal expression 
and enzyme induction seen in females.  The first feature that is evident in 
females is that basal and induced expression of Cyp2b10 are absent in all 
models in which CAR is knocked out (mPXR/CAR KO, HuPXR/CAR KO and 
PXR/CAR DKO).  This concurs with CAR’s role as the primary regulator of this 
enzyme.  No induction is seen in the wild-type, PXR KO/HuCAR and 
HuPXR/mCAR models, although basal expression is observed.  It is also 
interesting that in those models in which PXR has been humanized, but still 
possessing a functional CAR moiety (HuPXR/mCAR and PXR/CAR DHu) the 
basal expression of Cyp2b10 is marginally increased, suggesting that HuPXR 
does not function identically to its murine counterpart.  Induction is seen in the 
PXR KO/mCAR (1.6-fold), mPXR/HuCAR (2.3-fold) and PXR/CAR DHu (1.9-fold) 
models. 
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Figure 4.3.1: Induction of Cytochrome P450s in male wild type C57BL/6J 
and transgenic mouse models following 3 day treatment with 25 mg/kg 
Letrozole 
C57BL/6J mice and a panel of PXR and CAR transgenic models  (n=3 per group) 
were treated p.o. daily with either 25 mg/kg Letrozole (L) or 0.9% Saline vehicle 
control (V) for 3 days.  a) Western blots of pooled liver microsomes (n = 3 per 
group; 20g/well).  + = positive control - Liver microsomes from male C57BL/6J 
mouse treated with either phenobarbital (80 mg/kg/day for 3 days; 7.5g/well; 
Cyp1a, 2a, 2b, and 2c) or dexamethasone (50 mg/kg/day for 3 days; 5g/well; 
Cyp3a and POR).  b) Densitometry analysis - Fold induction/repression following 
drug treatment relative to saline control.  Numbers in red indicate >2 fold 
induction.  Densitometry is isoform specific for Cyp2b10 and Cyp3a11 only.  All 
other data represent densitometry for the full gene cluster. 
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Figure 4.3.2: Induction of Cytochrome P450s in female wild type C57BL/6J 
and transgenic mouse models following 3 day treatment with 25 mg/kg 
Letrozole 
C57BL/6J mice and a panel of PXR and CAR transgenic models  (n=3 per group) 
were treated p.o. daily with either 25 mg/kg Letrozole (L) or 0.9% Saline vehicle 
control (V) for 3 days.  a) Western blots of pooled liver microsomes (n = 3 per 
group; 20g/well).  + = positive control - Liver microsomes from male C57BL/6J 
mouse treated with either phenobarbital (80 mg/kg/day for 3 days; 7.5g/well; 
Cyp1a, 2a, 2b, and 2c) or dexamethasone (50 mg/kg/day for 3 days; 5g/well; 
Cyp3a and POR).  b) Densitometry analysis - Fold induction/repression following 
drug treatment relative to saline control.  Numbers in red indicate >2 fold 
induction. Densitometry is isoform specific for Cyp2b10 and Cyp3a11 only.  All 
other data represent densitometry for the full gene cluster 
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Unlike Cyp2b10, Cyp3a11 is expressed in both sexes and all genotypes, 
indicating its greater importance in drug metabolism.  Although basal 
expression is observed, there is no induction in the PXR KO genotypes (PXR 
KO/mCAR and PXR KO/HuCAR) in either sex, with a slight repression being 
seen in the PXR/CAR DKO model in males following letrozole treatment.  This 
can be attributed to PXR’s key role in Cyp3a11 regulation.  In males, induction is 
seen in all models wild-type for PXR (wild-type [1.5-fold], mPXR/HuCAR [2.4-
fold], mPXR/CAR KO [1.8-fold]) and also in the HuPXR/CAR KO models (1.7-
fold).  No induction is seen in the HuPXR/mCAR or PXR/CAR DHu models.  In 
females, no induction is seen in wild-type, PXR KO models, mPXR/CAR KO, 
HuPXR/mCAR or PXR/CAR DKO models.  Highest induction is found in the 
PXR/CAR DHu model (1.9-fold), followed by HuPXR/CAR KO (1.7-fold) and 
mPXR/HuCAR (1.6-fold).  Finally, variations are also seen in POR response to 
letrozole therapy.  No induction is seen in in the wild-type, PXR KO, HuPXR and 
mPXR models in males.  In females, significant induction is observed in the 
PXR/CAR DHu model only. 
4.3.1.2 ANASTROZOLE 
PXR/CAR status is also a key determinant of anastrozole-induced upregulation 
in both males (Figure 4.3.3) and females (Figure 4.3.4).  Once again, no 
inductions are seen in Cyp1a expression.  There is no significant induction of 
Cyp2a in males.  Perturbations in Cyp2c expression were not seen in any of the 
tested models in either sex, with two exceptions: induction is seen in 1) the 
mPXR/CAR KO model in males (1.7-fold), and 2) the PXR/CAR DHu model in 
females (1.9-fold).  No induction of POR is observed in either sex after 
anastrozole treatment, with the exception of the PXR/CAR DHu model in 
females (1.7-fold). 
As with letrozole analysis, the most interesting results are seen in Cyp2b10 and 
Cyp3a11 expression.  As observed following letrozole treatment, expression of 
Cyp2b10 is absent in any of the CAR KO models, highlighting the crucial role of 
CAR in the regulation of this enzyme.  In terms of induction pattern, anastrozole  
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Figure 4.3.3: Induction of Cytochrome P450s in male wild type C57BL/6J 
and transgenic mouse models following 3 day treatment with 20 mg/kg 
Anastrozole 
C57BL/6J mice and a panel of PXR and CAR transgenic models  (n=3 per group) 
were treated p.o. daily with either 20 mg/kg Anastrozole (A) or 0.9% Saline 
vehicle control (V) for 3 days.  a) Western blots of pooled liver microsomes (n = 3 
per group; 20g/well).  + = positive control - Liver microsomes from male 
C57BL/6J mouse treated with either phenobarbital (80 mg/kg/day for 3 days; 
7.5g/well; Cyp1a, 2a, 2b, and 2c) or dexamethasone (50 mg/kg/day for 3 days; 
5g/well; Cyp3a and POR).   b) Densitometry analysis - Fold induction/repression 
following drug treatment relative to saline control.  Numbers in red indicate >2 
fold induction. Densitometry is isoform specific for Cyp2b10 and Cyp3a11 only.  All 
other data represent densitometry for the full gene cluster. 
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Figure 4.3.4: Induction of Cytochrome P450s in female wild type C57BL/6J 
and transgenic mouse models following 3 day treatment with 20 mg/kg 
Anastrozole 
C57BL/6J mice and a panel of PXR and CAR transgenic models  (n=3 per group) 
were treated p.o. daily with either 20 mg/kg Anastrozole (A) or 0.9% Saline 
vehicle control (V) for 3 days.  a) Western blots of pooled liver microsomes (n = 3 
per group; 20g/well).  + = positive control - Liver microsomes from male 
C57BL/6J mouse treated with either phenobarbital (80 mg/kg/day for 3 days; 
7.5g/well; Cyp1a, 2a, 2b, and 2c) or dexamethasone (50 mg/kg/day for 3 days; 
5g/well; Cyp3a and POR).   b) Densitometry analysis - Fold induction/repression 
following drug treatment relative to saline control.  Numbers in red indicate >2 
fold induction. Densitometry is isoform specific for Cyp2b10 and Cyp3a11 only.  All 
other data represent densitometry for the full gene cluster. 
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induces expression in all genotypes possessing a CAR moiety in both males and 
females, although the magnitude of expression varies between sexes.  In males, 
the strongest induction is seen in the HuPXR/mCAR model (8.6-fold) followed 
by the PXR KO/mCAR (2.5-fold) and PXR/CAR DHu (2-fold) models.  Induction 
in wild-type and HuCAR models, whilst notable, does not exceed a two-fold 
induction threshold.  In females, the induction profile is slightly altered, with 
the strongest induction being recorded in the PXR KO/mCAR model (6.1-fold), 
closely followed by the HuPXR/mCAR (5.1-fold) and wild-type (4.6-fold).  The 
strongest induction in models containing hCAR is seen in the PXR/CAR DHu 
model (3.7-fold), followed by the mPXR/HuCAR (2.9-fold) and PXR KO/HuCAR 
(1.6-fold) models. 
The strongest inductions in Cyp3a11 expression following anastrozole 
treatment are seen in male mice, with the mPXR/HuCAR model demonstrating 
the highest induction (3.3-fold), followed by the HuPXR/CAR KO (2.7-fold) and 
mPXR/CAR KO (2-fold) models.     Induction was not seen in other models.  In 
females, induction is seen in the HuCAR models, mPXR/CAR KO model and 
PXR/CAR DHu model, although none of these exceed 2-fold.  Induction was not 
observed in other models. 
4.3.2 PROTEIN INDUCTION IS ASSOCIATED WITH INCREASED ENZYME ACTIVITY 
Understanding whether protein induction is associated with a change in 
enzyme activity is vital to our understanding of the pharmacokinetics of these 
drugs, and therefore coumarin and resorufin assays were analysed with respect 
to the Western blots discussed in Section 4.3.1.  All enzyme data is expressed as 
induction relative to vehicle control samples ± S.E.M, with statistical data 
describing induction relative to that observed in the wild-type. 
4.3.2.1 MALES 
Enzyme activity accords well with Western blot data when examining BFC and 
BQ (Figure 4.3.5), the probe substrates associated with Cyp3a, Cyp1a and 
Cyp2c activity, particularly when considering letrozole.  There is no induction in 
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BFC or BQ activity in the wild-type model following treatment with either drug, 
mirroring data from the Western blots.  No induction in enzyme activity is seen 
in the PXR KO, HuPXR or PXR/CAR DHu models.  A non-significant repression in 
activity is observed in the PXR/CAR DKO model.  Significant enzyme induction 
is seen for both BFC and BQ assays in the mPXR/CAR KO (4.0- vs 2.9-fold 
respectively) and mPXR/HuCAR (4.7- vs 3.5-fold respectively) models, 
representative of increased Cyp3a activity following letrozole treatment.  These 
findings accord well with protein induction data with the exception of the 
HuPXR/CAR KO model, in which induction in Cyp3a protein does not translate 
to an increase in enzyme activity.  Data following anastrozole treatment shows a 
similar pattern, with significant increases in enzyme activity relative to wild-
type being recorded in the mPXR/CAR KO and mPXR/HuCAR models, indicating 
that protein induction in these models does translate to an increase in enzyme 
activity.  Although a modest, non-significant induction in enzyme activity 
relative to wild-type is observed in the HuPXR/CAR KO model, it does not 
equate to the magnitude of induction observed on Western blot.  Also, non-
significant induction in BFC activity appears in the PXR KO/mCAR and 
HuPXR/mCAR models, which was not predicted by Western blot analysis.   
When analysing EFC and MFC (Figure 4.3.5), the probes associated with Cyp2b, 
Cyp2c and Cyp2e activity, a similar scenario is evident.  Unlike in the BFC and 
BQ assays, there is an induction of approximately 2-fold in both EFC and MFC 
activity following letrozole treatment in wild-type mice.  Induction at wild-type 
levels is seen in the PXR KO/mCAR, HuPXR/CAR KO, HuPXR/mCAR and 
PXR/CAR DHu models.  Activity is only significantly increased relative to wild- 
type in the mPXR/HuCAR model in the EFC assay, although not in MFC.  There is 
also a significant repression in EFC activity relative to wild-type following 
letrozole treatment in the PXR/CAR DKO and PXR KO/HuCAR models, with no 
induction relative to vehicle control being seen.  This is also reflected in the MFC 
activity assay, although the repression is non-significant.  Following anastrozole 
treatment, induction of approximately 3-fold is observed in both assays in the 
wild-type model.  Similar levels of activity are seen in both assays for the 
mPXR/HuCAR model, with lower induction of approximately 2-fold in the PXR
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Figure 4.3.5: Cytochrome P450 activity in a panel of male transgenic PXR and CAR mouse models treated with 25 mg/kg 
Letrozole or 20 mg/kg Anastrozole, as measured by fluorescent coumarin assay 
C57BL/6J mice and a panel of PXR and CAR transgenic mice (n=3 per group; male) were treated p.o. daily with either 0.9% Saline, Letrozole (25 
mg/kg/day) or Anastrozole (20 mg/kg/day) for 3 days.  Cytochrome P450 activity in liver microsomes was assessed using a panel  of coumarin probes 
(human P450 specificity in table).  Data is expressed as fold induction/repression relative to vehicle control ± S.E.M.  X-axis indicates genotype: m = 
murine, KO = knock-out, Hu = Human.  Statistics analysed average induction/repression relative to vehicle control for each genotype relative to W/T 
model.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  † = Saline control activity = 0 therefore analysis could  not be performed.  See inset table for specific 
activity data ± S.E.M. 
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Figure 4.3.6: Cytochrome P450 activity in a panel of male transgenic PXR and CAR mouse models treated with 25 mg/kg 
Letrozole or 20 mg/kg Anastrozole, as measured by fluorescent resorufin assay 
C57BL/6J mice and a panel of PXR and CAR transgenic mice (n=3 per group; male) were treated p.o. daily with either 0.9% Saline, Letrozole (25 
mg/kg/day) or Anastrozole (20 mg/kg/day) for 3 days.  Cytochrome P450 activity in liver microsomes was assessed using a panel  of resorufin probes 
(human P450 specificity in table).  Data is expressed as fold induction/repression relative to vehicle control ± S.E.M. X-axis indicates genotype: m = 
murine, KO = knock-out, Hu = Human.  Statistics analysed average induction/repression relative to vehicle control for each genotype relative to W/T 
model.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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KO, HuPXR/CAR KO and PXR/CAR DHu models.  None of these changes are 
significant relative to wild-type.  Enzyme activity is induced relative to wild-
type in both assays in the HuPXR/mCAR model only, although this is only 
significant in the MFC assay.  This is the model in which the strongest induction 
of Cyp2b was recorded on Western blot.  A non-significant repression in 
enzyme activity relative to wild-type is seen in the PXR/CAR DKO, with no 
induction being recorded in this model relative to vehicle control.  Finally, EFC 
and MFC activity is negligible in the mPXR/CAR KO model in both the basal and 
induced states, regardless of treatment cohort, indicating that this model is 
effectively incapable of metabolising these probes. 
To provide more specific data regarding isoform activation, a panel of resorufin 
probes was employed (Figure 4.3.6).  On Western blot, it was observed that 
Cyp1a was not induced in any genotype with either letrozole or anastrozole.  
This is largely corroborated by the results of MR and ER activity assays which 
are more specific for Cyp1a isoforms than the coumarins, in which no notable 
induction in expression is observed, with the exception of the wild-type model.  
There is a significant repression of MR activity observed in the PXR/CAR DKO 
and PXR KO/HuCAR models relative to wild-type, following letrozole treatment.  
No significant change in MR activity was recorded in any other model with 
letrozole, and in none of the models following anastrazole treatment.  Lower 
activity than wild-type is also a feature of the ER activity assay, with 
significantly reduced turnover of this probe relative to the wild-type model 
identified in the PXR/CAR DKO, PXR KO/HuCAR, HuPXR/mCAR, HuPXR/CAR 
KO, mPXR/HuCAR and PXR CAR DHu models after letrozole treatment.  For 
letrozole, the highest level of induction is seen in the wild-type model, in which 
a 2-fold induction is observed.  The BR assay, which has a greater specificity for 
Cyp2b than the EFC and MFC assays, was also employed.  Induction relative to 
wild-type was only seen in the mPXR/CAR KO model following letrozole 
treatment, and was strongest in the HuPXR/mCAR model following anastrozole 
treatment.  All inductions were non-significant relative to wild-type and only 
that identified following anastrozole treatment agrees with Western blot data.  
No induction was recorded in any other model for either drug. 
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4.3.2.2 FEMALES 
Protein induction data following letrozole treatment in females indicates that 
Cyp3a11 is only induced in PXR/CAR DHu, HuPXR/CAR KO and mPXR/HuCAR 
models.  Cyp2c is also induced in the mPXR/HuCAR model, a fact that could 
have implications for BFC activity.  Notable increases in BFC activity (Figure 
4.3.7) are seen in the mPXR/HuCAR and PXR/CAR DHu models, although these 
are non-significant relative to wild-type.  No induction is seen in any of the 
other models.  However, when we examine data from the more specific BQ 
activity assay following letrozole treatment (Figure 4.3.7), significant induction 
in cyp3a11 activity is observed in the mPXR/HuCAR model only.  Following 
anastrozole treatment, induction in BFC activity relative to vehicle control is 
seen in all models with the exception of the PXR/CAR DKO (Figure 4.3.7). 
There is a significant induction in BFC activity relative to wild-type following 
anastrozole treatment in the mPXR/HuCAR model, and activity is also notably 
increased, albeit non-significantly, in the PXR KO/HuCAR and mPXR/CAR KO 
models.  However, there were no significant inductions relative to wild-type 
observed in the BQ assay following anastrozole treatment, with notable 
induction being seen in the mPXR/HuCAR and PXR/CAR DHu models; No 
induction in response to anastrozole treatment is recorded in the wild-type BQ 
assay (Figure 4.3.7).   
Changes in EFC and MFC activity are also observed, with a significant induction 
relative to wild-type being identified for both probes in the mPXR/HuCAR 
model in response to letrozole treatment.  Activity was also induced in response 
to letrozole treatment in the PXR/CAR DHu model, being significantly induced 
relative to wild-type in the MFC, and non-significantly in the EFC assays.  No 
notable induction relative to vehicle control for EFC or MFC is observed in any 
other model with letrozole treatment.  The induction profile is very different 
following anastrozole treatment.  Enzyme activity in the EFC assay was strongly 
induced in the wild-type (7-fold), mPXR/HuCAR (10-fold), and HuPXR/mCAR 
(7-fold) models.  Induction relative to vehicle control was also recorded in the 
PXR KO/HuCAR, PXR KO/mCAR and PXR/CAR DHu models (4-5 -fold).  
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Figure 4.3.7: Cytochrome P450 activity in a panel of female transgenic PXR and CAR mouse models treated with 25 mg/kg 
Letrozole or 20 mg/kg Anastrozole, as measured by fluorescent coumarin assay 
C57BL/6J mice and a panel of PXR and CAR transgenic mice (n=3 per group; female) were treated p.o. daily with either 0.9% Saline, Letrozole (25 
mg/kg/day) or Anastrozole (20 mg/kg/day) for 3 days.  Cytochrome P450 activity in liver microsomes was assessed using a panel  of coumarin probes 
(human P450 specificity in table).  Data is expressed as fold induction/repression relative to vehicle control ± S.E.M.  X-axis indicates genotype: m = 
murine, KO = knock-out, Hu = Human.  Statistics analysed average induction/repression relative to vehicle control for each genotype relative to W/T 
model.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  † = Saline control activity = 0 therefore analysis could not be performed.  See inset table for specific 
activity data ± S.E.M. 
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Figure 4.3.8: Cytochrome P450 activity in a panel of female transgenic PXR and CAR mouse models treated with 25 mg/kg 
Letrozole or 20 mg/kg Anastrozole, as measured by fluorescent resorufin assay 
C57BL/6J mice and a panel of PXR and CAR transgenic mice (n=3 per group; female) were treated p.o. daily with either 0.9% Saline, Letrozole (25 
mg/kg/day) or Anastrozole (20 mg/kg/day) for 3 days.  Cytochrome P450 activity in liver microsomes was assessed using a panel  of resorufin probes 
(human P450 specificity in table).  Data is expressed as fold induction/repression relative to vehicle control ± S.E.M. X-axis indicates genotype: m = 
murine, KO = knock-out, Hu = Human.  Statistics analysed average induction/repression relative to vehicle control for each genotype relative to W/T 
model.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
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However, these inductions were non-significant relative to wild-type.  Activity 
was significantly reduced relative to wild-type in the HuPXR/CAR KO and 
PXR/CAR DKO models, with induction being weak in the former and absent in 
the latter.  Once again, no notable activity, either basal or induced, was recorded 
for the mPXR/CAR KO model in the EFC assay following both treatments.  
Although certain trends are repeated in the MFC assay, there are marked 
differences in comparison to the EFC.  Firstly, the strongest induction relative to 
vehicle control is found in the wild-type model (9-fold), with strong induction 
also identified in the mPXR/HuCAR, mPXR/CAR KO and HuPXR/mCAR models.  
Induction is also identified in the PXR KO/mCAR and PXR/CAR DHu models at 
similar levels to those observed in the EFC assay (5-fold).  Once again, none of 
these changes are significant relative to wild-type.  However, low levels of 
induction are observed in the PXR KO/HuCAR model (2-3 -fold), with no 
induction in the HuPXR/CAR KO and PXR/CAR DKO models.  These three 
models therefore demonstrate significant repression in activity relative to wild -
type. 
Interestingly, the resorufin probes MR and ER (Figure 4.3.8) identify a 
significant Cyp1a induction following letrozole treatment in females.  Extremely 
significant induction relative to wild-type was seen in the HuPXR/CAR KO 
model, with a significant but lower activity identified in the mPXR/HuCAR 
model in both assays.  Significant induction in MR activity relative to wild-type 
was also identified in the PXR/CAR DHu model, increasing to extremely 
significant in the ER assay.  No induction relative to vehicle control was seen in 
any of the other letrozole treated models, including wild-type.  MR activity 
following anastrozole treatment is significantly induced relative to wild-type in 
the PXR KO/HuCAR and HuPXR/CAR KO models, with non-significant, but 
notable, inductions in the mPXR/HuCAR and PXR/CAR DHu models.  Unlike in 
the MR assay, induction of ER activity relative to vehicle control is seen in the 
wild-type model, with comparable increases seen in the PXR KO/mCAR, PXR 
KO/HuCAR, mPXR/HuCAR, mPXR/CAR KO, HuPXR/CAR KO, HuPXR/mCAR and 
PXR/CAR DHu models.  Of these, there is a trend towards higher induction 
relative to wild-type in the PXR KO/HuCAR model, although this is non-
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significant.  No induction relative to vehicle control is seen in the PXR/CAR DKO 
and mPXR/CAR KO models. 
When investigating changes in BR probe activity (Figure 4.3.8) following 
letrozole treatment, no induction relative to vehicle control is seen in the wild-
type, PXR KO/HuCAR, HuPXR/mCAR or PXR/CAR DKO models.  Significant 
induction relative to wild-type is seen in the mPXR/HuCAR, mPXR/CAR KO, 
HuPXR/CAR KO and PXR/CAR DHu models. There is also a notable, but non-
signficant, induction in the PXR KO/mCAR model in response to letrozole.  Once 
again, treatment with anastrozole leads to higher induction of enzyme activity 
relative to vehicle control.  The highest activity is observed in the wild-type 
model (9-fold) with strong inductions also seen in the PXR KO, mPXR/HuCAR, 
HuPXR/mCAR and PXR/CAR DHu models (5-7 -fold).  Weaker inductions were 
recorded in the CAR KO models (approximately 2-fold) and no induction in the 
PXR/CAR DKO.  None of these changes are considered to be significantly 
different in comparison to the wild-type model. 
4.3.3 LETROZOLE PHARMACOKINETICS DEMONSTRATE TEMPORAL VARIATION 
AND SEXUAL DIMORPHISM 
4.3.3.1 MALES 
In addition to understanding the role of PXR and CAR in the control of letrozole 
pharmacokinetics, our experimental design allows the analysis of temporal 
variations and sexual dimorphism in response.  The pharmacokinetic curves 
following 1 day and 3 day treatment with letrozole in males are shown in 
Figures 4.3.9 and 4.3.10 respectively.  Figure 4.3.9 indicates that, with the 
exception of the mPXR/HuCAR model, variations in metabolism between any of 
the models tested in the one day treatment population appear to be minor.  
Looking at the pharmacokinetic parameters (Table 4.3.1 a), few significant 
differences are observed, partly as a result of the intra-population variation.  
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Figure 4.3.9: Pharmacokinetic curves from a range of male PXR and CAR transgenic mouse models following 1 day treatment 
with 25 mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; male) were treated once p.o. with 25 mg/kg L etrozole.  Serial 
blood sampling was performed immediately following drug dose.  Drug was extracted using a solvent extraction method.  Letrozo le concentration was 
measured by HPLC.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates CAR genotype (solid 
red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO. KO = knockout genotype, Hu = humanized genotype.  Error 
bars indicate S.E.M. 
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Figure 4.3.10: Pharmacokinetic curves from a range of male PXR and CAR transgenic mouse models following 3 day treatment 
with 25 mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; male) were treated p.o. daily for 3 days with 25 mg/kg Letrozole.  
Serial blood sampling was performed immediately following final drug dose.  Drug was extracted using a solvent extraction method.  Letrozole 
concentration was measured by HPLC.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates 
CAR genotype (solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO. KO = knockout genotype, Hu = 
humanized genotype.  Error bars indicate S.E.M. 
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Table 4.3.1: Pharmacokinetic parameters from a range of male PXR and 
CAR transgenic mouse models following 1 day or 3 day treatment with 25 
mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; 
male) were treated p.o. daily for 1 (a) or 3 (b) days with 25 mg/kg Letrozole.  Serial blood 
sampling was performed immediately following final drug dose.  Drug was extracted 
using a solvent extraction method.  Concentration was measured by HPLC and 
pharmacokinetic parameters calculated using a non-compartmental method.  Data 
expressed ± S.E.M.  Clearance data represents clearance ÷ bioavailability.  Statistics 
analysed each parameter for each genotype relative to W/T model.  * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001. 
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The most significant changes relative to wild-type are identified in the 
mPXR/HuCAR model, with a significantly lower terminal half-life (t½) and drug 
exposure (AUC (01440) & AUC (0∞)), together with an extremely 
significant increase in clearance.  T½ is also significantly increased in the PXR 
KO/mCAR model.  Finally, Cmax is increased in the HuPXR/CAR KO model, 
although other parameters show no variation. 
The first feature evident when examining the curves from the 3 day population 
(Figure 4.3.10) is that there is no drug accumulation in the wild-type model 
relative to one day treatment, whereas drug exposure in the PXR/CAR DHu 
model appears to have decreased over the same time period.  The latter 
observation is corroborated by the pharmacokinetic parameters (Table 4.3.1 
b), with t½ and drug exposure (AUC (01440) & AUC (0∞)) being decreased 
in the PXR/CAR DHu model, whilst clearance increases indicating faster drug 
metabolism after 3 days.  The next feature is that metabolism in the 
mPXR/HuCAR model has slowed between 1 and 3 days, with t½ approximately 
quadrupling relative to one day treatment course (1070 ± 133 mins vs 284 ± 
98.2 mins).  It is approximately twice that recorded in the wild-type model by 3 
days (1070 ± 133 mins vs 479 ± 19.2 mins), indicating slower metabolism in 
this genotype.  Although non-significant, clearance is also marginally repressed 
and absolute drug exposure (AUC (0∞)) is increased relative to wild-type.  
This suggests that metabolism has been repressed with continuing treatment 
with letrozole, leading to drug accumulation and a curve more closely 
resembling the wild-type model at the 72 hour time-point.  Another significant 
change is the faster t½ and increased clearance seen in the HuPXR/mCAR model.  
This indicates faster drug metabolism and yields a curve more closely 
resembling that of the PXR/CAR DHu model.  However, these changes are 
abolished in the HuPXR/CAR KO model, with curve and parameters mirroring 
those of the wild-type model.  The differential role of human and mouse PXR is 
again highlighted by the non-significant drug accumulation seen in the 
mPXR/CAR KO model.  Humanizing CAR has no effect on metabolism, although 
it does result in faster metabolism when working in synergy with HuPXR, and 
appears to marginally repress metabolism when working in concert with mPXR.  
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All parameters are consistent with the wild-type model in the PXR/CAR DKO 
model. 
4.3.3.2 FEMALES 
In females, variations in metabolism are more marked than in males.  At one 
day (Figure 4.3.11), it is clear that metabolism is significantly faster and overall 
drug exposure significantly reduced in the PXR/CAR DHu model relative to 
wild-type.   This is reflected in the PK parameters (Table 4.3.2 a), with Cmax and 
drug exposure (AUC (01440) & AUC (0∞)) being significantly reduced and 
clearance significantly increased.  Metabolism is also changed in HuPXR single -
transgenic models, with clearance being increased in both, although this is only 
significant in the HuPXR/CAR KO model.  However, in both models absolute 
drug exposure (AUC (0∞)) is significantly reduced.  Significantly reduced 
drug exposure is also seen in the PXR KO/HuCAR and mPXR/HuCAR models, 
with an associated extremely significant increase in clearance in the PXR 
KO/HuCAR model, and a significant decrease in Cmax being observed in the 
mPXR/HuCAR model..  The curve from the mPXR/HuCAR model closely 
overlays the metabolic curve derived from the PXR/CAR DHu model until the 8 
hour time point, at which time metabolism appears to slow.  This is reflected in 
the t½, which is similar to that of the wild-type model.  Although humanizing 
PXR and CAR does appear associated with changes in metabolic profile, 
knocking-out the innate receptors does not exert a significant effect.  No 
significant changes are seen in the PXR KO/mCAR or mPXR/CAR KO models.  
However, there is a significant change in increase in clearance relative to wild-
type seen in the PXR/CAR DKO, associated with a non-significant reduction in 
drug exposure and t½, and with the curve resembling that of the PXR KO/mCAR 
and mPXR/CAR KO models. 
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Figure 4.3.11: Pharmacokinetic curves from a range of female PXR and CAR transgenic mouse models following 1 day 
treatment with 25 mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; female) were treated once p.o. with 25 mg/kg Letrozole.  Serial 
blood sampling was performed immediately following drug dose.  Drug was extracted using a solvent extraction method.  Letrozo le concentration was 
measured by HPLC.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates CAR genotype (solid 
red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.  KO = knockout genotype, Hu = humanized genotype. Error 
bars indicate S.E.M. 
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Figure 4.3.12: Pharmacokinetic curves from a range of female PXR and CAR transgenic mouse models following 3 day 
treatment with 25 mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; female) were treated p.o. daily for 3 days with 25 mg/kg Letrozole.  
Serial blood sampling was performed immediately following final drug dose.  Drug was extracted using a solvent extraction method.  Letrozole 
concentration was measured by HPLC.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates 
CAR genotype (solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.  KO = knockout genotype, Hu = 
humanized genotype. Error bars indicate S.E.M. 
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Table 4.3.2: Pharmacokinetic parameters from a range of female PXR and 
CAR transgenic mouse models following 1 day or 3 day treatment with 25 
mg/kg Letrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; 
female) were treated p.o. daily for 1 (a) or 3 (b) days with 25 mg/kg Letrozole.  Serial 
blood sampling was performed immediately following final drug dose.  Drug was 
extracted using a solvent extraction method.  Concentration was measured by HPLC and 
pharmacokinetic parameters calculated using a non-compartmental method.  Data 
expressed ± S.E.M.  Clearance data represents clearance ÷ bioavailability.  Statistics 
analysed each parameter for each genotype relative to W/T model.  * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001. 
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Variation in the wild-type model reduces the analytical power of the 1 day 
population, particularly when examining t½, in which the variation is so 
significant that there is insufficient statistical power to provide meaningful 
analysis.  However, although statistical significance cannot be calculated, trends 
can be seen.  Mean t½ is strongly reduced in the PXR KO/HuCAR (293 ± 19.8), 
HuPXR/CAR KO (397 ± 14.4), HuPXR/mCAR (257 ± 44.0) and PXR/CAR DHu 
(461 ± 76.0) models relative to wild-type (1030 ± 409).  It is also reduced in the 
mPXR/CAR KO and PXR/CAR DKO models, although to a lesser extent.  There is 
no change seen in the mPXR/HuCAR or the PXR KO/mCAR models.  It therefore 
appears that metabolism is faster in many models, particularly in those in which 
PXR is humanized. 
Differential metabolism between the native and humanized mo dels is further 
accentuated by 3 days (Figure 4.3.12).  There is clear drug accumulation, based 
on AUC data, in the wild-type model between the 1 and 3 day populations, with 
no change being seen in t½ or clearance.  However, accumulation is marginal in 
the PXR/CAR DHu model as a result of the faster metabolism observed in the 
one day population.  When examining the PK parameters (Table 4.3.2 b), 
significant changes are seen in all parameters in the PXR KO, HuPXR and 
PXR/CAR DHu models relative to wild-type, with the exception of t½ in which 
statistical power is insufficient to provide valid statistical conclusions.  This is 
corroborated when examining the curves, with those from both PXR KO models 
closely resembling the PXR/CAR DHu model, and those from the HuPXR models 
having maintained the profile derived from the 1 day population.  Significant 
reductions in Cmax and drug exposure are also observed in the PXR/CAR DKO 
model, indicating faster metabolism than in the wild-type, although only a 
marginal increase in clearance is recorded.  Significant reductions in Cmax and 
drug exposure are observed in the HuCAR models, with both mirroring the 
PXR/CAR DHu profile.  However, knocking-out CAR has little effect when 
coupled with the murine PXR receptor, although faster metabolism is observed 
when PXR is humanized or knocked-out.  No significant changes are seen in Cmax 
or clearance in the mPXR/CAR KO model, although there is a significant 
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reduction in drug exposure, indicating slower metabolism in the wild-type 
model is primarily driven by native PXR. 
4.3.4 ANASTROZOLE PHARMACOKINETICS DEMONSTRATE INTER-SPECIES 
VARIATION AND SEXUAL DIMORPHISM 
4.3.4.1 MALES 
From the curves, it is obvious that anastrozole metabolism is different in the 
PXR/CAR DHu model vs the wild-type following both treatment regimes 
(Figure 4.3.13 & 4.3.14).  At one day (Figure 4.3.13), t½ is significantly 
reduced to approximately 50% that of the wild-type, indicating faster 
metabolism (Table 4.3.3 a).  Although there are no other significant changes in 
PK parameters with this model, there is a trend towards higher systemic 
exposure in the PXR/CAR DHu model, with Cmax and drug exposure (AUC 
(01440) & AUC (0∞)) being increased, and clearance being decreased.  This 
suggests that drug uptake is more efficient in the PXR/CAR DHu model.  
Examining the single HuPXR models, the importance of crosstalk between PXR 
and CAR is highlighted, with increased metabolism being observed in the 
HuPXR/mCAR model, as indicated by the significant reduction in t½ and 
increase in clearance recorded in this model, together with reduced, although 
non-significant, drug exposure.  However, the reverse is observed in the 
HuPXR/CAR KO model, with no change in t½, a significant increase in Cmax, 
increases in drug exposure and reduction in clearance, although the latter two 
findings are non-significant.  Humanizing CAR does not have a significant effect 
on PK parameters, with marginal trends towards increased drug exposure and 
Cmax observed, together with slight reductions in clearance.  However, t½ is 
significantly reduced in the PXR KO/HuCAR model, but unchanged in the 
mPXR/HuCAR model.   
Knocking-out receptors does influence metabolism, with the curves derived 
from both PXR KO models, as well as the PXR/CAR DKO model, shifting towards  
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Figure 4.3.13: Pharmacokinetic curves from a range of male PXR and CAR transgenic mouse models following 1 day trea tment 
with 20 mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; male) were treated once p.o. with 20 mg/kg Anastrozole.  Serial 
blood sampling was performed immediately following drug dose.  Drug was extracted using a solvent extraction method.  Anastro zole concentration was 
measured by UPLC-MS/MS.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates CAR genotype 
(solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.  KO = knockout genotype, Hu = humanized genotype. 
Error bars indicate S.E.M. 
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Figure 4.3.14: Pharmacokinetic curves from a range of male PXR and CAR transgenic mouse models following 3 day treatment 
with 20 mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; male) were treated p.o. daily for 3 days with 20 mg/kg 
Anastrozole.  Serial blood sampling was performed immediately following final drug dose.  Drug was extracted using a solvent extraction method.  
Anastrozole concentration was measured by UPLC-MS/MS.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = 
HuPXR).  Line indicates CAR genotype (solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.  KO = 
knockout genotype, Hu = humanized genotype. Error bars indicate S.E.M. 
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Table 4.3.3: Pharmacokinetic parameters from a range of male PXR and 
CAR transgenic mouse models following 1 day or 3 day treatment with 20 
mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; 
male) were treated p.o. daily for 1 (a) or 3 (b) days with 20 mg/kg Anastrozo le.  Serial 
blood sampling was performed immediately following final drug dose.  Drug was 
extracted using a solvent extraction method.  Concentration was measured by HPLC and 
pharmacokinetic parameters calculated using a non-compartmental method.  Data 
expressed ± S.E.M.  Clearance data represents clearance ÷ bioavailability.  Statistics 
analysed each parameter for each genotype relative to W/T model.  * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001.  † = statistical power too low for statistical analysis. 
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the profile seen in the PXR/CAR DHu.  This shift in the PXR KO models is 
associated with a significant decrease in t½, particularly in the PXR KO/HuCAR 
model.  Cmax is increased in both, with an increase in drug exposure and 
reduction in clearance being observed in the PXR KO/HuCAR model only.  No 
change in drug exposure or clearance is observed in the PXR KO/mCAR model.  
None of the latter variations are significant.  In the PXR/CAR DKO model, no 
significant changes are seen as a result of intra-population variation, although 
there is an indication the Cmax, clearance and drug exposure have changed in a 
similar manner to the PXR KO models.  Removing CAR appears to have a greater 
effect on systemic exposure, with significant increases in Cmax being recorded in 
the mPXR/CAR KO model, together with near significant increases in drug 
exposure (p=0.06) and a non-significant reduction in clearance, although it’s 
influence on t½ is negligible.  A similar pattern is seen in the HuPXR/CAR KO 
model, although intra-population variation is too great to achieve significance. 
These differences are more marked in the 3 day population, with metabolic rate 
appearing to have increased in both wild-type and PXR/CAR DHu models 
(Figure 4.3.14).  Although Cmax is unchanged in the wild-type model in 
comparison to the one day population, there is a reduction in t½ and drug 
exposure, and increase in clearance, all suggesting that metabolic rate has 
increased.  In contrast, there is a marked increase in the drug entering the 
system in the PXR/CAR DHu model, with a significant increase in Cmax relative to 
wild-type (Table 4.3.3 b).  There are also non-significant increases in drug 
exposure, and a reduction in clearance in the PXR/CAR DHu model, although t½ 
remains unchanged relative to wild type.  The effect of humanizing PXR is 
dependent on CAR status.  In the HuPXR/CAR KO model, the curve resembles 
that of the wild type.  Although there are no significant changes in the PK 
parameters, there is a trend towards higher systemic exposure, with increased 
t½ and reduced clearance being recorded.  There is no change in C max and a 
marginal increase in drug exposure.  However, in the HuPXR/mCAR model 
there is reduced systemic exposure, with the curve located below that of the 
wild-type.  There is an extremely significant increase in clearance, and this leads 
to a non-significant reduction in Cmax and drug exposure.  Likewise, the effect of 
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humanizing CAR is dependent on PXR status, although the variation in effect is 
not as marked as in the HuPXR models.  Again, both curves more closely 
resemble the wild-type than the PXR/CAR DHu, with changes in PK parameters 
being non-significant.  Indeed, those recorded in the PXR KO/HuCAR model 
effectively overlay those from the wild-type.  However, the mPXR/HuCAR 
model displays a slower t½ indicative of slower metabolism. 
Variation is also pronounced in the knockout models, and particularly in the 
PXR/CAR DKO where significant increases in Cmax and drug exposure are 
observed, together with non-significant increase in t½ and reduction in 
clearance.  This is indicative of slower metabolism and drug accumulation, and 
reflected in the significantly altered curve.  The only single knockout model to 
reflect this finding is the mPXR/CAR KO model, in which significant increases in 
Cmax and drug exposure, together with a non-significant increase in t½ and 
reduction in clearance.  However, marginal increases in drug exposure and t½, 
and marginal reduction in clearance rate are observed in the HuPXR/CAR KO 
model.   Although both PXR KO curves overlay each other, a notable but non-
significant increase in t½ is recorded in the PXR KO/mCAR model.  However, 
this genotype displays significant inter-individual variation in both clearance 
and t½.  In contrast, the PK parameters for the PXR KO/HuCAR model are 
comparable to those of the wild-type model. 
4.3.4.2 FEMALES 
Sexual dimorphism is evident in the female response to anastrozole (Figure 
4.3.15 & 4.3.16).  The first key feature is that drug exposure, clearance and Cmax 
are significantly lower in the PXR/CAR DHu model relative to wild-type in the 1 
day population (Table 4.3.4 a).  This is in contrast to the males, in which 
significantly higher systemic exposure is seen in the PXR/CAR DHu model 
relative to wild-type.  As in the males, the lowest systemic exposure is seen in 
the HuPXR/mCAR model, with extremely significant reductions in Cmax and drug 
exposure, and increase in clearance.  There is also a non-significant reduction in 
t½.  Significant reduction in exposure is also seen in the HuPXR/CAR KO model, 
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Figure 4.3.15: Pharmacokinetic curves from a range of female PXR and CAR transgenic mouse models following 1 day 
treatment with 20 mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; female) were treated once p.o. with 20 mg/kg Anastrozole.  Serial 
blood sampling was performed immediately following drug dose.  Drug was extracted using a solvent extraction method.  Anastrozole concentration was 
measured by UPLC-MS/MS.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = HuPXR).  Line indicates CAR geno type 
(solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.  KO = knockout genotype, Hu = humanized genotype. 
Error bars indicate S.E.M. 
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Figure 4.3.16: Pharmacokinetic curves from a range of female PXR and CAR transgenic mouse models following 3 day 
treatment with 20 mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; female) were treated p.o. daily for 3 days w ith 20 mg/kg 
Anastrozole.  Serial blood sampling was performed immediately following final drug dose.  Drug was extracted using a solvent extraction method.  
Anastrozole concentration was measured by UPLC-MS/MS.  Marker indicates PXR genotype (solid red = mPXR, hollow red = PXR KO, solid purple = 
HuPXR).  Line indicates CAR genotype (solid red = mCAR, dashed red = CAR KO, solid purple = HuCAR).  Green line indicates PXR/CAR DKO.   KO = 
knockout genotype, Hu = humanized genotype. Error bars indicate S.E.M. 
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Table 4.3.4: Pharmacokinetic parameters from a range of female PXR and 
CAR transgenic mouse models following 1 day or 3 day treatment with 20 
mg/kg Anastrozole 
C57BL/6J mice (W/T) and a panel of PXR and CAR transgenic models (n=3 per group; 
female) were treated p.o. daily for 1 (a) or 3 (b) days with 20mg/kg Anastrozole.  Serial 
blood sampling was performed immediately following final drug dose.  Drug was 
extracted using a solvent extraction method.  Concentration was measured by HPLC and 
pharmacokinetic parameters calculated using a non-compartmental method.  Data 
expressed ± S.E.M.  Clearance data represents clearance ÷ bioavailability.  Statistics 
analysed each parameter for each genotype relative to W/T model.  * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001. 
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with Cmax and drug exposure decreasing, and clearance increasing more than is 
seen in the PXR/CAR DHu model.  There is a non-significant reduction in t½ in 
the HuPXR/CAR KO model relative to wild-type.  Similar pharmacokinetic 
effects are observed in the HuCAR models, with significant changes in all 
parameters except t½.  The greatest effect is seen in the PXR KO/HuCAR model, 
in which clearance approximately triples with respect to wild-type, resulting in 
significantly lower drug exposure.  However, clearance is more than doubled in 
the mPXR/HuCAR model, and drug exposure more than halved, suggesting that 
humanizing CAR has a significant effect on anastrozole metabolism in the 
females.  Cmax does not change between HuCAR models.   
Knocking-out both receptors has a significant effect on the metabolism of 
anastrozole, with Cmax and drug exposure decreasing and clearance increasing 
significantly relative to wild-type.  The effect on metabolism is very similar to 
that seen in the PXR/CAR DHu model, again indicating the differing roles of the 
murine and human receptors.  Knocking-out PXR alone has a more significant 
effect than knocking-out both PXR and CAR, with Cmax approximately halved 
relative to wild-type, and clearance and drug exposure significantly altered.  
The scale of these changes is dependent on CAR status.  In the PXR KO/mCAR 
model, drug exposure is significantly reduced and clearance strongly, although 
non-significantly, increased.  Once again, inter-individual variation is marked in 
the analysis of drug clearance in this model, accounting for the lack of 
significance.  However, in the PXR KO/HuCAR model, clearance is very 
significantly increased and drug exposure reduced. T½ is non-significantly 
reduced in both these models.  Knocking-out CAR has a much smaller, but 
significant, effect with both curves resembling those of the PXR/CAR DKO 
model.  However, when looking at the parameters, the importance of PXR status 
becomes apparent, again highlighting the significant cross-talk between these 
receptors.  Significant reductions in Cmax and drug exposure are a feature of the 
mPXR/CAR KO model, and commensurate with the variations observed in the 
curve.  However, a no variation in clearance is seen as a result of inter -
individual variability, together with an extremely significant increase in t½.  
However, if we examine the HuPXR/CAR KO model we see greater reductions in 
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Cmax and drug exposure, and these are associated with a clearance value more 
than double that of the wild-type and a non-significant reduction in t½.  The 
magnitude of inter-model variation is significantly reduced by 3 days (Figure 
4.3.16).  Of particular note is the alteration in wild-type pharmacokinetics, in 
which Cmax and drug exposure are reduced and clearance increased, suggesting 
an increase in metabolism, although t½ is not appreciably reduced (Table 4.3.4 
b).  Importantly, this moves the curve marginally below that of the PXR/CAR 
DHu, with no significant difference in parameters between these two models.  
Once again, the effect of humanizing PXR is dependent on CAR status.  In the 
HuPXR/CAR KO model, there are marginal, but non-significant, changes in 
parameters relative to wild-type, with small increases in Cmax and drug 
exposure, and small reductions in clearance and t½.  These changes yield a curve 
which is located slightly above that of the PXR/CAR DHu model.  However, the 
significantly lower systemic exposure observed in the HuPXR/mCAR model in 
the 1 day population is maintained in the 3 day population, with significantly 
higher clearance and lower Cmax being recorded, together with non-significant 
reductions in drug exposure and t½.  A similar situation is seen when CAR is 
humanized, with metabolism being strongly dependent on PXR status.  There is 
no difference in metabolism in the PXR KO/HuCAR model, with the curve 
mirroring that of the wild-type model.  However, systemic exposure is reduced 
in the mPXR/HuCAR model, with a significant increase in clearance being 
recorded, together with non-significant reductions in Cmax and drug exposure.   
Knocking-out both receptors influences the metabolism of anastrozole, with 
clearance being significantly increased and marginal reductions being recorded 
in Cmax and drug exposure, although t½ is not changed.  There is no significant 
change in metabolism in the PXR KO/HuCAR model.  However, although 
clearance is unchanged in the PXR KO/mCAR model, there are non-significant 
reductions in Cmax and drug exposure, together with a notable increase in t½.  In 
contrast to the PXR KO models, the effect of knocking-out CAR appears to be 
species-specific.  The profile derived from the mPXR/CAR KO model displays 
minimal differences to that of the wild-type, with no change in clearance, Cmax 
and drug exposure, although there is a non-significant increase in t½.  In 
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contrast, although there are no significant changes in the HuPXR/CAR KO 
model, there is a trend towards higher systemic exposure, with increases in Cmax 
and drug exposure, together with a reduction in clearance.  There is also a slight 
reduction in t½. 
4.3.5 THE AROMATASE INHIBITORS INDUCE CYP2B6 IN THE rCYP2B6-LACZ 
REPORTER MOUSE 
Expression of lacZ is induced in all models treated with aromatase inhibitors, 
although only two thirds of mice treated with letrozole demonstrate induction 
of the reporter gene, indicating inter-individual variation (Figure 4.3.17 & 
4.3.18).  In all subjects in which induction is seen, the reporter is expressed in 
zone 2 of the liver acinus, and localised in the cytoplasm and nucleus of the 
hepatocytes (Figure 4.3.19).  Anastrozole induces a significantly stronger 
response than letrozole, and the magnitude of response is sexually dimorphic in 
the mPXR/mCAR background model, with lacZ expression being stronger in the 
males than in the females.  However, magnitude of response is also significantly 
species-specific, with reporter expression in response to letrozole treatment 
being significantly lower in the human background than the mouse.  Sexual 
dimorphism and species-specificity with respect to anastrozole treatment could 
not be assessed in the hPXR/hCAR background as a result of low mouse 
numbers.  Few significant differences in biochemical markers can be seen, 
although there was significant intra-population variability in the majority of 
assays.  However, significant increases in blood creatinine concentrations were 
observed in both males and females following letrozole therapy, and in females 
only following anastrozole treatment, on the murine PXR/CAR background 
(Figure 4.3.20).  No changes in creatinine concentrations were observed on the 
human PXR/CAR background. 
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Figure 4.3.17: LacZ staining following 3 day drug treatment (10x magnification) 
CYP2B6-LacZ (mPXR/mCAR; male and female) and CYP2B6-LacZ (hPXR/hCAR; male only) reporter mice  (n=3 per group) were treated p.o. daily for 3 
days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and se ctioned before staining 
for nuclear fast red, followed by LacZ.  Photos were taken at 10x magnification and are representative of the treatment group.  Scales indicate 100mm.  
Numbers in brackets indicate number of group for which the photo is representative.  Percentages indicate the percentage of cells exhibiting LacZ 
staining according to densitometry 
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Figure 4.3.18: LacZ staining following 3 day drug treatment (40x magnification) 
CYP2B6-LacZ (mPXR/mCAR; male and female) and CYP2B6-LacZ (hPXR/hCAR; male only) reporter mice (n=3 per group) were treated p.o. daily for 3 
days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and sectioned be fore staining 
for nuclear fast red, followed by LacZ.  Photos were taken at 40x magnification and are representative of the treatment group.  Scales indicate 20mm.  
Numbers to lower right of photos indicate number of group for which the photo is representative. 
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Figure 4.3.19: LacZ staining following 3 day treatment of CYP2B6-LacZ (mPXR/mCAR) mice with 20 mg/kg Anastrozole (100x 
magnification) 
Male and female CYP2B6-LacZ (mPXR/mCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with  20 mg/kg Anastrozole.  Livers were 
harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Two photos were taken from each section at 
100x magnification and are representative of the treatment group.  Scales indicate 10mm. 
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Figure 4.3.20: Biochemical blood marker analysis following 3 day drug 
treatment 
CYP2B6-LacZ (mPXR/mCAR; male and female) and CYP2B6-LacZ (hPXR/hCAR; male 
only) reporter mice  (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline, 
25 mg/kg Letrozole or 20 mg/kg Anastrozole (mouse background only).  Serum was 
separated from heparinized whole blood by centrifugation and analysed for creatinine, 
ALT, glucose, total bilirubin and LDH concentrations at the Clinical Pathology Service, 
MRC Harwell. Graphs indicate average concentration ± S.D.  Statistics analysed 
concentration following drug treatment vs vehicle control.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = 
p ≤ 0.001. 
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4.4 DISCUSSION 
In this chapter, the aromatase inhibitors are shown to induce P450s in a PXR- 
and CAR-specific manner, demonstrating species-specific and sex-specific cross-
talk between these receptors, with PXR/CAR-mediated variations being 
observed in downstream pharmacokinetics.  All data is summarized in Tables 
4.3.1 & 4.3.2, with all relevant inductions/repressions indicated by arrows.  It 
must also be noted that Western blot data is expressed relative to vehicle 
control, whereas data derived from fluorigenic P450 activity assays and PK 
analysis is expressed relative to wild-type data.  
4.4.1 CYTOCHROME P450 EXPRESSION IS PXR/CAR DEPENDENT AND 
DEMONSTRATES SPECIES SPECIFICITY 
Prior to analysis of drug pharmacokinetics, it was important to examine 
changes in the P450 expression profile to provide a potential basis for 
pharmacokinetic variations.  The induction profile of several key P450s was 
therefore characterised using Western blot and fluorescent P450 assays.  Only 
those enzymes displaying enzyme induction will be discussed in this section, 
and therefore no reference will be made to Cyp2c or POR, neither of which 
displayed significant induction.   
4.4.1.1 Cyp1a 
No variations were observed in Cyp1a protein expression or activity following 
treatment with either drug in males (Figures 4.3.1, 4.3.3, 4.3.5 & 4.3.6).  
However, although there is no Cyp1a protein induction in females, Cyp1a 
activity is induced in various genotypes: 1) mPXR/HuCAR, HuPXR/CAR KO and 
PXR/CAR DHu following letrozole treatment, and 2) PXR KO/HuCAR, 
mPXR/HuCAR, HuPXR/CAR KO and PXR/CAR DHu following anastrozole 
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Sex 
Genotype Gene Activity probe PK parameter 
PXR CAR 
Cyp
1a 
Cyp
2a 
Cyp
2b 
Cyp
2c 
Cyp
3a 
POR 
BFC 
3A4 
BQ 
3A4 
EFC 
2B/
2C 
MFC 
2B/
2C 
MR 
1A2 
ER 
1A1
/2 
BR 
2B6 
T½ Cmax CL 
AUC 
1 
AUC 
2 
M
a
le
 
M M   0  ↑ 1.5              
KO M   0        ↓        
KO Hu   0      ↓⋆  ↓⋆ ↓⋆⋆⋆    ↓⋆   
M Hu   0  ↑ 2.4  ↑⋆⋆⋆ ↑⋆⋆⋆ ↑⋆⋆⋆  ↓ ↓⋆⋆  ↑⋆⋆⋆  ↓  ↑ 
M KO   0  ↑ 1.8  ↑⋆⋆⋆ ↑⋆⋆⋆     ↑    ↑ ↑ 
Hu KO   0  ↑ 1.7 ↑ 1.4      ↓⋆       
Hu M   0   ↑ 1.3     ↓ ↓⋆⋆⋆  ↓⋆  ↑⋆   
KO KO   0  ↓ 0.6  ↓ ↓ ↓⋆⋆ ↓ ↓⋆ ↓⋆⋆⋆ ↓   ↓⋆   
Hu Hu   0 ↑ 1.5  ↑ 1.6     ↓ ↓⋆⋆  ↓  ↓⋆ ↓ ↓ 
F
e
m
a
le
 
M M                   
KO M   ↑ 1.6        ↑ ↑ ↑ ↓ ↓⋆⋆⋆ ↑⋆⋆⋆ ↓⋆⋆⋆ ↓⋆⋆⋆ 
KO Hu              ↓ ↓⋆⋆⋆ ↓⋆ ↓⋆⋆⋆ ↓⋆⋆⋆ 
M Hu   ↑ 2.3 ↑ 1.6 ↑ 1.6 ↑ 1.5 ↑ ↑⋆⋆ ↑⋆⋆⋆ ↑⋆⋆⋆ ↑⋆ ↑⋆ ↑⋆⋆⋆  ↓⋆⋆⋆ ↑ ↓⋆⋆⋆ ↓⋆ 
M KO   0          ↑⋆ ↓ ↓  ↓⋆⋆ ↓⋆ 
Hu KO   0  ↑ 1.7 ↑ 1.5     ↑⋆⋆⋆ ↑⋆⋆⋆ ↑⋆ ↓ ↓⋆⋆ ↑⋆ ↓⋆⋆⋆ ↓⋆⋆⋆ 
Hu M              ↓ ↓⋆⋆ ↑⋆⋆ ↓⋆⋆⋆ ↓⋆⋆⋆ 
KO KO   0           ↓ ↓⋆⋆ ↓ ↓⋆⋆ ↓⋆ 
Hu Hu ↑ 1.5  ↑ 1.9  ↑ 1.9 ↑ 2.0 ↑ ↑ ↑ ↑⋆ ↑⋆ ↑⋆⋆⋆ ↑⋆⋆⋆ ↓ ↓⋆⋆⋆ ↑⋆⋆⋆ ↓⋆⋆⋆ ↓⋆⋆⋆ 
Table 4.4.1: Summary of all data following 3 day letrozole treatment 
Western blot data expressed relative to vehicle control, activity and PK data expressed relative to wild-type.  ↑ = induced, ↓ = repressed.  AUC 1 = 
AUC(01440), AUC 2 = AUC(0∞).  Statistics represent the comparison of transgenic data vs wild-type.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  Red 
= >2-fold induction, Green = >2-fold repression, 0 = no expression. Superscript numbers indicate densitometry data relative to vehicle control (fold 
induction).  Cyp2b and Cyp3a densitometry data refers to Cyp2b10 and Cyp3a11 isoforms only.   Main isoform detected by P450 assay given in title. 
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Genotype Gene Activity probe PK parameter 
PXR CAR 
Cyp
1a 
Cyp2
a 
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2b 
Cyp
2c 
Cyp
3a 
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3A4 
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3A4 
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2B/
2C 
MR 
1A2 
ER 
1A1
/2 
BR 
2B6 
T½ Cmax CL 
AUC 
1 
AUC 2 
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a
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M M   ↑ 1.7                
KO M   ↑ 2.5    ↑ ↑ ↓ ↓    ↑  ↓⋆⋆   
KO Hu   ↑ 1.6       ↓         
M Hu   ↑ 1.8  ↑ 3.3  ↑⋆⋆⋆ ↑⋆⋆⋆      ↑     
M KO  ↑ 1.6 0 ↑ 1.7 ↑ 2.0  ↑⋆⋆⋆ ↑⋆⋆⋆      ↑ ↑⋆ ↓⋆⋆ ↑⋆ ↑⋆ 
Hu KO   0  ↑2.7  ↑ ↑ ↓ ↓   ↓ ↑  ↓ ↑ ↑ 
Hu M   ↑ 8.6    ↑ ↑ ↑ ↑⋆   ↑  ↓ ↓⋆⋆⋆ ↓ ↓ 
KO KO  ↓ 0.6 0    ↓  ↓ ↓   ↓ ↑ ↑⋆ ↓ ↑⋆⋆ ↑⋆⋆ 
Hu Hu  ↓ 0.7 ↑ 2.0      ↓ ↓   ↓  ↑⋆⋆⋆ ↓ ↑ ↑ 
F
e
m
a
le
 
M M   ↑ 4.6                
KO M   ↑ 6.1      ↓ ↓   ↓ ↑ ↓ ↓⋆⋆⋆ ↓ ↓ 
KO Hu   ↑ 1.6  ↑ 1.9  ↑  ↓ ↓⋆ ↑⋆⋆⋆ ↑ ↓      
M Hu  ↑ 1.6 ↑ 2.9  ↑ 1.8  ↑⋆ ↑ ↑  ↑  ↓  ↓ ↑⋆ ↓ ↓ 
M KO   0  ↑ 1.6  ↑     ↓ ↓ ↑  ↓⋆⋆⋆   
Hu KO   0      ↓⋆ ↓⋆⋆ ↑⋆⋆⋆  ↓ ↓ ↑ ↓ ↑ ↑ 
Hu M   ↑ 5.1           ↓ ↓⋆ ↑⋆⋆⋆ ↓ ↓ 
KO KO   0    ↓  ↓⋆⋆ ↓⋆⋆  ↓ ↓  ↓ ↑⋆ ↓ ↓ 
Hu Hu  ↑ 1.6 ↑3.7 ↑ 1.9 ↑ 1.6 ↑ 1.7   ↓ ↓ ↑  ↓      
Table 4.4.2: Summary of all data following 3 day anastrozole treatment 
Western blot data expressed relative to vehicle control, activity and PK data expressed relative to wild-type.  ↑ = induced, ↓ = repressed.  AUC 1 = 
AUC(01440), AUC 2 = AUC(0∞).  Statistics represent the comparison of transgenic data vs wild-type.  * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  Red = 
>2-fold induction, Green = >2-fold repression, 0 = no expression. Superscript numbers indicate densitometry data relative to vehicle control (fold 
induction).  Cyp2b and Cyp3a densitometry data refers to Cyp2b10 and Cyp3a11 isoforms only.   Main isoform detected by P450 assay given in title. 
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treatment (Figure 4.3.8).  Notably, induction in Cyp1a activity is not observed 
in any model possessing mCAR, indicating a species-specific effect.  It is highly 
likely that the isoform responsible for this increase in activity is the Cyp1a2 
isoform, being the only member of the Cyp1 family of enzymes expressed in the 
liver in wild-type mice (Hrycay and Bandiera, 2009), and concurring with the 
observed increase in MR assay, which is more specific for the Cyp1a2 isoform 
(Figure 4.3.8).   
Although there are no specific genotype influences that can be identified 
following letrozole treatment, there is a stronger association between hCAR and 
increased Cyp1a activity following anastrozole treatment (Figure 4.3.8).  
Although the Cyp1a genes are prototypically induced by the aryl hydrocarbon 
receptor (Nukaya et al., 2009), a recent study has described a novel 
transcriptional circuit associating CYP1A1 and CYP1A2 induction with CAR 
activation, in which CAR can both activate CYP1A expression and enhance aryl 
hydrocarbon receptor-induced activation (Yoshinari et al., 2010).  It is also 
gender specific, with the increased activity appearing in females only, in 
contrast to previously published data that suggests CYP1A2 activity is higher in 
males (Schwartz, 2007; Waxman and Holloway, 2009).  However, this 
observation does give further corroboration to the involvement of CAR in the 
induction of CYP1A, with literature suggesting that CAR is more active and more 
highly expressed in females than males (Forman et al., 1998; Lamba et al., 2003; 
Petrick and Klaassen, 2007; Hernandez et al., 2009b).   
4.4.1.2 Cyp2a 
No variations were seen in Cyp2a protein expression following letrozole 
treatment in either sex, although the female bias in constitutive expression 
previously reported was observed (Hernandez et al., 2006; Hrycay and 
Bandiera, 2009).  This could have significant repercussions in terms of drug 
pharmacokinetics, because it suggests that letrozole metabolism could be 
slower in males than females as a result of the lower constitutive expression of 
the Cyp2a enzymes.  However, because no activity data is available for this 
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enzyme group, it is impossible to assess what the downstream effects on 
pharmacokinetics will be. 
There was also no significant variation in Cyp2a in males following anastrozole 
treatment.  However, in females marginal induction of Cyp2a enzymes is 
observed in those genotypes possessing the hCAR moiety.  This concurs with 
the role of CAR as a key regulator of Cyp2a4 and Cyp2a5, two of the most 
important members of the Cyp2a family in mice, as well as the two members 
demonstrating sex-specific regulation (Wei et al., 2002; Honkakoski et al., 2003; 
Hernandez et al., 2006; Hrycay and Bandiera, 2009).  This effect is species-
specific, with no response observed in mice possessing native CAR.  It is also 
gender-specific, again as a probable result of the higher expression and activity 
of CAR in mice.  These data add further evidence to the role of anastrozole as an 
activator of hCAR.  
4.4.1.3 Cyp2b 
Cyp2b10 expression and activity is induced in response to treatment with 
letrozole and anastrozole in a PXR/CAR- and gender-dependent manner 
(Figure 4.3.1-4.3.8).  Expression is seen only in those models possessing a 
functional variant of CAR, thus demonstrating its key role in the regulation of 
Cyp2b10.  The regulation of Cyp2b10 by CAR is also gender-specific in nature, 
showing higher CAR-related basal expression and induction in females than 
males, concurring with previous reports (Hrycay and Bandiera, 2009).  This can 
be attributed to the higher expression and activity of both Cyp2b10 and CAR in 
females (Jarukamjorn et al., 2002; Lamba et al., 2003; Petrick and Klaassen, 
2007; Hernandez et al., 2009b).  Cyp2b10 is induced to a significantly greater 
extent following anastrozole treatment than letrozole.  Although basal and 
induced expression is seen in all CAR models in females following letrozole 
treatment, not only is there no induction of Cyp2b10, there is no expression in 
any model in the male cohort.  However, Cyp2b10 is induced in all models 
carrying a functional CAR moiety following anastrozole treatment, regardless of 
gender, although the latter still displays stronger basal expression and 
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significantly stronger induction than the males.  Protein expression and activity 
data concur in most groups.   However, the extent of induction does not mirror 
that predicted from protein expression data in females treated with 
anastrozole. 
The specificity of these drugs in inducing Cyp2b10 suggests that both are likely 
to interact with CAR, the main regulator of Cyp2b10, with anastrozole being the 
stronger inducer.  This hypothesis is given further credence by the lack of 
Cyp2b10 protein and enzyme activity induction in all models in which CAR is 
knocked-out, as well as the identification of modest CAR differential variations 
in Cyp1a and Cyp2a proteins following anastrozole treatment.  It is impossible 
to assess whether these drugs bind directly to CAR or act indirectly from this 
data.  However, given that the majority of identified CAR modulators act 
indirectly, and that the magnitude of response is significantly smaller than 
observed following treatment with known prototypical CAR ligands (Scheer et 
al., 2008; Ross et al., 2010), it is probable that the aromatase inhibitors are 
indirect modulators of CAR activity.  Also, because the aromatase inhibitors 
modulate sex-hormone levels, it is likely that any change in CAR activation is 
likely to be enhanced, if not caused, by the pharmacological action of these 
drugs.  It is well documented that 17-oestradiol and oestrone both activate 
mCAR by enhancing the interaction of mCAR with co-activators, such as SRC-1, 
and co-repressors, such as NCoR, following xenobiotic treatment (Kawamoto et 
al., 2000; Mäkinen et al., 2003; Min, 2010; Dau et al., 2012).  The ability of 
oestradiol to activate hCAR and synergistically induce CYP2B6 with the 
activated oestrogen receptor at high concentrations has also been recently 
reported (Koh et al., 2012).  Various androgens have also been shown to repress 
CAR activity (Forman et al., 1998; Gillberg et al., 2006; Hernandez et al., 2009b; 
Monostory and Dvorak, 2011).  However, the lack of data regarding circulating 
oestrogen concentrations in this study, together with the lack of mechanistic 
studies regarding CAR activation by aromatase inhibitors, prevents any 
conclusions being drawn regarding the regulation of CAR activity. 
There also appears to be significant species-specificity in the magnitude of 
response related to PXR/CAR crosstalk which is particularly evident when 
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examining the anastrozole treated cohorts as a result of the higher induction 
levels observed.  Firstly, the presence of hCAR induces Cyp2b10 to a similar 
extent to that seen in the wild-type model, regardless of PXR genotype.  This 
indicates that hCAR activation alone is sufficient to achieve induction of this 
protein.  However, induction as a result of mCAR activation is strongly affected 
by PXR genotype, being higher than wild-type when mCAR is combined with 
hPXR.  There is also an induction in Cyp2b10 relative to wild-type when mCAR 
is present on the PXR KO background, although this is gender-specific, being 
significant in females but marginal in males.  These data are also  reflected in the 
Cyp2b10 activity assays.  This suggests two possibilities in terms of crosstalk 
between these receptor variants.  Firstly, mPXR constrains the ability of mCAR 
to induce Cyp2b10 expression, as illustrated by the increased protein 
expression recorded following anastrozole treatment in the PXR KO/mCAR 
model, with gender specificity likely to be as a result of the higher activity of 
CAR in females.  Secondly, mCAR synergizes with hPXR to achieve maximal 
induction following anastrozole treatment.   
4.4.1.4 Cyp3a 
Cyp3a11 is also induced in response to AI treatment, and is subject to species -
dependent regulatory crosstalk between PXR and CAR.  Being dependent on 
other nuclear receptors, such as hepatocyte nuclear factor 4, for its 
constitutive expression, Cyp3a11 is visible in all models.  Also in agreement 
with human expression data, this gene is more highly expressed in females than 
males (Hunt et al., 1992; Down et al., 2007; Greenblatt and Von Moltke, 2008; 
Hu and Zhao, 2010).   
Sexual dimorphism is a key feature of the control of Cyp3a11 by PXR/CAR in 
response to AI treatment.  In males, both AIs induce Cyp3a11 expression in the 
HuPXR/CAR KO and two mPXR models, with the highest induction recorded in 
the mPXR/HuCAR model (Figures 4.3.1 & 4.3.3).  There is also a marginal 
repression in response to both treatments in the PXR/CAR DKO model.  These 
findings concur with data from the Cyp3a activity assays (BFC and BQ), in which 
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the highest activity is detected in the mPXR models (Figure 4.3.5).  This 
suggests that the impact of AI treatment on the expression of Cyp3a11 in males 
is regulated by a common, species-dependent PXR/CAR-related mechanism.  
The data indicates that the primary regulator of AI induced Cyp3a11 expression 
in males is PXR, as demonstrated by the induction observed in both CAR KO 
models, the lack of induction in PXR KO models and the repression observed in 
the PXR/CAR DKO model, a finding in keeping with the prototypical role of PXR 
in Cyp3a11 induction (Quattrochi and Guzelian, 2001; Stanley et al., 2006; di 
Masi et al., 2009).  These data also suggest that activation of mPXR in response 
to treatment is sufficient to elicit a Cyp3a11 response, regardless of CAR status, 
although mPXR and hCAR do appear to synergize to achieve maximal induction.  
This is in contrast to hPXR-mediated regulation, in which upregulation in 
response to activation is strongly related to CAR status, occurring only in the 
CAR KO model, indicating that both mCAR and hCAR interact with hPXR to 
repress Cyp3a11 induction.   
In females, the induction of Cyp3a11 in response to AI therapy is significantly 
smaller than that observed in males, although basal expression is greater 
(Figures 4.3.2 & 4.3.4).  The only common observation between the two drug 
treatments is a marginal induction in the PXR/CAR DHu model, which is greater 
in the letrozole treated cohort, although still less than 2-fold in both groups.  
There is also a slight induction in the mPXR/HuCAR model that translates to an 
approximately 2-fold induction in enzyme activity in the BFC and BQ assays.  No 
other significant changes in Cyp3a11 expression can be seen following letrozole 
treatment.  Stronger induction, reflected in the activity assays, is observed in  
the female anastrozole cohort (Figures 4.3.4 & 4.3.7).  As recorded in the 
males, induction is observed in both mPXR models, with the mPXR/HuCAR 
model demonstrating the stronger effect.  However, the strongest induction in 
Cyp3a11 protein expression, although not the highest activity, was recorded in 
the PXR KO/HuCAR model.  These observations suggest that although mPXR is 
associated with Cyp3a11 regulation, and particularly with maximal enzyme 
activity, there is also a strong hCAR element involved in anastrozole-mediated 
induction.  Although surprising given the data obtained from the male cohort, 
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these observations are not without precedent, since Cyp3a11 has also been 
identified as a CAR target gene, upregulated in response to CAR ligands, such as 
nonylphenol and TCPOBOP (Wei et al., 2002; Wagner et al., 2005; Down et al., 
2007; Hernandez et al., 2009b).  This hypothesis also corroborates observations 
gathered from the Cyp1a, Cyp2a and Cyp2b10 genes, all of which suggest that 
anastrozole is an hCAR activator.  mCAR appears to have a repressive effect on 
Cyp3a11 induction, with no variation being observed in any model possessing 
this moiety.  Also, except in the presence of hCAR, hPXR has no effect on 
Cyp3a11 expression, indicating that anastrozole activates mPXR only. 
The repression identified in the PXR/CAR DKO model in both male treatment 
groups is also observed in the female letrozole group.  Unfortunately, as a result 
of poor band separation in the female anastrozole cohort, it is impossible to 
identify any repression in Cyp3a11 for this treatment group.  However, from the 
data available, it appears that this effect is sex-independent.  It is likely that the 
repression in Cyp3a11 expression recorded in the PXR/CAR DKO model in 
response to both drugs is as a result of drug action on one of the constitutive 
regulators of basal protein expression, such as HNF-4(Kamiya et al., 2003; 
Wiwi et al., 2004; Inoue et al., 2011).  However, the dissection of this effect is 
outwith the scope of this study. 
Once again, the ability of these drugs to directly bind to PXR cannot be 
ascertained from these data, although it is more likely given the highly 
promiscuous nature of the PXR ligand binding domain.  However, it is also 
probable that there will be some indirect modulation of PXR activity as a result 
of the pharmacological action of these drugs.  hPXR has previously been shown 
to be activated by oestrone and oestradiol, suggesting that overall PXR activity , 
and thus Cyp3a11 expression, is likely to be reduced in those mice treated with 
AIs (Mnif et al., 2007; di Masi et al., 2009).  A recent study has also described an 
inhibitory crosstalk mechanism between PXR and the androgen receptor, in 
which both receptors inhibit the activity of the other, a mechanism of 
importance when considering the male population (Kumar et al., 2010).  This 
aspect of PXR control is of importance when considering response to endocrine 
modulators, and therefore requires further analysis.  Unfortunately, the data 
161 
 
 
generated in this study is insufficient to test this hypothesis, and therefore this 
would be a task for future investigation.  However, assuming that PXR activity is 
repressed in response to the hormonal changes that characterize the clinical 
response to AI therapy, these data indicate that AIs activate PXR, either directly 
or indirectly.   
4.4.2 LETROZOLE PHARMACOKINETICS ARE PXR/CAR DEPENDENT, BUT NOT 
INFLUENCED BY CYTOCHROME P450 EXPRESSION 
Although PXR/CAR status does impact on drug clearance, the small clearance 
values returned by this study relative to the rate of hepatic blood flow in mice 
(90 ml/min/kg; Davies et al., 1993) suggest that the predominant route of 
letrozole excretion could be renal.  Maximal renal clearance is defined by the 
glomerular filtration rate in mice, which is given as 14 ml/min/kg (Davies and 
Morris, 1993).   It is evident from the study data that clearance is significantly 
lower than this in our models, and that it varies according to PXR/CAR 
genotype, although further studies are required to confirm the role of renal 
elimination in murine letrozole disposition.  If renal elimination is proved, it is 
highly unlikely that variations in P450 expression and activity in the liver will 
have a significant effect on letrozole clearance in these models, with the most 
likely mediators of this effect being the drug transporters.  Both PXR and CAR 
have been associated with the regulation of various membrane bound drug 
transporter proteins expressed in the kidney, liver and enterocytes including 
Mdr1, Mrp1-6 and various OATP transporters (Klaassen and Aleksunes, 2010).  
This discussion will therefore focus on potential perturbations in these 
proteins, although reference will be made to P450 expression if deemed 
relevant.   
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4.4.2.1 LETROZOLE PHARMACOKINETICS ARE SPECIES-SPECIFIC WITH RESPECT TO 
PXR AND CAR 
To assess the impact of PXR and CAR on letrozole pharmacokinetics, the 72 
hour data were analysed (Figure 4.3.10 & 4.3.12, Tables 4.3.1b & 4.3.2b) .  An 
important feature common to both sexes is that letrozole pharmacokinetics are 
altered in the PXR/CAR DHu model relative to wild-type, with drug being 
cleared significantly faster in this model, and especially in females.  This sexual 
dimorphism is driven entirely by the sex-dependent pharmacokinetics 
demonstrated by the wild-type model, in which females demonstrate slower 
elimination than males.  There is no variation in letrozole pharmacokinetics in 
the PXR/CAR DHu model between males and females.  This therefore indicates 
that the human receptors have a greater activity in response to letrozole 
treatment than the murine, and also that murine receptor activity is subject to 
sexually dimorphic control. 
Isolating murine and human CAR indicates that there is no species-specific 
variation in activity between these two moieties, with both producing profiles 
most closely resembling those of the PXR/CAR DHu model.  This indicates that 
CAR activation by letrozole in the absence of PXR is sufficient to elicit faster 
drug clearance.  In contrast, PXR exerts a predominantly repressive effect on 
letrozole clearance when working in isolation.  mPXR exerts a significant 
repressive influence on mCAR activity in the wild-type model, a hypothesis 
given further credence by the observation that pharmacokinetics in the 
mPXR/CAR KO and mPXR/HuCAR models most closely resemble those of the 
wild-type.  It is therefore suggestive that mPXR is the driving factor underlying 
pharmacokinetics in these models.  In contrast, although the profile of the 
HuPXR/CAR KO model is most closely related to that of the wild-type, it is clear 
that synergism with CAR, regardless of species, results in high letrozole 
clearance, with synergy between the human receptors inducing the greatest 
increase.   
Earlier protein analysis indicated that PXR and CAR interact in a species-specific 
manner to control P450 induction and activity in response to letrozole.  
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However, when examining the pharmacokinetic data, there is little conformity 
with P450 expression trends.  A good example of this disparity is that of the 
mPXR/HuCAR model, in which Cyp3a11 was most strongly induced in response 
to letrozole treatment, combined with a marginal induction in the expression of 
Cyp2a in females only, and therefore faster metabolism may have been 
expected.  However, pharmacokinetic analysis demonstrates reduced 
elimination in both sexes relative to wild-type.  This is strongly suggestive of an 
alternative elimination route, such as renal clearance, and thus implicates other 
elements of the drug metabolism pathway, such as drug transporters.  One 
possible exception to the disparity between P450 induction and 
pharmacokinetics is the observation that mPXR constrains mCAR-mediated 
Cyp2b10 induction, a finding concurrent with the pharmacokinetic data.  To 
date, no analysis has identified a role for CYP2B6 in letrozole metabolism.  
However, no systematic analysis of letrozole metabolism in mice is available in 
the literature, and therefore it is possible that this enzyme mediates letrozole 
metabolism in this species, thus providing a rationale for the pharmacokinetics 
observed in the wild-type. 
Further evidence for an alternative elimination route is provided by the 
PXR/CAR DKO model, in which elimination occurs at a rate between that of the 
wild-type and PXR/CAR DHu models.  This indicates that neither PXR nor CAR 
are obligate for letrozole elimination in mouse, although data from the other 
models demonstrates that PXR/CAR-mediated modulation does occur.  
Interestingly, gender-differential elimination is also seen in this model, being 
faster in males than females.  Once again, these observations do not equate to 
data from the Western blots, in which repression of Cyp3a11 and Cyp2a are 
stronger in the males, which would suggest that metabolism is likely to be 
slower in this cohort if P450 related.  This further corroborates the theory that 
P450 metabolism plays a minor role in letrozole disposition in mice.   
These data clearly demonstrate that letrozole pharmacokinetics are modulated 
by PXR/CAR, although neither are obligate.  CAR activation is required to 
achieve maximum clearance in mice, regardless of species.  However, the 
magnitude of elimination is strongly associated with species-specific PXR 
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interaction, with mPXR repressing CAR activity whilst hPXR 
maintains/promotes activity observed in the PXR KO models, both regardless of 
species of CAR.  It is therefore evident that letrozole interactions with PXR are 
strongly species-dependent.  Gender-differential pharmacokinetics are also 
observed in both the wild-type and PXR/CAR DKO models.  Significant gender-
related influences on the metabolism and pharmacokinetics of letrozole in rats 
have been previously described (Liu et al., 2000; Tao et al., 2007; Wempe et al., 
2007), demonstrating the importance of considering gender in pre-clinical drug 
assessment.   
Further study is required to establish the mechanisms underlying both species- 
and gender-differential variations in pharmacokinetics.  It is also of importance 
to identify the regulator involved in the control of letrozole clearance in the 
PXR/CAR DKO model, as well as to perform a full analysis of letrozole 
metabolism in mice to establish the role of Cyp2b10 in letrozole disposition.  
Unfortunately, comparison between this data and that previously gener ated is 
not possible because no pre-clinical data regarding letrozole pharmacokinetics 
in mice is available in the literature, with data regarding metabolism in other 
species, such as rats, being minimal.  This study is therefore the first to describe 
gender- and species-specific clearance of this drug in mice.     
4.4.2.2 PHARMACOKINETIC VARIATIONS ARE PROBABLY A RESULT OF DRUG 
TRANSPORTER MODULATION 
The previous section was primarily concerned with the clearance parameter, 
possibly the most important to pharmacokinetics because it is a measure of the 
ability of the body to permanently eliminate a drug (Toutain and Bousquet-
Mélou, 2004b).  However, as a result of the oral dosing mechanism employed, 
clearance data generated by non-compartmental modelling actually represents 
clearance ÷ bioavailability, and therefore can be influenced by any factor that 
impacts bioavailability, in addition to those that affect clearance itself.  This 
therefore suggests three potential explanations for the variations observed in 
these data, all of which are related to the expression of drug efflux transporters: 
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1) Letrozole bioavailability varies with PXR/CAR genotype; 2) Tissue 
distribution varies with PXR/CAR genotype; and 3) Differential renal clearance 
is regulated by PXR/CAR. 
Bioavailability is defined as the extent and rate at which a drug or active moiety 
is extracted from its pharmaceutical formulation and becomes available to the 
general circulation (Toutain and Bousquet-Mélou, 2004a).  As such, it can be 
influenced by the physicochemical properties of the drug itself, such as pKa and 
lipophilicity, by physiological factors, such as intestinal transit time and 
absorption mechanism, and also by the effects of first pass metabolism (Song et 
al., 2004).  It is most likely that any PXR/CAR related variation in bioavailability 
will be as a result of alterations in first-pass metabolism or the absorption of 
drug by transporter proteins.  Previous studies have indicated that first pass 
metabolism in the intestine and liver are of limited importance in the 
distribution of letrozole, as indicated by the high bioavailability described for 
this drug in humans (Sioufi et al., 1997a).  Study data concurs with the limited 
role of hepatic metabolism in the disposition of this drug.  However, in order to 
exclude intestinal metabolism of letrozole as a potential source of variation in 
bioavailability, expression and activity analysis must be performed using small 
intestinal microsomes, such as was performed on the liver samples.   
The most important potential source of variation in bioavailability lies in the 
expression of the drug transporters by the enterocytes, which can influence 
both drug entry into the circulation and increase the opportunity for intestinal 
first-pass metabolism by increasing drug efflux into the intestinal lumen 
(Nicolas et al., 2009; Klaassen and Aleksunes, 2010).  This has already been 
demonstrated to be of importance to letrozole disposition in a study in rats, 
and, with oral bioavailability being significantly lower in males than females (≈ 
38% vs ≈ 95%), and terminal half-life significantly slower in females, as a result 
of variations in letrozole absorption.  Of concern is the potential role of the 
drug-efflux transporters located at the apical surface of the enterocytes in 
reducing letrozole uptake into the circulation, which include Mrp2, Bcrp and P-
glycoprotein, all of which are targets of PXR/CAR (Klaassen and Aleksunes, 
2010).  Of particular importance to this study is the identification of P-
166 
 
 
glycoprotein as a primary downstream target of PXR activation, although recent 
evidence also implicates CAR activation in its regulation (Burk et al., 2005; Teng 
and Piquette-Miller, 2008; Bebawy and Chetty, 2009; Harmsen et al., 2010; 
Klaassen and Aleksunes, 2010; Wang et al., 2010; Chan et al., 2011; Chen et al., 
2012).  Any interaction between letrozole, this transporter and PXR/CAR could 
therefore result in significantly altered bioavailability. 
Another hypothesis is that the level of drug distribution in the body is variable, 
resulting in changes to the quantity of drug available to the circulation for 
elimination.  An indication of altered tissue distribution can be obtained from 
the analysis of apparent volume of distribution (Vd), a parameter that can be 
derived from t½, although it cannot be used diagnostically for this purpose 
without further direct information regarding intra-tissue drug concentrations 
(Toutain and Bousquet-Mélou, 2004c).  Variations in this parameter can 
indicate changes in tissue distribution and bioavailability, both of which rely on 
the expression and activity of drug transporters in various tissues.  P-
glycoprotein is expressed in numerous different tissues, including lungs, 
intestine and brain in mouse, and more extensively in human tissues (Klaassen 
and Aleksunes, 2010; Chen et al., 2012).  It has a vital role in tissue distribution, 
protecting tissues from chemical injury by ejecting drug from the tissue into the 
circulation, and consequently changing Vd.  The mPXR/HuCAR model is 
particularly interesting from this perspective, demonstrating a high t½ 
associated with a marginally altered clearance relative to wild-type.  It is also 
likely that volume of distribution is larger in the females then the males, an 
expected finding given the higher fat content of the female contingent, together 
with the lipophilicity of letrozole. 
Given the main route of excretion, as suggested by clearance, the simplest 
explanation for the variations observed is that drug transporters in the 
proximal renal tubules are differentially modulated in response to letrozole.  
Various transporters have been identified in the kidneys, including P-
glycoprotein, Mrp2, Mrp4 and BCRP on the apical membrane, all of which have 
been implicated in excreting drug into the proximal tubules, and all of which are 
regulated by PXR and CAR in the liver (Klaassen and Aleksunes, 2010; Chen et 
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al., 2012).  Data regarding the regulation of these proteins in the kidney is very 
limited, although a recent study has identified PXR as a potential regulator of 
renal efflux transporters in type I diabetes and pregnancy mouse models 
(Yacovino and Aleksunes, 2012).  Further analysis is required to characterise 
the control of renal efflux transporters, in addition to a full assessment of the 
role of renal clearance in letrozole elimination in mice, before any conclusions 
regarding the role of PXR and CAR can be assessed.   
It is highly likely that the actual explanation will encompass aspects of all three 
hypotheses, given that all theories centre on the PXR/CAR-mediated differential 
regulation of transporters.  However, the data set gathered by this study is 
insufficient to provide any firm evidence to support these hypotheses.  
Numerous experiments are therefore required to establish the role of drug 
transporters in the disposition of letrozole in mice.  These include 
bioavailability studies for letrozole in each of the models tested, combined with 
tissue analysis for drug transporter expression and activity, and a closer 
examination of the expression and activity of intestinal P450 enzymes to rule 
out first-pass metabolism effects.  An ideal study should also include the 
measurement of faecal and urinary excretion, as well as employing a detection 
method that can detect letrozole and its metabolites in plasma.  The 
combination of these data streams will provide a robust basis on which 
conclusions regarding letrozole metabolism can be generated. 
4.4.2.3 LETROZOLE PHARMACOKINETICS DEMONSTRATE TEMPORAL VARIATION IN 
A SEXUALLY DIMORPHIC AND SPECIES-SPECIFIC MANNER 
When contrasting data from the 1 day cohort with that from the 3 day, it is clear 
that temporal variation in these models is highly dependent on gender, as well 
as on PXR/CAR genotype (Figures 4.3.9-4.3.12, Tables 4.3.1 & 4.3.2) .  
Examining males, it is noteworthy that there is no temporal variation in 
pharmacokinetics in the two PXR KO models, and only a marginal change in 
half-life in the PXR/CAR DKO model, indicating that temporal changes in 
pharmacokinetics in males are driven by PXR.  PXR genotype also appears to be 
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important to temporal pharmacokinetic changes in females, with no variations 
observed in the PXR KO/HuCAR and PXR/CAR DKO models.  However, drug 
elimination is increased by approximately 50% relative to one day cohort in the 
PXR KO/mCAR model, suggesting that mCAR has greater activity to effect 
temporal changes in the female than the male. 
Interesting trends can also be developed from the comparison of temporal 
changes in wild-type and PXR/CAR DHu pharmacokinetics, which is also 
associated with significant gender-specificity.  In the wild-type model, 
pharmacokinetic parameters indicate drug accumulation between 1 day and 3 
day cohorts, which is marginal in males but notable in females, a finding 
consistent with data suggesting that letrozole is not completely eliminated from 
the bloodstream in this model within 24 hours.  In contrast to wild-type data, a 
significant temporal change in pharmacokinetics is observed in the male 
PXR/CAR DHu model, with faster drug elimination and lower systemic exposure 
being apparent, but only marginal variation is observed in the females.  This 
could indicate a gender-specific variation in bioavailability, as reported by 
Wempe et al. (2007) in rats.  With several transporters having been reported as 
being expressed in a sexually dimorphic manner in intestine (Klaassen and 
Aleksunes, 2010), this is a theory that requires closer scrutiny.  This could also 
be a result of transporter induction leading to faster renal clearance.  I f so, it 
suggests that transporter regulation varies between wild-type and PXR/CAR 
DHu models, as well as between sexes, a factor that has yet to be characterised 
in this model panel. 
Perhaps the most extreme temporal variation was seen in the male 
mPXR/HuCAR model, in which higher systemic exposure and slower drug 
elimination are recorded.  This variation is male-specific, with female 
pharmacokinetics showing little temporal variation.  Although a marginal 
increase in drug exposure and reduction in clearance is a temporal feature of 
mPXR/CAR KO pharmacokinetics, changes on the scale observed in the 
mPXR/HuCAR model are specific to this genotype and suggest cross-talk 
between these receptors leading to aberrant target gene regulation. 
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Finally, HuPXR single transgenic models demonstrate little temporal variation 
in females.  However, in males the temporal variation is profound, and is also 
CAR status dependent.  Both models demonstrate reduced drug exposure.  
However, although clearance is marginally increased in the HuPXR/CAR KO 
model between the two time points, it is increased to a similar level to that of 
the PXR/CAR DHu model in the HuPXR/mCAR model, indicating that co -
operative regulation by HuPXR and CAR is required for temporal variation in 
males. 
From this analysis, it is clear that temporal variation in letrozole 
pharmacokinetics is a feature of all PXR genotypes in males, although species of 
PXR and CAR status are important when assessing the magnitude of variation.  
As previously discussed, pharmacokinetic changes in these models are likely to 
be as a result of species- and gender-specific variations in transporter activity, 
with many systemic drug transporters having been identified as expressed in a 
gender-specific manner (Morris et al., 2003; Klaassen and Aleksunes, 2010).  To 
date, a systematic analysis of transporter localization, expression and activity in 
this model panel, examining both sexes, has not been published.  However, this 
data indicates that it is likely to be differential with respect to PXR/CAR 
genotype and gender, and therefore this analysis should be performed as a 
matter of urgency to enable a full assessment of drug disposition, and to aid in 
the drawing of conclusions regarding PXR/CAR dependent regulation of non -
hepatic drug disposition.  However, it is also important to note that the P450-
mediated metabolism cannot be completely excluded until a full analysis of 
letrozole metabolism in mice is performed. 
4.4.3 ANASTROZOLE PHARMACOKINETICS ARE DEPENDENT ON PXR AND CAR 
STATUS, WITH A GREATER DEPENDENCE ON HEPATIC CLEARANCE THAN 
LETROZOLE 
It is clear from a rudimentary examination of pharmacokinetic data that 
anastrozole disposition is significantly associated with PXR/CAR genotype.  As 
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with letrozole, clearance data obtained following anastrozole treatment 
suggests that the primary route of elimination in many of the test models could  
be renal, having a clearance well below the glomerular filtration rate, although 
further analysis is required to confirm this hypothesis.  However, unlike 
letrozole, pharmacokinetic data also indicates that hepatic metabolism is of 
relevance in several models, and particularly in the female cohorts, with 
clearance being greater than the glomerular filtration rate, although still 
significantly lower than the rate of hepatic blood flow.  Anastrozole 
pharmacokinetics in these models will therefore be discussed with reference to 
protein expression and activity, although other hypotheses will also be 
postulated. 
4.4.3.1 ANASTROZOLE PHARMACOKINETICS ARE PXR/CAR DEPENDENT AND 
DEMONSTRATE GENDER SPECIFICITY 
A cursory analysis of the 72 hour pharmacokinetic parameter data for both 
sexes clearly indicates that anastrozole pharmacokinetics are differentially 
modulated according to PXR/CAR genotype in both sexes (Figures 4.3.14 & 
4.3.16, Tables 4.3.3b & 4.3.4b) .  However, equally clear is that these 
pharmacokinetics show significant gender variation, with a good rule of thumb 
being that males display lower drug elimination and higher drug exposure than 
the females.   
A key example of both conclusions is demonstrated by the comparison of 
pharmacokinetics in the wild-type and PXR/CAR DHu models.  Wild-type 
pharmacokinetics, whilst displaying sexual dimorphism, also illustrate one of 
the exceptions to the generalization given above, with higher clearance, faster 
drug elimination and lower drug exposure in the males than in the females.  
These changes do not equate to the variations recorded in P450 expression, 
suggesting that P450-mediated metabolism has no influence on anastrozole 
pharmacokinetics in this model.  This concurs with the low clearance value 
which indicates a potentially more significant role for renal clearance in this 
model, and thus implicates transporter expression as a potential mediator of 
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inter-gender variability.  Low clearance values are also observed in the 
PXR/CAR DHu model.  However, whereas the PK profile in females is 
predominantly the same as that of the wild-type, indicating little variation in 
drug elimination between the two models, the profile in males is substantially 
different, demonstrating reduced clearance, slower elimination and increased 
drug exposure.  Once again, P450 data does not equate to the observed changes 
in pharmacokinetics, suggesting that PXR/CAR mediated modulation is 
mediated by another entity, such as the drug transporters or UGTs.  This clearly 
demonstrates not only that murine PXR/CAR and human PXR/CAR interact to 
regulate anastrozole elimination in a species-specific manner, but also that 
species-differential regulation is dependent on gender. 
Gender variation is also evident when isolating the effects of each receptor.  
mPXR interacts with CAR to promote anastrozole clearance in a gender specific 
manner.  In females, the profiles indicate that there is limited variation in 
pharmacokinetics between the wild-type and mPXR/CAR KO model, suggesting 
that mPXR drives wild-type pharmacokinetics in females.  However, receptor 
synergy in the mPXR/HuCAR species hybrid model promotes a significant 
increase in clearance, indicative of faster elimination and consistent with the 
induction in Cyp3a enzyme activity observed in this model, a key element in 
hepatic anastrozole metabolism (Figure 4.1.2).  In contrast, anastrozole 
clearance in males is maintained at wild-type levels in the presence of CAR, 
regardless of species.  However, when mPXR is isolated from CAR, clearance 
reduces by approximately 50% and is associated with a significant increase in 
drug exposure, indicating reduced drug elimination.  This is surprising when 
concurrently analysing pharmacokinetic data with that from the activity assays, 
in which anastrozole induces Cyp3a activity in the mPXR/CAR KO model, which 
would suggest an increase in metabolism, and thus clearance.   
Gender- and species-specific metabolism is also observed when examining the 
HuPXR models. Isolating hPXR in males results in a reduced elimination in 
comparison to wild-type, although not as marked as that observed in the 
PXR/CAR DHu model, indicating a negative synergistic interaction between the 
human receptors.  In females, a similar reduction in clearance is observed 
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relative to wild-type when hPXR is isolated.  However, in contrast to the males, 
synergistic functioning between the two human receptors results in wild-type 
level clearance.  One common feature between sexes is observed in the 
HuPXR/mCAR model, in which clearance is very significantly increased r elative 
to wild-type, although this is stronger in males than females.  However, none of 
these traits concur with observed Cyp3a activity profiles, indicating either that 
the increased elimination is via a non-hepatic (renal) route, or possibly that the 
UGT mediated N-glucuronidation pathway has a greater role in metabolism in 
the HuPXR/mCAR model. 
Although PXR/CAR genotype does cause differential modulation of anastrozole 
pharmacokinetics, the analysis of the PXR/CAR DKO model demonstrates that 
neither receptor is essential for anastrozole metabolism.  They also 
demonstrate that the moiety causing pharmacokinetic variation in this model 
acts in a sexually dimorphic manner, with the profiles in males and females 
demonstrating opposing effects.  In males, clearance is markedly reduced 
relative to wild-type, yielding the lowest level of any model tested, and is 
associated with a significant increase in drug exposure.  However, the 
parameter profile shows similarities to that of the PXR/CAR DHu model, 
suggesting that the interaction between hPXR and hCAR could be non-
functional in males, and thus that pharmacokinetics in this model actually 
reflect control by another regulatory protein, such as the AhR, HNF-1 or HNF-
4.  In females, the data suggests that PXR/CAR function could repress 
anastrozole elimination in all models excepting the two species-hybrid 
genotypes.  This is demonstrated by an increased clearance and decreased drug 
exposure in the PXR/CAR DKO model relative to wild-type, yielding a profile 
resembling that of the mPXR/HuCAR model.  Once again, it raises the question 
as to whether the similarity in profile indicates that the interaction between 
mPXR and hCAR is non-functional, and therefore that the pharmacokinetics 
observed in this model reflect an alternative regulatory pathway.   
In summary, these data suggest that PXR and CAR are involved in the regulation 
of anastrozole elimination, although data from the PXR/CAR DKO model 
demonstrates that they are not essential.  The role of PXR is both gender - and 
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species-specific.  mPXR has stronger activity with respect to anastrozole 
disposition in females than males, being able to maintain wild-type clearance 
levels in the absence of CAR in contrast to the males.  The species of CAR is of 
limited relevance with respect to mPXR activity, with the only notable variation 
being hCAR exerting a female-specific induction in clearance when working in 
conjunction with mPXR.  However, species of CAR is of greater significance with 
respect to hPXR, with mCAR synergizing with hPXR in a gender-independent 
manner to promote the highest clearance recorded in any model.  In contrast, 
hCAR interacts with hPXR in a gender-dependent manner, resulting in reduced 
clearance in males, but enhanced clearance in females relative to  the 
HuPXR/CAR KO model.  Interestingly, CAR acting in isolation promotes wild-
type level clearance in both sexes, regardless of species, and therefore suggests 
that gender-differential pharmacokinetics are a direct result of interactions 
between CAR and PXR.  It also demonstrates that Cyp3a activity alone is 
insufficient to explain variations in anastrozole pharmacokinetics, and provides 
further evidence that a non-P450 mediated elimination route, such as renal 
clearance or UGT-mediated N-glucuronidation, is responsible for the 
elimination of anastrozole.   
These hypotheses cannot be assessed without further analysis, including 
investigating metabolite production profiles in these mice.  It must also be 
remembered that a systematic analysis of anastrozole metabolism in mice has 
not been performed, and therefore potential inter-species variations in 
metabolism must be considered.  Although of no physiological or clinical 
relevance, the identification of abnormally enhanced elimination in the two 
species hybrid models also provides a caution against using single PXR/CAR 
humanized mouse models in isolation to draw conclusions, requiring further 
confirmation from models with a greater clinical relevance to control for 
aberrant inter-species regulatory crosstalk.  
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4.4.3.2 ANASTROZOLE PHARMACOKINETICS ARE LIKELY TO BE INFLUENCED BY 
DRUG TRANSPORTER AND UDP-GLUCURONOSYLTRANSFERASE ACTIVITY 
To this point, this study has demonstrated that PXR/CAR genotype does impact 
on anastrozole pharmacokinetics.  However, pharmacokinetic analysis has 
revealed that the primary route of anastrozole elimination in the majority of 
models could be renal, thus implicating the drug-transporters.  The rationale 
underlying the theories that anastrozole pharmacokinetics and bioavailability 
are influenced by modulation of transporters and potential variations in volume 
of distribution has already been discussed in Section 4.3.2.2.  However, firm 
conclusions cannot be formed without a systematic analysis of drug transporter 
activity with respect to anastrozole.  However, the proposed metabolic pathway 
of anastrozole (Figure 4.1.2) also implicates the UGTs in pharmacokinetic 
regulation of this drug, and in particular with bioavailability.  Numerous human 
and mouse UGTs are regulated by PXR and CAR (Chen et al., 2003; Xie et al., 
2003; Zhou et al., 2005; Buckley and Klaassen, 2009a; Li et al., 2009b; Yueh et 
al., 2011; Xu et al., 2012).  Frequently this regulation is positive, yielding an 
increase in UGT expression.  However, a recent report by Yueh et al. (2011) has 
demonstrated negative regulation of human UGT2B7, caused by CAR-mediated 
disruption of HNF-4 binding to promoter elements.  This could be of particular 
relevance to those models demonstrating reduced anastrozole clearance as a 
result of the UGT-mediated metabolic pathways described by Kamdem et al. 
(2010)(Figure 4.1.2).  Another important feature of mouse UGT expression is 
that several isoforms demonstrate sexually dimorphic expression profiles 
(Buckley and Klaassen, 2009b), and thus could partially explain the gender-
differential pharmacokinetics previously described.   
Unfortunately, the UGT catalysed metabolism of anastrozole in mice has not 
been characterised with respect to specific isoforms, and consequently all 
hypotheses are based on human metabolic data.  Although certain orthologues 
have been identified in mice, the significant divergence between the human and 
murine UGT systems prevents direct translation of metabolic data between 
species.  For instance, the murine orthologue of the human UGT1A4 gene, 
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ugt1a4, is a non-functional pseudogene (Buckley and Klaassen, 2007; Shiratani 
et al., 2008).  In addition, no orthologue of the UGT2B7 gene has been identified 
in mice, although it is clear that murine UGTs are capable of metabolising 
UGT2B7 catalysed reactions, such as morphine-O-glucuronidation (Buckley and 
Klaassen, 2007; Shiratani et al., 2008).  A systematic analysis of anastrozole 
metabolism by UGTs in mice is essential to assess whether these enzymes have 
a meaningful role in anastrozole metabolism and to identify which isoforms are 
implicated.  This analysis must also include tissue specific expresion/activity to 
assess the potential role of the UGT system in first-pass metabolism, and thus 
bioavailability.   
4.4.3.3 ANASTROZOLE PHARMACOKINETICS DEMONSTRATE TEMPORAL VARIATION 
AND GENDER DIMORPHISM 
Anastrozole pharmacokinetics demonstrate temporal variation in the majority 
of models, with this variation displaying both gender- and species-dimorphism 
(Figures 4.3.13-4.3.16, Tables 4.3.3 & 4.3.4).  Temporal variation in 
pharmacokinetics indicates a regulatory response which modulates the 
proteins associated with anastrozole disposition.  This data set therefore 
indicates a regulatory interaction in the wild-type, PXR KO/HuCAR, 
mPXR/HuCAR, HuPXR/CAR KO and HuPXR/mCAR models.  In the wild-type 
model, an increase in clearance of approximately 50% is consistently observed 
between the 1 and 3 day treatment cohorts in both sexes, and is associated with 
reduced drug exposure and t½.  However, there is no temporal variation in PK 
parameters in the PXR/CAR DHu model in either sex.  This provides further 
evidence that anastrozole interacts with PXR/CAR in a species specific manner. 
Interestingly, temporal variation is not recorded in the mPXR/CAR KO or CAR 
KO/mPXR models, indicating that synergistic functioning between murine 
PXR/CAR is required to induce variation in the wild-type.   
Data also indicates that synergism between the murine and human receptors 
can induce temporal variation.  However, whereas increased clearance is 
observed in the mPXR/HuCAR model in both sexes, synergism between hPXR 
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and mCAR induces a temporal response in males only.  Also, although no 
temporal variation is observed in the PXR/CAR DHu model, it is recorded in 
both the PXR KO/HuCAR and HuPXR/CAR KO models.  However, the direction 
of change is dependent on gender, with clearance being enhanced in males 
between the two time points, but repressed in females.  Interestingly, gender -
specific induction in clearance is also observed in the PXR/CAR DKO model, 
with a female-specific induction in drug clearance.  This clearly demonstrates 
that a non-PXR/CAR related regulatory mechanism is capable of modulating 
anastrozole disposition. 
In summary, it is clear that PXR/CAR genotype has a significant influence on 
temporal variation in anastrozole pharmacokinetics, with a probable regulatory 
role in the wild-type, PXR KO/HuCAR, mPXR/HuCAR, HuPXR/CAR KO and 
HuPXR/mCAR models.  Their ability to modulate pharmacokinetics in isolation 
suggests that hPXR and hCAR have a greater activity with respect to anastrozole 
than their murine counterparts, which require PXR to promote temporal 
change.  However, synergy between hPXR and hCAR appears to be non-
functional with respect to anastrozole-induced regulation of downstream 
proteins, thus demonstrating the importance of species-specific response to this 
analysis.  Gender-specific response is also observed in the PXR KO/HuCAR, 
HuPXR/mCAR and HuPXR/mCAR models, although this data set is unable to 
provide any indication of the mechanism underlying the gender dimorphic 
effect.  Further studies are therefore required to elucidate this phenomenon, 
potentially incorporating hormonal profiles, a full analysis of murine-specific 
anastrozole disposition and potential enzyme inhibition profiles.  Data from the 
PXR/CAR DKO model is also suggestive of gender-specific regulation of genes 
involved in anastrozole disposition by a non-PXR/CAR-mediated regulatory 
system. Although variations in the PK parameters suggest the involvement of 
these receptors in the regulation of genes associated with anastrozole 
disposition, this alternative pathway needs to be further characterised before 
the role of PXR/CAR in the temporal variation of anastrozole pharmacokinetics 
can be fully assessed. 
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4.4.4 AROMATASE INHIBITORS INDUCE CYP2B6 IN A SPECIES- AND GENDER-
SPECIFIC MANNER 
It is clear from these observations that both anastrozole and letrozole induce 
the expression of the CYP2B6-lacZ reporter in this model (Figures 4.3.17-
4.3.19; Appendix A).  Expression of the lacZ reporter is located in hepatic zone 
2, in common with other data generated in our lab (Cameron & Chatham, 
unpublished).  This is unusual because most P450 expression has been reported 
in the perivenous region (zone 3), although CYP2B6 expression has also been 
reported throughout zone 1 (Jungermann and Kietzmann, 1996; Wang and 
Tompkins, 2008; Colnot et al., 2011).  Interestingly, the differential in 
magnitude observed mirrors that previously recorded for Cyp2b10, with 
anastrozole inducing a much stronger response than letrozole.  This provides 
more evidence for the role of anastrozole as the stronger CAR activator,  as 
previously discussed in Section 4.3.1.3.   
Sexual dimorphism is also a notable feature of aromatase induced expression of 
CYP2B6, with stronger expression observed in the males than in the females in 
the mPXR/mCAR background CYP2B6-lacZ reporter line.  This is a very unusual 
finding because the expression of CYP2B6, in common with that of Cyp2b10, has 
been reported to be greater in females than males (Lamba et al., 2003; 
Parkinson et al., 2004; Loryan et al., 2012), and thus it implies that this 
construct is not able to replicate gender-defined variations in expression.  This 
could be impacted by modulations of oestrogen concentrations induced by 
aromatase inhibitor therapy, but given the primary role of growth hormone 
pulses in the control of gender-specific expression, this seems unlikely 
(Waxman et al., 1991; Jaffe et al., 2002; Dhir et al., 2006).  Unfortunately, 
sexually dimorphic expression could not be assessed in the hPXR/hCAR 
CYP2B6-lacZ reporter line because of low mouse numbers.  However, 
identifying the cause of this effect in both backgrounds could be imperative to 
the future utility of this model. 
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Finally, there is clear species-specificity in the regulation of CYP2B6 expression 
by PXR and CAR following letrozole treatment in males, with substantially 
lower expression observed in the model on the human background than on the 
murine.  This presents two possibilities in terms of regulation.  Firstly, the 
murine receptors have a greater affinity for the CYP2B6 promoter regions than 
their human counterparts, resulting in greater expression of the transgene.  
Secondly, that letrozole is a stronger activator of mPXR/mCAR than hPXR/hCAR 
with respect to CYP2B6.  However, both scenarios could be caused by 
differential recruitment and interaction with other transcription factors and co -
factors required for maximal CYP2B6 expression.  A greater ability of the innate 
PXR/CAR system to interact with native co-factors would be consistent with the 
differential expression observed.  Unfortunately, the low numbers of available 
mice have prevented full analysis of both aromatase inhibitors in both sexes, 
and thus reduced the evidence base for this observation.  In order to further 
investigate this phenomenon, future experiments examining the CYP2B6-lacZ 
construct bred onto the full panel of PXR/CAR models would provide a greater 
insight into the species-specific regulation of CYP2B6 in these transgenic 
models. 
In addition to reporter expression analysis, common blood biochemical 
markers were examined in these models (Figure 4.3.20).  The majority of 
markers showed no variation relative to vehicle control, although in part this 
could be ascribed to the significant inter-individual variation observed.  
However, of concern is the observation that creatinine concentration is 
significantly increased in the CYP2B6-lacZ model on the mPXR/mCAR 
background following letrozole treatment in males, and following both 
treatments in females.  This indicates the possibility of kidney damage 
occurring in these models, a significant concern given that the clearance of both 
drugs is primarily renal in mice.  Unfortunately kidney pathology was not 
examined and therefore the potential extent of any tissue damage cannot be 
assessed, although given the scale of this increase and the time-scale of the 
experiment this is unlikely to be significant. 
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In conclusion, it is clear that both aromatase inhibitors induce the expression of 
CYP2B6 in these models.  Although significant analysis is still required to assess 
the cause of this species- and gender-specific induction, this could be an 
important clinical finding given the key role of CYP2B6 in the disposition of 
several chemotherapeutic agents, most notably cyclophosphamide (Wang and 
Tompkins, 2008).  The induction of CYP2B6 in humans could potentially result 
in a greater risk of toxicity in subsequent cytotoxic treatment as a result of 
increased conversion of cyclophosphamide to its active moiety.  The induction 
of CYP2B6 in humans in response to aromatase inhibitors should therefore be 
clarified with urgency to allow effective dose modulation to maintain clinical 
efficacy minimize overt toxicity in downstream treatment regimes. 
4.5 CONCLUSIONS 
This chapter demonstrates that both letrozole and anastrozole interact with 
PXR and CAR to modulate P450 expression and activity, as well as 
pharmacokinetics.  Analysis has demonstrated that anastrozole exerts the 
stronger effect on P450 induction at the dose tested relative to letrozole, and 
that this effect is strongest in those models possessing the hCAR genotype, 
indicating the hCAR has a greater affinity for anastrozole than mCAR.  The key 
role of CAR in the regulation of anastrozole-induced P450 expression is 
highlighted by the strong and species-differential induction of Cyp2b10 in all 
models possessing a CAR moiety.  P450 modulation following letrozole 
treatment is more constrained than that observed following anastrozole 
treatment, and demonstrates notable gender-specificity, with Cyp2b10 
induction seen only in females but the greatest Cyp3a11 induction observed in 
males.  The former trait is mediated by CAR, being observed in females only in 
those models possessing a functional CAR protein, and has been attributed to 
the higher activity of Cyp2b10 and CAR previously reported in females 
(Jarukamjorn et al., 2002; Lamba et al., 2003; Petrick and Klaassen, 2007; 
Hernandez et al., 2009b).  The latter trait has been associated with the 
activation of PXR, and particularly mPXR which shows the greatest activity 
following letrozole treatment regardless of CAR genotype, in contrast to hPXR, 
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which is unable to induce Cyp3a11 in the presence of CAR.  Both nuclear 
receptors are therefore implicated in the induction of P450s follo wing 
treatment with these drugs, although whether this is through direct or indirect 
interaction cannot be established from this dataset. 
An unexpected finding was that the primary elimination route of both drugs in 
mice is potentially renal, and thus hepatic P450 metabolism could have a 
minimal impact on drug pharmacokinetics.  This was corroborated by the lack 
of correlation between pharmacokinetic and protein expression trends.  
However, although P450 metabolism may have little role in the control of 
aromatase inhibitor pharmacokinetics in mice, it is evident that PXR and CAR 
are involved in the pharmacokinetic regulation of both drugs, although neither 
are obligate, and also that both receptors interact in a species-specific manner.  
This was best demonstrated by pharmacokinetic data obtained following 
letrozole treatment, in which the PXR/CAR DHu models demonstrated 
significantly faster drug elimination than wild-type, indicating that the human 
receptors have a greater activity with respect to letrozole than their murine 
orthologues.  It was further demonstrated that hPXR promotes faster drug 
elimination in combination with CAR, mPXR represses innate CAR activity.  CAR 
promotes faster drug elimination regardless of species, but this activity is 
modulated by PXR.  Interestingly, PXR/CAR status is also a key determinant of 
temporal pharmacokinetic variation between the 1 day and 3 day cohorts, with 
PXR being found to drive variations between the two timepoints.  However, 
there is also a gender differential effect observed, with mCAR also 
demonstrating activity with respect to temporal variation in females.  These 
data therefore demonstrate the importance of assessing species- and gender-
specific PXR and CAR activity, with the activity of both being differential.   
Dissecting the role of PXR and CAR in anastrozole pharmacokinetics is more 
complex, in part because of the increased prevalence of sexual dimorphism, 
which is observed in the majority of genotypes.  It is clear that murine and 
human PXR have a differential activity when functioning individually, with 
murine PXR enhancing anastrozole elimination whilst the human receptor 
represses elimination relative to wild-type.  It is also evident that synergistic 
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functioning between PXR and CAR is an important element of anastrozole 
disposition, although there is marked gender dimorphism in terms of the 
importance and effects of receptor synergy.  Most notably, the temporal 
variation observed in the wild-type model is lost in the PXR/CAR DHu model, 
regardless of sex.  However, the presence of gender-dimorphic temporal 
variation in the species-hybrid and PXR/CAR DKO models makes it both 
impossible to dissect further receptor specific effects, and indicates the 
presence of a non-PXR/CAR-mediated regulatory mechanism which requires 
characterisation before the role of PXR and CAR in anastrozole-induced 
temporal mediation can be fully assessed. 
Although hepatic P450 expression, and particularly that of Cyp3a11, may have a 
role in anastrozole metabolism, it appears to be of less relevance to letrozole 
metabolism.  Other potential mediators of these effects are the drug-
transporters, and, in the case of anastrozole, the UGTs, all of which have 
previously been associated with PXR/CAR-mediated regulation.  These entities 
mediate drug influx to and efflux from the system and thus can significantly 
affect both absorption and excretion.  However, this study does not have 
sufficient information to enable the role of these proteins in drug disposition to 
be fully analysed, and literature data regarding the elimination of letrozole and 
anastrozole in mice does not exist.  Among the experiments required to address 
this problem are a systematic in vitro assessment of transporter interactions 
and UGT metabolism, primarily in the enterocytes, liver and kidneys.  In order 
to address the role of gender-differential metabolism, the impact of AI therapy 
on oestrogen levels should also be assessed, as oestradiol and oestrone have 
both been shown to regulate PXR and CAR activity (Kawamoto et al., 2000; 
Mäkinen et al., 2003; Mnif et al., 2007; di Masi et al., 2009; Min, 2010; Dau et al., 
2012; Koh et al., 2012).  Without this basic data, the role of PXR and CAR in 
regulation of drug pharmacokinetics, and specifically the latter hypothesis, 
cannot be addressed.  Also of importance is to increase the number of subjects 
enrolled in these studies, to enable more subtle trends to be dissected. 
One weakness of this study is that our methodology only analyses 
pharmacokinetics from a loss of parent drug perspective, instead of analysing 
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both parental loss and generation of metabolites.  This approach is therefore 
unable to specifically dissect disruptions in drug absorption, metabolism, and 
excretion relying instead on Western blot and activity data to provide support 
for any conclusions.  However, a stronger approach would be to analyse both 
parent drug and its metabolites simultaneously to give more specific data 
regarding variations in pharmacokinetics, using a method such as has been 
recently described for letrozole in which letrozole and its two metabolites are 
simultaneously analysed by LC-MS/MS (Precht et al., 2012).  At present no 
comparable method is available for the simultaneous analysis of anastrozole 
and its metabolites, most likely as a result of the comparative complexity of its 
metabolism.  This methodology provides data to enable the impact of variations 
in P450-mediated metabolism to be directly related to pharmacokinetic effects, 
to detect any changes in UGT-mediated glucuronidation, as well as to help 
identify any non-metabolic processes affecting pharmacokinetics, such as 
transporter interactions that affect the absorption or excretion of the drug.  To 
provide fuller supporting data for this technique, it is essential that a full in vitro 
analysis of drug metabolism in mice is performed to characterise the P450s, 
UGTs and drug transporters involved in the metabolism of these drugs. 
Although this model panel has previously been used to assess species-specific 
regulatory crosstalk following phenobarbital treatment (Scheer et al., 2008), 
this is the first study to describe species-dependent variations in cross-talk in 
response to drug treatment.  It is also the first study using these models to 
demonstrate the influence of gender-specificity on the regulation of P450-
mediated metabolism.  However, this study also highlights the importance of 
prior consideration of the role of regulatory cross-talk between nuclear 
receptors when using transgenic models in which a native gene has been 
replaced with one from another species.  In both protein assays and 
pharmacokinetic analysis, notable disruptions have been identified in the two 
species-hybrid models (mPXR/HuCAR and HuPXR/mCAR) relative both to wild 
type and other related genotypes.  It is highly probable that these variations are 
as a result of aberrant cross-talk between the two receptors, yielding 
pharmacokinetics and protein expression that is non-physiological.  Although 
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this effect is limited in this study by the use of a full panel of PXR/CAR 
combinations, this is of particular concern given the widespread use of the 
single humanized models as a sole methodology, because without the full 
complement of genotype combinations, or corroborative evidence from an 
alternative model, aberrant receptor interactions cannot be identified.  This 
could result in false conclusions being assigned to the non-native gene when the 
observation is actually driven by non-native crosstalk.  This highlights the 
importance of selecting a methodology which can circumvent this issue, without 
which conclusions derived from the single-humanized models regarding 
regulatory control of xenobiotic metabolism must be treated with caution.  This 
also highlights the importance of developing more complex models in which 
multiple genes are humanized, because it decreases the risk of aberrant 
crosstalk causing flawed data.  However, without replacing all genes relating to 
drug metabolism and its control, aberrant crosstalk will always be a potential 
pitfall of using transgenic models, and therefore data should ideally be 
compared against that from a more clinically relevant model. 
One final point of interest is the identification of a potential source of drug-drug 
interaction not previously described for these drugs, namely the potential 
induction of CYP2B6 by both aromatase inhibitors.  Although this appears to be 
lower in the reporter line on a human PXR/CAR background, it is still 
identifiable.  The lack of mouse numbers for the human background has limited 
the utility of this analysis.  However, as a result of the role of CYP2B6 in drug 
disposition for many downstream chemotherapeutic agents, it is a finding that 
should be thoroughly investigated in more clinically relevant systems, such as 
primary human hepatocytes, liver slices, or ideally clinical trials, in which a 
probe substrate for CYP2B6, such as bupropion, could be employed to assess in 
vivo enzyme kinetics.  Although this is a promising finding, it is important to 
note that these models require greater characterisation with respect to CYP2B6 
regulation, with expression of the transgene being identified in an unusual 
location and with the reversal of expected sexually dimorphic induction 
patterns.  Data generated should therefore be treated with caution. 
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Overall, this chapter has demonstrated that crosstalk between PXR and CAR is 
implicated in the regulation of letrozole and anastrozole pharmacokinetics.  
However, given that elimination of these drugs in mice is primarily renal, there 
is a limited relationship between P450 induction and pharmacokinetics, 
although the former is still of interest to the assessment of potential drug-drug 
interactions.  The primary regulator of pharmacokinetics in this case is likely to 
be the drug transporters, and possibly the UGTs in the case of anastrozole.  
Significant research is still required to assess the involvement of these proteins, 
and their effects on the formation of metabolites.  However, of particular 
importance is the demonstration that care must be taken when assigning 
conclusions to data from single humanized models, without first considering the 
role of aberrant crosstalk.   
Study data therefore suggests that the null hypothesis for this study (“AIs 
interact with PXR/CAR in a species- and gender-specific manner to promote 
drug metabolism via the P450 enzyme system”) is false, as a result of the 
potentially limited role of P450-mediated metabolism in AI disposition.  
However, further analysis of the disposition of these drugs is required to 
confirm this.   
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5 CHAPTER 5 
A SUMMARY OF CONCLUSIONS 
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5.1 AROMATASE INHIBITOR PHARMACOKINETICS ARE 
DEPENDENT ON PXR/CAR STATUS, BUT NOT P450-
MEDIATED METABOLISM IN MICE 
Nuclear receptor activation, and particularly that of PXR and CAR, is becoming 
increasingly recognised as a key determinant in the development of DDIs.  
Various methods are available to investigate the activation of these receptors in 
response to drug challenge, including reporter gene assays, primary human 
hepatocytes and certain simple transgenic mouse models.  However, these 
models lack the sophistication to effectively assess inter-receptor cross-talk, a 
key regulatory mechanism in the control of drug metabolism.  By using the 
novel panel of transgenic mouse models (Scheer et al., 2008; Ross et al., 2010; 
Scheer et al., 2010), this study was designed to specifically dissect the role of 
cross-talk between PXR and CAR in the metabolism and pharmacokinetics of 
commonly available pharmaceuticals.  This approach also allowed species-
differential activation of these nuclear receptors, as well as the potential impact 
of aberrant cross-talk between receptors of two species, to be analysed.   
In the first phase of the study (Chapter 3), the aromatase inhibitors, letrozole 
and anastrozole, were identified as potential activators of PXR and CAR, on the 
basis of their induction of the prototypical target genes, Cyp3a11 and Cyp2b10, 
and thus were selected for further study.  In these early experiments, sexually 
dimorphic P450 activity was also observed, potentially suggesting sex-specific 
changes in PXR/CAR activity.  Gefitinib and cyclophosphamide were also 
implicated as ligands for both nuclear receptors, but demonstrated a lower 
response level than letrozole, and thus were not selected.  However, with 
respect to cyclophosphamide, these data agree with a recent study which 
identifies cyclophosphamide as an activator of both PXR and CAR (Wang et al., 
2011). 
Interaction with PXR and CAR is a key modulator of P450 expression and 
activity, as well as drug pharmacokinetics (Chapter 4).  The activity of PXR/CAR 
was species-specific with respect to AI pharmacokinetics.  Letrozole has higher 
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activity with respect to human PXR/CAR than murine, resulting in significantly 
faster drug elimination.  Species-specificity in letrozole response is 
predominantly driven by PXR modulation of CAR activity, with CAR being 
essential for higher drug metabolism, irrespective of species.  PXR has also been 
identified as the key mediator of temporal changes in pharmacokinetics, 
although mCAR also demonstrates activity in the female cohort only.  
Anastrozole pharmacokinetics also demonstrate species-specificity with respect 
to PXR, although in this case mPXR demonstrates the higher activity.  However, 
gender-dimorphic pharmacokinetics observed in the majority of genotypes 
complicates the identification of genotypic influences.  Limited conclusions 
could therefore be drawn regarding receptor interactions, although synergistic 
functioning between PXR/CAR remains an important regulatory factor.  There is 
also evidence of PXR/CAR dependency in the control of temporal variation in 
anastrozole pharmacokinetics.  However, although AI pharmacokinetics are 
modulated by PXR/CAR genotype, neither PXR/CAR are obligate for drug 
elimination, therefore suggesting a role for an alternative regulatory pathway.  
The data also illustrate the importance of considering potential aberrant cross -
talk between non-species linked nuclear receptors to avoid false conclusions 
derived from single humanized models.  Failure to consider the potential for 
non-native cross-talk and to plan methodology to limit its potential impact 
could impact the relevance of data generated in these models. 
Contrary to published data derived from humans and rats, drug elimination in 
mice appears to rely on renal, as opposed to hepatic excretion, although further 
studies are required to confirm this hypothesis.  If proven, it is most likely that 
the PXR/CAR mediated modulations in AI pharmacokinetics are as a result of 
modulation of drug transporter or UGT activity.  However, there is still notable 
induction of P450s with respect to many genotypes, in particular Cyp3a11 and 
Cyp2b10, a finding which could have significant ramifications for combination 
therapy.  Of particular note is the induction of Cyp2b10 in all models expressing 
CAR, which has not been reported in previous analyses of P450 induction 
following AI treatment.  Species-specific response demonstrates higher activity 
in hPXR models than mPXR, with the latter requiring interaction with CAR.  The 
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data also demonstrate gender-specific regulation of this gene following both 
treatments, with expression being higher in females than males, in agreement 
with previous studies indicating a female-specific increase in CAR activity 
(Jarukamjorn et al., 2002; Lamba et al., 2003; Petrick and Klaassen, 2007; 
Hernandez et al., 2009b).  It also suggests that anastrozole is a stronger inducer 
of CAR than letrozole.  Induction of the CYP2B6-LacZ reporter was also 
observed in all samples following drug treatment, although response is 
strongest in models under the control of murine PXR/CAR, as well as in males.  
This observation therefore has potential importance in human pharmacokinetic 
studies. Further characterization of these models, combined with analysis of 
CYP2B6 induction in a relevant human model, such as the HepaRG cell line (see 
below), is required to confirm this finding.  However, the identification of 
previously unreported induction of Cyp2b10/CYP2B6 could have significant 
therapeutic implications for those drugs that rely on these enzymes for their 
metabolism.  A key example is cyclophosphamide, a drug widely used in the 
treatment of breast cancer, for which CYP2B6 is essential for the conversion of 
the pro-drug to the active moiety, and therefore this effect should be further 
investigated as a matter of urgency. 
In summary, this study has identified a number of drugs with the potential to 
interact with PXR and CAR.  It has further demonstrated that PXR and CAR are 
activated by the AIs, and that this activation is reflected in variations in 
pharmacokinetics.  However, in contrast to published evidence, this is unlikely 
to be a result of P450-mediated induction, with pharmacokinetics suggesting 
possible renal clearance and thus implicating the drug transporters and UGTs.  
This also indicates that although evidence suggests interaction with PXR and 
CAR, a mouse model is not appropriate for the full analysis of the metabolism of 
these drugs, and therefore the findings of this study should be progressed to a 
more relevant model to provide corroboration.  It is essential to consider cross-
talk between these receptors, with species-specific effects having been 
observed in both pharmacokinetics and protein expression, in addition to 
aberrant pharmacokinetics and protein activity in non-species linked receptor 
models with respect to AIs.  Gender-specificity is also evident in the response to 
189 
 
 
drug treatment, although further research needs to be performed to identify if 
the effect is mediated by direct binding of AIs to the nuclear receptors, or 
whether it is mediated indirectly through another pathway.  Of particular 
interest is the oestrogen receptor pathway, with 17-oestradiol and oestrone 
having both shown activity with respect to PXR and CAR, and with which 
system the AIs interact (Kawamoto et al., 2000; Mäkinen et al., 2003; Mnif et al., 
2007; di Masi et al., 2009; Min, 2010; Dau et al., 2012; Koh et al., 2012).  In 
conclusion, although the PXR/CAR model panel was not appropriate for the 
analysis of AI drug metabolism, they have demonstrated their efficacy for the 
assessment of regulatory cross-talk and should be considered a useful tool for 
future studies. 
5.2 FUTURE DIRECTIONS 
5.2.1 AI STUDY: ASSESSING DRUG-TRANSPORTER EXPRESSION AND ACTIVITY 
In order to provide data to support the hypotheses suggested, a systematic 
analysis of AI metabolism, encompassing P450s, UGTs and drug transporters in 
these subjects is required.  Studies should include recombinant 
enzymes/transporters, in addition to relevant cell fractions derived from frozen 
liver and intestinal fractions.  Unfortunately, relevant kidney samples are not 
available, and therefore differential modulation of renal transporter/UGT 
expression and activity cannot be examined without repeating the study in a 
new cohort of mice.  These studies should also include experiments to 
specifically analyse renal excretion, and include pharmacokinetic studies 
examining the creation of metabolites, in order to provide a robust basis for 
conclusions regarding primary route of elimination in mice.  However, given 
that the metabolism of the AIs in mice and humans appears to be very different, 
any further use of mice for this purpose is unlikely to be ethical and therefore 
careful consideration should be given as to the ethics of performing this study.   
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5.2.2 CHARACTERISATION OF AI INTERACTIONS WITH PXR/CAR IN IN VITRO 
MODELS 
As discussed above, mouse models are clearly not suitable for the assessment of 
the effects of PXR/CAR activation on AI pharmacokinetics as a result of species 
differential metabolism.  However, the PXR/CAR related modulations in 
pharmacokinetics identified in mice does suggest some form of interaction with 
these nuclear receptors, and thus requires further analysis in a more relevant 
model. 
One such model is that of the HepaRG cell line.  First described in 2002, this cell 
line was derived from hepatocarcinoma isolated from a female patient, and 
differentiates into a co-culture of biliary and hepatocyte-like cells (Gripon et al., 
2002; Kanebratt and Andersson, 2008a; Kanebratt and Andersson, 2008b).  It is 
unusual for an immortal cell line in that it stably expresses many elements of 
the drug metabolism pathways following differentiation, including P450s, Phase 
II enzymes, drug transporters, and the nuclear receptors, PXR and CAR, at levels 
close to those identified in hepatocytes (Gripon et al., 2002; Aninat et al., 2006; 
Le Vee et al., 2006; Anthérieu et al., 2010; Anthérieu et al., 2012).  In addition, 
once differentiated, this cell line exhibits limited changes in gene expression 
profile for four weeks, provided they are not DMSO deprived (Jossé et al., 2008; 
Anthérieu et al., 2010; Anthérieu et al., 2012).  This allows the analysis of drug 
metabolism in an immortal cell line, thus reducing study variability and also 
removing three of the major problems associated with studies in PHHs, 
requiring no ethical approval, having no issues with supply and being stable for 
prolonged, although not indefinite, periods of time.  Monolayer cultures have  
therefore become a common model used for the assessment of drug toxicity and 
metabolism (Guillouzo et al., 2007; Kanebratt and Andersson, 2008a; Kanebratt 
and Andersson, 2008b; Kaneko et al., 2009; Lambert et al., 2009a; Lambert et 
al., 2009b; McGinnity et al., 2009; Turpeinen et al., 2009; Andersson et al., 
2012).  Recently, the power of this model has been increased by the 
development of 3D culture bioreactors which demonstrate in vivo liver-like 
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morphology, and which also appears to extend the stability of this cell line with 
respect to drug metabolism (Darnell et al., 2011; Darnell et al., 2012; Leite et al., 
2012; Nibourg et al., 2012a; Nibourg et al., 2012b; Nibourg et al., 2012c).  Of 
particular interest is their potential use as a biocomponent in bioartificial liver 
reactors, with a recent study demonstrating their efficacy in this role, with 
survival time being increased by 50% in rats with acute liver failure (Hoekstra 
et al., 2011; Nibourg et al., 2012a; Nibourg et al., 2012b).  This model therefore 
has significant potential for use both in toxicity testing, as well as in the support 
of those with severe liver suppression. 
With respect to this study, the HepaRG model could be used to provide further 
clarification of the role of PXR and CAR in the regulation of AI metabolism.  The 
stability of expression demonstrated by this cell line means that extended drug 
treatments can be used, and thus delayed metabolic reactions to drug challenge 
can be analysed.  In situ pharmacokinetic studies could also be performed at 
several points over an extended period, allowing temporal variations to be 
analysed.  Assays involving prototypical probe substrates for elements of the 
drug elimination cascade could also be employed to give real-time, in situ 
analysis of changes in protein activity modulation in these cultures (Feidt et al., 
2010; Videau et al., 2010; Prot et al., 2011; Rhodes et al., 2011; Kozakai et al., 
2012; Liu et al., 2012).  One further peculiarity of this cell line is its ability to be 
transfected, something that is traditionally challenging in a hepatocyte cell line 
(Laurent et al., 2010).  This presents the possibility of introducing siRNA 
targeted against PXR/CAR to enable the role of cross-talk between these 
receptors in the regulation of AI pharmacokinetics to be assessed in a relevant 
hepatocyte-like model.  With correct methodology selection, experiments in this 
model could therefore provide significant evidence to corroborate or disprove 
those observations generated in the mouse panel with respect to AI interactions 
with PXR/CAR. 
In order to provide a more mechanistic assessment of AI interactions with 
PXR/CAR, reporter gene assays can be employed.  To facilitate this, I have 
adapted the mPXR and hPXR luciferase reporter assays kindly donated by 
Luisella A. Vignati (Perlmann and Jansson, 1995; Bertilsson et al., 1998; 
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Blumberg et al., 1998; Vignati et al., 2004), to enable the activation of mCAR and 
hCAR by direct ligand binding to be assessed.  The reporter consists of the LBD 
of mCAR/hCAR linked to the DNA-binding domain of GAL-4.  Once activated by 
CAR ligand binding, the GAL-4 DNA-binding motif binds to the GAL-4 
recognition sequence linked to luciferase on a second plasmid, thus inducing 
luciferase induction.  The pCMX Gal4-mCAR-LBD model has been fully validated 
and previously published (Finn et al., 2009).  The pCMX Gal4-hCAR-LBD is still 
awaiting full validation.  Once completed, this panel of assays will allow the 
transcriptional activity of PXR/CAR in response to direct ligand induction to be 
assessed, and thus could provide useful data regarding species-dependent 
interactions of the AIs with these receptors.  However, one limitation of these 
models is that they are unable to analyse induction caused by indirect 
activation, and therefore data should be combined with other experimental 
approaches, such as the HepaRG approach described above. 
5.2.3 DEVELOPING THE STUDY METHODOLOGY 
Although the mouse model panel was not suitable for the assessment of AI 
pharmacokinetic modulation, the variations observed clearly demonstrate its 
utility for PXR/CAR regulatory cross-talk studies investigating other drugs.  It 
could therefore be of use in the analysis of those other drugs in Chapter 3 
identified as potential modulators of PXR/CAR activity.  However, one aspect 
lacking from the current methodology is a link from pharmacokinetic 
modulation to changes in tumour growth.  Ideally, this panel would be bred 
onto an immuno-deficient background, such as SCID, or immunocompromised 
through neonatal thymectomy + gamma irradiation, to enable xenograft studies, 
and thus provide a more clinically relevant output.  However, the former is a 
costly and time-consuming process, whilst the latter is complex and requires 
ethical approval.  An alternative methodology to avoid these problems is to use 
a syngeneic tumour model, in which mice are implanted with cells from a 
tumour raised in a relevant murine background.  Although the clinical relevance 
is likely to be reduced by this approach, it is able to give important information 
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regarding variations in drug efficacy in a physiological system which can then 
be translated to other models.   
As a result of the tumour-resistant properties of the C57BL/6J background, 
there are fewer models available for use in this panel than those derive d on 
alternative backgrounds, such as BALB/C.  However, among such models, one 
that has been well characterised is the E0771 cell line (Sirotnak et al., 1993; 
Ewens et al., 2005; Ewens et al., 2006; Gu et al., 2009; Stagg et al., 2010; Gu et al., 
2011).  E0771 is an aggressive medullary breast adenocarcinoma derived from 
a C57BL/6J background, and thus can be implanted into the PXR/CAR mouse 
panel.  When injected I.V. into the tail vein, extensive metastatic lung cancer is 
engendered, resulting in death within 12-15 days (Sirotnak et al., 1993).  
However, when grown more conventionally, by sub-cutaneous injection near 
the 4th mammary fat pad, the doubling rate for these tumours is approximately 
7 days, with all mice possessing tumours having been euthanized by 50 days 
post-injection (Ewens et al., 2005).  There is also a low failure rate following 
transplantation, with 97% of all subjects developing identifiable tumours.  
These therefore demonstrate potential utility for studies investigating drugs 
commonly used in the treatment of breast cancer.   
A small-scale initial characterisation experiment was therefore performed in 
wild-type C57BL/6J and PXR/CAR DHu mice, to assess growth kinetics in these 
two models, although the cells were injected sub-cutaneously into the flanks of 
each mouse.  This initial study demonstrated both that growth kinetics were 
comparable to those published by Ewens et al. (2005), and also that there was 
no difference in growth kinetics between the two genotypes (Appendix B).  
Tumours developed in 9/10 of subjects following injection, 5 of which 
demonstrate muscle attachment (only 1 with possible invasion), 1 being 
attached to skin and 2 showing no attachment.  In contrast to the study by 
Ewens et al. (2005), no distant metastases were identified on visual inspection.  
However, it is likely that this is as a result of the more conservative 
requirements regarding maximum tumour size employed in this study, 
requiring euthanasia when the tumour reaches a GMD of 12.5mm2 instead of 
the larger measurement of 20mm in any dimension used by Ewens et al. (2005).  
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This reduces the risk of invasion, with only one subject showing any potential 
muscle-layer invasion in this study, whereas 76% of subjects demonstrated 
invasion of peritoneal muscle in the Ewens et al. (2005) study.  These data 
suggest that the E0771 model can be effectively used in the transgenic PXR/CAR 
mouse models to provide a direct readout of therapeutic efficacy.  However, 
prior to initiating such studies, a larger scale characterisation study is required 
to fully assess growth kinetics in each of the different genotypes, as a result of 
potential differential modulation of inflammatory processes associated with the 
individual PXR/CAR transgenics which could interfere with published growth 
kinetics. 
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Figure A.I: LacZ staining following 3 day drug treatment of female CYP2B6-LacZ (mPXR/mCAR) reporter mice (10x 
magnification) 
Female CYP2B6-LacZ (mPXR/mCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg 
Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Photos were taken 
at 10x magnification.  Scales indicate 100mm. Numbers refer to treatment subject. 
 
 
 
 
Figure A.II: LacZ staining following 3 day drug treatment of female CYP2B6-LacZ (mPXR/mCAR) reporter mice (40x 
magnification) 
Female CYP2B6-LacZ (mPXR/mCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg 
Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Photos were taken 
at 40x magnification.  Scales indicate 20mm. Numbers refer to treatment subject. 
 
 
 
 
Figure A.III: LacZ staining following 3 day drug treatment of male CYP2B6-LacZ (mPXR/mCAR) reporter mice (10x 
magnification) 
Male CYP2B6-LacZ (mPXR/mCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg 
Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Photos were taken 
at 10x magnification.  Scales indicate 100mm. Numbers refer to treatment subject. 
 
 
 
 
Figure A.IV: LacZ staining following 3 day drug treatment of male CYP2B6-LacZ (mPXR/mCAR) reporter mice (40x 
magnification) 
Male CYP2B6-LacZ (mPXR/mCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline, 25 mg/kg Letrozole or 20 mg/kg 
Anastrozole.  Livers were harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Photos were taken 
at 40x magnification.  Scales indicate 20mm. Numbers refer to treatment subject. 
 
 
 
 
Figure A.V: LacZ staining following 3 day drug treatment of male CYP2B6-LacZ (hPXR/hCAR) reporter mice (10x magnification) 
Male CYP2B6-LacZ (hPXR/hCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline or 25 mg/kg Letrozole.  Livers were 
harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Pho tos were taken at 10x magnification.  
Scales indicate 100mm. Numbers refer to treatment subject. 
 
 
 
 
Figure A.VI: LacZ staining following 3 day drug treatment of male CYP2B6-LacZ (hPXR/hCAR) reporter mice (40x 
magnification) 
Male CYP2B6-LacZ (hPXR/hCAR) reporter mice (n=3 per group) were treated p.o. daily for 3 days with 0.9% Saline or 25 mg/kg Letrozole.  Livers were 
harvested into 1% PFA (w/v), cryofixed and sectioned before staining for nuclear fast red, followed by LacZ.  Photos were taken at 40x magnification.  
Scales indicate 20mm. Numbers refer to treatment subject. 
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Figure B.I: E0771 syngeneic mouse model pilot growth data 
C57BL/6J wild type (n=5) and PXR/CAR DHu  transgenic (n=4) mouse models were 
innoculated with 2.5 x 106  E0771 metastatic breast adenocarcinoma cells into their right 
flanks under Euthatal anaesthesia (Day 0).  Geometric mean dimension was measured 
twice weekly, with mice being euthanised when tumours reached 12.5mm2 (a).  Body 
weight was measured daily (b) and liver weight noted following harvest (c).  Tumours did 
not form in one C57BL/6Jwild type mouse.  This has been excluded from these data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C 
RECENT PUBLICATION 
 
 
8 Transcriptional Regulation
of Cytochrome P450 Genes
EMILY A. FRASER, COLIN J. HENDERSON, and C. ROLAND WOLF
Division of Cancer Research, University of Dundee, Medical Research Institute,
Ninewells Hospital & Medical School, Dundee, UK
8.1 Introduction 1
8.2 Transcriptional regulation of cytochrome P450s 2
8.3 Other considerations for transcriptional regulation of cytochrome P450s 18
8.4 Conclusion 23
Abbreviations 23
References 24
8.1 INTRODUCTION
Our mechanistic understanding of the transcriptional regulation of cytochrome P450
(P450) expression has increased significantly in recent years, with the discovery and
characterization of “orphan” nuclear receptors such as the constitutive androstane recep-
tor (CAR) and the pregnane X receptor (PXR). The role of these receptors as mediators
of the inductive effects of xenobiotics continues to be the subject of intensive inves-
tigation and has added a further layer of complexity to an already burgeoning area of
research.
It has become clear that significant variability exists at almost every level of the pro-
cesses that contribute to the ultimate functionality of P450 proteins, and transcriptional
regulation is no exception. Expression of these proteins is controlled by transcription
factors that not only vary in their expression level and the degree to which they bind
and respond to different classes of ligands but are also themselves subject to alternative
splicing, producing variant receptor forms with different spatiotemporal expression and
functionality. It is clear that only by gaining a detailed understanding of these receptors
will we have a greater appreciation of the intricacies of transcriptional regulation of
P450s.
This chapter concentrates on those transcription factors involved in xenobiotic-
induced expression, giving an overview of regulatory interactions and raising issues
that have a bearing on transcriptional regulation, such as polymorphisms, splice vari-
ants, and species specificity. However, it is important to note that other transcription
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factors that are not covered in this review - including the peroxisome proliferator acti-
vated receptors α and γ, the vitamin D receptor, and the oestrogen receptors α and β -
are also involved in regulation of endogenous and basal cytochrom P450 expression.
8.2 TRANSCRIPTIONAL REGULATION OF CYTOCHROME P450s
8.2.1 Pregnane X Receptor (PXR)
The pregnane X receptor (PXR, also known as SXR, PAR, and NR1I2) is the most
recently identified of the three main regulators of xenobiotic-induced CYP expression,
with the mouse ortholog having been first identified by Kliewer et al . in 1998, closely
followed by the identification of the human form by Blumberg et al . [1,2]. A ligand-
activated orphan nuclear receptor was named the pregnane X receptor because of its
activation by pregnenolone derivatives. Acting as a xenosensor, PXR is one of the
key controllers of drug metabolism, in particular, for the expression of the CYP3A
enzyme isoforms. In addition to the CYP3A enzymes, PXR, bound as a heterodimer
to its partner, the retinoid X receptor (RXR), regulates a wide variety of P450s, as
well as phase II enzymes and phase III drug transporters (Table 8.1). PXR is also
promiscuous, being able to accommodate and be activated by a wide range of different
ligands, both endogenous and exogenous (Table 8.2). This protein is expressed in many
tissues, including those of heart, colon, stomach, and certain brain regions, although it is
primarily expressed in the liver and small intestine [3]. Several splice variants have also
been identified, which affect PXR-mediated transcriptional regulation (Section 8.3.3).
Flexibility in the ligand-binding domain (LBD) of PXR is the reason for its wide
substrate specificity, with the binding pocket able to expand from its resting 1150 A˚3
to more than 1600 A˚3 when ligand bound. Large molecules, such as the macrolide
antibiotic rifampicin (RIF), can therefore activate the receptor using an induced-fit
TABLE 8.1 Examples of Human Cytochrome P450s Regulated by Human
PXR, CAR, and AHR
Gene PXR CAR AHR References
CYP1A1 — — ↑a [4]a
CYP1A2 ↑ ↑b ↑a [5]b and [4]a
CYP1B1 ↑ ↔ ↑ [6,7]
CYP2A6 ↑b ↑ — [8]b
CYP2B6 ↑ ↑ ↔ —
CYP2C8 ↑ ↑ — [9]
CYP2C9 ↑ ↔ ↔b [10] and [4]b
CYP2C19 ↑ ↑ — —
CYP3A4 ↑ ↑ ↔ —
CYP7A1 ↓b ↓a ↔c [11],b [12],a and [4]c
CYP8B1 ↓b ↓p — [11]b and [13]
CYP24A1 ↑ ↑ — [14]
Bold arrows indicate strong induction.
↑, induced; ↓, repressed; ↔, no change/basal expression; p , putative interaction in humans. a,
b, or c on each line refers change in nuclear receptor expression to the corresponding citation.
Source: Unless otherwise stated, data was extracted from Ref. 15.
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TABLE 8.2 Example Modulators of Human PXR, CAR, and AHR
Class Compound PXR CAR AHR References
Classical Rifampicin + + PXR/CAR:
[7,15–21]
AHR: [6,22]
CITCO ++
TCDD ++
3-Methylcholanthrene ++
Drug Omeprazole + +
Thiabendazole +
Nicotine +
Caffeine +
Paclitaxel +
Methadone + +
Clotrimazole −
Ketoconazole − −
17α-Ethinylestradiol +
Mifepristone +
SR12 813 +
Phenytoin +
Primaquine +
Spironolactone +
Herb Hyperforin ++
Cryptotanshinone +
Artemisinin + +
Ginkgo biloba + +
Schisandrin A-C +
Dietary β-Carotene + +
Vitamin E +
Flavonoids ±
Curcumin +
Endogenous Androstanol +
Corticosterone +
17β-Estradiol + +
Vitamin K2 +
Tryptophan metabolites +
Bilirubin +
Environmental/
industrial
Benzyl butyl phthalate +
Chlordane +
Phthalic acid (DHEP) + +
Nonylphenol + +
Polychlorinated biphenyls +
Toxaphene +
Triclopyr +
Benzo(a)pyrene +
1-Methyl-1-phenylhydrazine +
Blank spaces indicate no data is available.
++, very strong agonist; +, agonist; –, antagonist (or inverse agonist, CAR only); ±, antagonist/agonist,
dependent on cell context.
For further information see reviews [6,15–17].
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mechanism, which allows molecules to adopt various binding orientations before
selecting the optimal configuration [23–25]. The LBD is predominantly hydrophobic
in character, with Met243, Ser247, Gln285, Trp299, His407, and Phe420 commonly
interacting with ligands [26,27]. Site-directed mutagenesis studies have indicated that
even small changes in the LBD can have significant effects on the ligand-induced
activation of PXR [25,26]. Interspecies variability in this region therefore has
significant effects on the ligand activation profile (Section 8.3.2).
Nuclear translocation is a controlling factor in PXR-mediated P450 induction. How-
ever, because of difficulties with investigating translocation in vitro, namely, when PXR
is overexpressed it spontaneously translocates to the nucleus [28], data regarding this
mechanism remains limited. It has been reported that when inactive, PXR is bound in
a complex with cytoplasmic CAR retention protein (CCRP) and HSP90, which retains
the receptor in the cytoplasm [29,30]. Although the mechanism underlying PXR disso-
ciation from the complex and translocation to the nucleus has not yet been elucidated,
it is likely that a mechanism similar to that governing CAR dissociation from the reten-
tion complex is involved (Section 8.2.2). Once released from the cytoplasmic retention
complex, PXR nuclear localization signals (NLSs) are targeted by importin-α proteins
for nuclear import [29].
Upon entering the nucleus, PXR heterodimerizes with its binding partner, the
RXRα, before binding to response elements in the promoter and enhancer regions of
target genes (Fig. 8.1). PXR heterodimers preferentially bind direct repeat sequences
possessing the half site AG(G/T)TCA separated by three nucleotides (DR3) and
everted repeats of the half site separated by six nucleotides (ER6), that is, AG(G/T)
TCAnnnAG(G/T)TCA and TGA(A/C)CTnnnnnnAG(G/T)TCA, respectively [15,16].
However, they are also able to bind other recognition sites, such as DR4, DR5, and
ER8 motifs, although with lower affinity [31], thus accounting for the cross talk
between receptors, which is an important contributor to P450 regulation.
A key component of transcriptional activation by nuclear receptors is the recruitment
of coactivators and corepressors to promoter regions, following DNA binding. Coacti-
vators of PXR, CAR, and AHR (aryl hydrocarbon receptor) are given in Table 8.3. As
an example, PXR is a binding partner for the p160/SRC (steroid receptor coactivator)
coactivator family, which recruits histone acetyltransferase complexes, such as cAMP
response element binding protein/p300 (CREB), thus providing access to DNA strands
for RNA-polymerase-catalyzed transcription [25]. These coactivators possess three
LXXLL motifs that bind to the AF-2 helix, interacting with two charged residues
on the receptor surface (Lys259 and Glu427) to form a charge clamp [24]. Crystal
structures of SR12813 in complex with PXR and SRC-1 indicate that in the presence of
coactivator, the ligand will bind in a single orientation. The combination of ligand and
SRC-1 binding stabilizes the protein structure to restrict the flexibility of the LBD once
an active ligand conformation has been achieved [25]. In contrast, corepressors are
thought to bind in the absence of ligand, or in the presence of antagonists, retaining the
AF-2 helix in a nonactive conformation [16]. Corepressors of PXR include the nuclear
receptor corepressor (NCoR) and the silencing mediator of retinoid and thyroid hor-
mone receptor (SMRT). SMRT possesses both ID1 and ID2 interacting domains, which
consist of a CoRNR box (I/LXXI/VI) and the motif LXXXIXXXI/L, respectively
[32]. PXR binds to the ID2 motif preferentially over the ID1, with the key interacting
residues being Lys259, Gly270, and Pro423 of the PXR LBD and Arg2347, Lys2348,
and Leu2350 of SMRT [32]. Site-directed mutagenesis studies show that mutation
Also binds DR3, DR4,
DR5 and ER8 elements
Also binds DR4, DR5,
elements
ER6
RXRα ARNT
AHR
(activated)PXR(activated)
CAR
(activated)
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Figure 8.1 Activation mechanisms of (a) PXR, (b) CAR, and (c) AHR. (See color insert.)
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TABLE 8.3 Coactivators and Corepressors Associated with PXR, CAR, and AHR
Coregulator
Type
Coregulator PXR CAR AHR References
Coactivators SRC-1 * * * AHR: 33,34
PXR/CAR: 12, 15, 16, 35
NCOA2 (GRIP1, SRC-2) * * *
p/CIP (SRC-3) * *
P300 *
CBP *
RIP 140 * *
CARM1 *
PRMT1 *
PGC-1α * *
PBP * *
ASC-2 *
SMC-1 *
Corepressors ANKRA2 *
SMRT * *
NCoR * *
SHP *
aCorepression of AHR via the AHR repressor [36].
of charged residues within the PXR LBD (Arg410Asn, Asp205Ala, Glu321Ala, and
Arg413Ala) increases the binding affinity for corepressors, indicating a core role for
these residues in the maintenance of basal PXR activation [32]. Acting in concert, the
recruitment of coregulators therefore controls the expression of target genes, such as
P450s, by regulating access of RNA polymerases to the promoter regions.
A further aspect of PXR-mediated regulation of P450s is posttranslational modifica-
tion of PXR by phosphorylation. This modification is known be critical to the correct
function of other nuclear receptors, including CAR and AHR, but, until recently, had
not been subjected to a systematic analysis with respect to PXR. Research from the
Staudinger group has indicated that protein kinase A (PKA) interacts with PXR, but
in a species-specific manner, synergizing with ligand activation in mice but repressing
ligand-induced activation in rats and humans [37]. Protein kinase C (PKC) and CDK2
signaling has also been implicated. A recent mutagenesis study, in which 18 serine and
threonine residues identified by either in silico site prediction or comparison with other
receptors, has shed more light on the role of phosphorylation in PXR activity. These
studies have shown that the phosphorylation state of certain key residues (Ser8, Thr57,
Ser208, Ser305, Ser350, and Thr408) is involved in the control of heterodimerization,
DNA binding, corepressor recruitment, and nuclear translocation [38]. The phospho-
rylation state of PXR therefore appears to be important in controlling gene expression.
However, these observations require further studies to fully understand the role of
phosphorylation in PXR function.
In summary, PXR is a key controller of P450 regulation, being associated with
a wide variety of target genes. It also has an important role in many endogenous
processes, including control of glucose homeostasis and the cholesterol and bile acid
metabolism [15,16]. However, most importantly from a pharmaceutical perspective
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is its role as the key regulator of the CYP3A enzymes, which are responsible for
the metabolism of a significant proportion of currently used pharmaceuticals, and as a
consequence involved in a significant number of drug–drug interactions [39]. As a key
regulator of P450s, xenobiotics that interact with PXR could have a profound effect on
their own metabolism as well as on the metabolism of other drugs given concomitantly.
The promiscuity of PXR in terms of its ligand interactions and the wide range of genes
it transactivates can result in severe drug–drug interactions [40–43]. As a consequence,
PXR transactivation is investigated as a part of preclinical drug development programs.
Regulation of this signaling pathway is still incompletely understood, although it is
clear that it involves a complex interaction between coregulators, protein structure,
and phosphorylation state.
8.2.2 Constitutive Androstane Receptor (CAR)
Initially identified in humans in 1994 as MB67 [44], and in the mouse in 1997
[45], the constitutive androstane receptor (CAR, NR1I3) is well established as a
key regulator of P450 expression [16,39,46–57]. The genes targeted by CAR are
numerous and varied, encompassing P450s (Table 8.1), phase II enzymes such as
UDP-glucuronyltransferases, and phase III drug transporters, with CYP2B6 being
prototypically induced (Cyp2b10 in mice, CYP2B1/2 in rat) [58,59]. Lacking a physio-
logical ligand, this protein was also classed as an orphan nuclear receptor. However, as
a nuclear receptor, CAR has some unusual properties, having both a different protein
structure and displaying constitutive transcriptional activity [60].
As a consequence of the constitutive activity of CAR, molecules such as androstanol
and androstenol have been referred to as inverse agonists because they actively repress
constitutive CAR activity instead of antagonizing in the classical sense [61]. While not
as promiscuous as PXR, CAR can be activated by numerous compounds (Table 8.2), but
few operate by binding directly to CAR. Its constitutive basal activity means that it can
transactivate genes without ligand binding, in response to externally acting signals that
induce nuclear translocation [62]. This indirect activation pathway is a key mechanism
in CAR-mediated transactivation, with phenobarbital (PB) induction of CYP2B being
the classic example, and is suggested to be the major activation pathway for this
molecule [63,64]. These phenomena are dependent on several key structural features
of CAR and the increasingly understood mechanism of nuclear translocation, which
are considered below.
Structurally, a protein consists of three domains: (i) a highly conserved N-terminal
DNA-binding domain, (ii) a hinge region, and (iii) a variable C-terminal domain
associated with ligand binding (AF-2 domain), dimerization with the CAR-binding
partner (RXRα), and transcriptional activation [54]. The ligand-binding pocket (LBP)
is significantly smaller than that of PXR at approximately 675 A˚3 in humans and is
predominantly hydrophobic in nature. The conformation of the AF-2 domain within
the LBP is thought to be vital to the constitutive activity of the protein, although it is
not accessible for ligand binding, being protected by the side chains of Phe161 (also
key in constitutive activity), Asn165, Phe234, and Tyr326, which are conserved across
all mammalian orthologs of CAR [65,66]. It has also been suggested that disruption
of the AF-2 conformation is responsible for switching CAR to its inactive form, such
as is seen upon inverse agonist interaction [27].
8 TRANSCRIPTIONAL REGULATION OF CYTOCHROME P450 GENES
Although CAR is described as constitutively active, it is unable to activate transcrip-
tion of downstream genes in the absence of an external signal because of regulatory
mechanisms controlling its translocation to the nucleus. In the absence of ligand or
indirect activation, CAR is sequestered in the cytoplasm, bound to a complex consist-
ing of CCRP and HSP90, along with other accessory proteins [67,68]. In response to
direct or indirect ligand challenge, NLSs are activated, resulting in dissociation from
this complex. Once the ligand is activated and released from the cytoplasmic reten-
tion complex, active CAR is translocated into the nucleus via an importin/Ran-GTP
mediated process involving NLS binding to IPO13 [69].
The molecular trigger for, and underlying mechanism of, nuclear translocation is
still unclear, although recent research has implied an essential role for cellular signal-
ing pathways and phosphorylation status, especially in indirect control [28]. Although
the role of phosphorylation state in CAR translocational control had been described
previously, it was not until 2009 that the Thr38 amino acid was identified as the key
residue in regulation of human constitutive androstane receptor (hCAR) translocation.
Phosphorylation of Thr38 by PKC inactivates CAR by destabilizing the helix contain-
ing the C-terminal region of the first zinc finger, resulting in ablation of DNA binding
[70]. However, on Thr38 dephosphorylation, the disrupted helix regains its stability,
resulting in nuclear translocation and transactivation of downstream genes. It has been
suggested that an essential process in PB-induced activation is the recruitment of pro-
tein phosphatase 2A (PP2A) to the retention protein complex in mouse hepatocytes,
subsequently inducing translocation [71,72]. PP2A has therefore been suggested as a
candidate for the dephosphorylation of this residue, acting in concert with other cofac-
tors recruited to the CCRP/HSP90 complex. In addition, a recent report by Koike et al .
identifies extracellular signal-regulated kinase (ERK) 1/2 as the endogenous signal con-
trolling sequestration of CAR in the cytoplasm, with dephosphorylation of ERK 1/2
being sufficient to induce nuclear translocation [73]. AMP-activated protein kinase has
also been suggested to influence CAR localization following PB treatment, although
currently available data is conflicting [64,74–77]. Mutoh et al . suggest a model for both
direct and indirect activators, in which PKC phosphorylates and PP2A dephosphory-
lates Thr38 to control nuclear translocation. The signal controlling the phosphorylation
state of this residue appears to be extracellular signal-regulated kinase (ERK) 1/2
[70,73]. However, a membrane-bound regulatory subunit of protein phosphatase 1b,
PPP1R16A, has recently been shown to interact with CAR, inducing translocation,
which agrees with a report which localizes CAR at the cell surface in addition to the
cytoplasm [78,79]. This suggests another layer of complexity in controlling nuclear
translocation.
Once in the nucleus, CAR binds to RXRα in a head to tail arrangement and the
resulting heterodimer binds to response elements in the promoter of target genes
(Fig. 8.1). CAR will preferentially bind to three binding motifs: (i) DR4 (e.g.,
AGTTCAnnnnAGTTCA), (ii) DR5 (e.g., AGTTCAnnnnnAGTTCA), and (iii) ER8
(e.g., TGAACTnnnnnnnnAGTTCA). However, CAR can bind other motifs, such as
ER5–ER10 types, but with lower affinity [15,80]. Unusually, CAR is also able to
bind to DNA as a monomer, having a preference for DR4 motifs [80]. The optimal
binding site for monomeric CAR was found to be AGAGTTCA. Binding to these
motifs as a monomer is as strong as that of the T3 thyroid hormone receptor, and the
preference for monomeric binding is more marked in humans than in mice. However,
if the 5′ nucleotide flanking sequences contain pyrimidine nucleotides, the binding
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tendency of monomeric CAR is greatly reduced. All these binding motifs have been
identified in the phenobarbital response element (PBREM) commonly found in CAR
target genes [80]. Once bound, activated CAR will recruit coactivators/corepressors
to modulate gene expression (Table 8.3).
Although this chapter has concentrated on the role(s) of CAR in xenobiotic
metabolism, it is important to remember that CAR also has many endogenous
functions. It is particularly important in control of lipid metabolism and energy home-
ostasis, appearing to act as an energy sensor, and influencing metabolism accordingly
[17,81–86]. CAR is also involved in the control of bilirubin metabolism and heme
biosynthesis, as well as bile acid and steroid/thyroid hormone homeostasis. For a
recent review of this area, see di Masi et al . [15]. The range of endogenous roles with
which CAR is involved means it is vital to consider the potential for functional cross
talk between endogenous control and xenobiotic metabolism. For instance, the energy
state of an organism can have significant effects on the uptake and pharmacokinetics
of a drug because nutritional state can influence the induction of P450s by CAR
[17]. Other considerations relating to CAR-induced xenobiotic metabolism include
differential regulation due to species specificity, gender-specific induction, and the
circadian control. Species specificity is discussed in more detail later in this chapter.
Circadian control is a potentially important determinant of CAR expression and
induction. CAR exhibits a circadian expression profile in mice because of its regulation
by the PAR-domain basic leucine zipper transcription factors DBP (albumin D-box
binding protein), TEF (thyrotroph embryonic factor), and HLF (hepatic leukemia
factor), all of which are regulated by core components of the circadian machinery
[87]. This results in a temporal induction of CAR target genes. Since downstream
genes, such as P450s, are likely to display circadian expression profiles as a result, it is
understandable that the clinical profile of certain drugs, such as cyclophosphamide and
mitoxantrone, improves when dosing time in terms of circadian cycle is considered
[87]. This feature should always be considered when investigating compounds that
are likely CAR interactors, particularly in mouse models.
Overall, CAR regulation of P450 expression is complex, involving structural activa-
tion, regulation by signaling pathways, and interaction with various factors influenced
downstream by CAR, including energy metabolism. It is, therefore, important when
investigating compounds that appear to induce P450s via a CAR-dependent mechanism
to consider that the endogenous control of CAR and the way in which it influences
other homeostatic mechanisms, such as energy homeostasis, can have a significant
effect on P450 expression profile and thus xenobiotic metabolism.
8.2.3 Aryl Hydrocarbon Receptor
The AHR has been known significantly longer than PXR and CAR, having been first
identified in 1976 as the cytosolic receptor mediating 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD)-dependent induction of aryl hydrocarbon hydroxylase activity [88].
However, unlike PXR and CAR, the AHR is not a nuclear receptor but is the only
known ligand-activated member of the basic helix-loop-helix (bHLH)/period (PER)-
aryl hydrocarbon receptor nuclear translocator (ARNT)-single minded (Sim) (bHLH-
PAS) family of transcription factors. AHR ligands can be classified as synthetic, for
example, dioxins and halogenated polycyclic aromatic hydrocarbons, and naturally
occurring, such as flavonoids, indoles, and arachidonic acid metabolites [6,22,89]. As
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a family, these proteins are implicated in the regulation of physiological processes,
including organ development, metabolism, and stress and immune response [90]. How-
ever, one of the key roles of AHR is the control of xenobiotic metabolism.
AHR is responsible for the transactivational control of a variety of P450s (Table 8.1),
most notably CYP1A1, CYP1A2, and CYP1B1, with CYP1A1 being considered a
model enzyme for studying AHR-mediated gene activation. In order to modulate tran-
scription, AHR heterodimerizes with its binding partner ARNT [33]. The transcriptional
activation domains (TADs) of both molecules, once activated by ligands, activate tran-
scription by inducing DNA binding via a subdomain N-terminal to the HLH domain.
Both AHR and ARNT possess one TAD in the C-terminal region, with both con-
taining glutamine and hydrophobic residues. However, the TAD of AHR also has
acidic characteristics, whereas that of ARNT is rich in serine, threonine, and proline
[91]. It is worth noting that while the N-terminal domain of AHR is well conserved
across species, the C-terminal domain, and thus the TAD, is significantly divergent
(58% identity between human and mouse forms) [92–94]. As a consequence, there
are significant species differences in response to ligands (see Section 8.3.2 for details).
Following activation, the AHR/ARNT heterodimer binds to the xenobiotic response
element (XRE) in the promoter and/or enhancer regions of target genes (Fig. 8.1).
Unlike classical bHLH proteins, the AHR/ARNT heterodimer binds to an asymmetric
recognition site, binding to the core sequence of the XRE—TNGCGTG [92,95,96]. It
has also been suggested that nucleotides adjacent to, but not part of, the core binding
sequence are important for regulation of some genes [95]. Following DNA binding,
AHR/ARNT recruits coactivators (Table 8.3) and other proteins, such as Mediator D
and TFIID, resulting in chromatin remodeling and recruitment of RNA polymerases
and in the initiation of gene expression (for a review of DNA binding, see Ref. 95).
Nuclear translocation is also a key step in the control of AHR-induced transcrip-
tional regulation. AHR protein, which is inherently unstable in the absence of ligand,
is stabilized in the cytoplasm by a complex consisting of two molecules of HSP90 and
one each of hepatitis B virus X-associated protein 2 (XAP2) and the co-chaperone p23
[97–99]. The E3 ubiquitin ligases, C-terminal of HSP70 interacting protein (CHIP),
and Cullin 4B also bind to AHR, which could explain the rapid degradation of free,
monomeric AHR within cells [97]. In response to a molecular trigger, AHR disso-
ciates from the core complex and localizes to the nucleus where it heterodimerizes
with its binding partner to activate gene expression. At present, the signals regulating
nuclear translocation are still being elucidated; however, there appears to be at least
two separate mechanisms depending on whether the receptor is activated by ligand or
an endogenous signal.
HSP90 has an important role in maintaining AHR stability and structure, with the
central region binding to both the bHLH and PAS domains of AHR. HSP90 appears
to be essential for maintaining AHR in its ligand-binding conformation, with AHR
losing its dioxin-induced activity when HSP90 is disrupted in vitro [100–102]. Ligand
binding appears to disrupt the binding of HSP90 to the PAS domain, which is adjacent
to or just within the LBD, but not to the bHLH region, resulting in a conformational
change that retains HSP90 binding during nuclear translocation. To explain this phe-
nomenon, McGuire et al . [101] postulate that after ligand binding, HSP90 promotes
a conformational change to accommodate the binding by AHR’s dimerization partner,
ARNT, following translocation to the nucleus, and therefore remains bound to AHR
through the bHLH domain during nuclear shuttling. XAP2 is a 38-kDa protein with
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significant homology to the immunophilins, such as FKBP52 [99]. Although not abso-
lutely required for the structural integrity of the cytoplasmic core complex, XAP2 does
appear to have a significant role in maintaining cytoplasmic localization [103]. In mice,
nuclear localization appears to rely on importin β, which recognizes the bipartite NLS
found in AHR. In the cytoplasm, XAP2 binding in the core complex masks the NLS,
preventing importin binding and subsequent nuclear localization [103]. Ligand bind-
ing induces a conformational change in XAP2, resulting in dissociation of XAP2 and
HSP90 from AHR. This unmasks the bipartite NLS, making it available for importin
binding and thus nuclear import [98,104]. However, XAP2 does not seem to fulfill
the same role in humans, as it appears to shuttle into the nucleus still bound to AHR
[105,106]. This mechanism also involves PKC-mediated phosphorylation of two serine
residues adjacent to the NLS—Ser12 and Ser36—which inhibits nuclear translocation
by masking the NLS from importins [107].
Although ligand-dependent nuclear translocation seems to rely on ligand-induced
conformational change of XAP2 and HSP90, evidence for another pathway involving
cyclic-nucleotide-dependent signaling has been reported [97,98,108,109]. cAMP has
been shown to interact with the AHR core complex and induce nuclear translocation
[109]. However, the conformational change induced by this interaction reduced the
ability of AHR to dimerize with ARNT, changed the DNA recognition sequence of
AHR, and reduced dioxin-induced target expression [98,109].
Following nuclear translocation, it has been reported that phosphorylation of AHR
and ARNT is essential for heterodimerization and thus DNA-binding activity [22]. The
kinases involved were PKC and members of the ERK/MEK signaling pathway. This
once again illustrates the importance of cooperative control with endogenous signaling
pathways in xenobiotic metabolism. A novel nuclear binding partner has also been
identified, which acts through the cAMP-related signaling pathway: the RelB subunit
of NF-κB [110–112]. This heterodimer behaves in a PKA phosphorylation-dependent
manner, with AHR DNA binding identified in the promoter region of interleukin-8.
Although this alternative binding partner has a role in coregulation of inflammatory
genes, acting in concert with the NF-κB pathway, any possible role in P450 regulation
has yet to be investigated.
In summary, AHR is a promiscuous receptor that has a key role in metabolic
response to environmental and dietary toxins. The mechanisms regulating AHR-
induced P450 regulation are complex, requiring cross talk between many signaling
and physiological processes. It is worthy to note that the majority of AHR research to
date has been conducted in vitro, especially using murine cell lines. This has a number
of limitations, including, in particular, AHR function is linked with a number of
physiological processes, therefore important interactions will be missed and there are
significant species differences in the structure and function of AHR. The application
of AHR-humanized mice could be of use to further establish the in vivo regulation of
this signaling pathway [113].
8.2.4 Receptor Cross Talk
In order to maintain a robust response to chemical challenge, multiple transcription fac-
tors have evolved to modulate P450 expression. This has created a complex interacting
network of gene regulation [114]. The cross talk between the transcription factors, both
in the ligands with which they interact and the downstream genes that they regulate,
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allows the systems to be fine-tuned for the detoxification of specific compounds and
the interactions between endogenous and exogenous pathways to be controlled. It is,
therefore, imperative to understand the degree to which this phenomenon controls both
in vitro and in vivo drug-metabolizing enzymes. This section discusses the cross talk
between the three main transcription factors and the regulation of certain key P450s
involved in drug metabolism.
8.2.4.1 CYP1A1/2. The CYP1A enzymes are associated with the metabolism of
environmental toxins and aromatic hydrocarbons, providing protection against acute
dioxin-induced hepatocellular necrosis and hepatic inflammation [4,5,115,116]. They
are primarily under the control of AHR, with Cyp1a1 and Cyp1a2 possessing con-
served XRE clusters in their proximal promoters [116]. However, other response
elements have been located in the promoters of these genes, suggesting regulatory roles
for other transcription factors. Also, PXR ligands can induce AHR target genes through
the transcriptional regulation of AHR [4]. Yoshinari et al . [5] recently provided evi-
dence that binding of the hCAR/RXRα heterodimer to a conserved ER8 motif within the
proximal promoter of the CYP1A1 and CYP1A2 genes increases their expression. This
finding suggests that drugs that activate CAR could alter the metabolism of CYP1A1
and CYP1A2 substrates and therefore be a source of drug–drug interactions. Gluco-
corticoid response elements (GREs) have also been identified in the promoter region
of the rat CYP1A1 gene, which, once activated, interact with the initiation complex
to enhance AHR-induced transcription [54]. However, regulation by this mechanism
appears to be species specific and does not occur in humans.
Inflammation has been reported to negatively regulate CYP1A1 expression, with
exposure to UV-B repressing the induction of CYP1A1 immediately following irra-
diation, although CYP1A1 is induced in an AHR-dependent manner several hours
following irradiation [115,117]. This was attributed to direct interaction between AHR
and the NFκB RelA (p65) subunit, interfering with cofactor recruitment to the pro-
moter. The repression of Cyp1a1 expression in response to oxidative stress had been
reported by Morel and Barouki, who identified nuclear factor 1 (NF1) as the media-
tor of this effect [118]. Reciprocal cross talk between AHR and Nrf2 has also been
recently reported, with XRE sequences being located in the Nrf2 promoter [12], and
ARE sequences in the AHR promoter [119]. It has been suggested that a functional
protein interaction may also exist between these molecules, although no data is cur-
rently available [120]. The reciprocal cross talk between these two systems further
highlights the key role of AHR in the protection of the body from damage caused by
electrophilic metabolites.
Regulation of CYP1A expression is therefore controlled by a number of core inter-
acting transcription factors. However, because of the many endogenous roles played
by the AHR, they are also subject to regulatory control by diverse signaling pathways,
including those involved with inflammation and oxidative stress response, playing a
key role in protecting the body from xenobiotic challenge.
8.2.4.2 CYP2B6. CYP2B6 metabolizes a wide range of drugs, including cyclophos-
phamide, valproic acid, ketamine, aminopyrine, methadone, and bupropion [59]. Its
overall role in drug metabolism in man, however, has been considered minor [59,121].
CYP2B6 is induced by activators of hCAR, with the activated hCAR/RXRα het-
erodimer binding to the DR4 motif in the phenobarbital-responsive-element module
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(PBREM) in the promoter [54,59]. However, cross talk with human pregnane X
receptor (hPXR) has also been implicated in CYP2B6 regulation, through binding
to the DR4 motif, all be it with lower affinity. A response element termed the distal
xenobiotic responsive enhancer module (XREM) has also been identified as activated
by either hCAR/RXRα or hPXR/RXRα [122]. This element works synergistically with
the activated PBREM [59,122].
Although cross talk with PXR is reported to be part of the mechanism in the control
of CYP2B6, other receptors are also implicated. For instance, in rodents, the glucocor-
ticoid receptor (GR) directly activates CYP2B/Cyp2b expression [123,124]. Although
the GR does not directly activate CYP2B6 in humans, it can affect CYP2B6 expression
indirectly through induction of CAR and PXR [59]. Recent studies from the Negishi
group have suggested that for maximal activity, the CYP2B6 promoter can be syner-
gistically activated by the PBREM and a novel 52-bp response element, known as the
okadaic acid response element (OAREKI) (Fig. 8.2) [125]. The OAREKI contains a DR1
motif, which possesses an HNF4α binding site, a CACCC motif, which binds early
growth response 1 (EGR1) protein, and an E box motif. EGR1 binding is required
for maximal CAR-induced CYP2B6 activity, facilitating CAR/HNF4α cross talk by
inducing DNA looping to bring the proximal OAREKI into proximity with the distal
PBREM [126]. A recent study has demonstrated that the CCAAT/enhancer binding
protein α (C/EBPα) and HNF4α cooperate with CAR to control CYP2B6 expression
[121]. HNF4α binding to a proximal element located in the OAREKI (–217 bp) favors
If HNF4α binds to the distal module,
cooperative interaction with CEBPα is
favoured. If it binds to the proximal
element, interaction between HNF4α and
CAR bound to the PBREM is favoured.
CAR also synergises with CEBPα bound to
the distal elements.
CEBPα bound to the proximal
element is associated with basal
expression. No mechanism has
yet been determined.
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CAR interaction, whereas binding to the distal region (–1642 bp) favors interaction
with C/EBPα (Fig. 8.2). Variation in expression and binding of HNF4α and C/EBPα
to the CYP2B6 promoter has been correlated to interindividual variations in CYP2B6
expression and activity, suggesting their importance in the regulation of this gene [121].
It is clear that CAR-induced transcriptional regulation of CYP2B6 involves intricate
cross talk between CAR, HNF4α, EGR1, and C/EBPα as a minimum. However, the
role of PXR in this mechanism remains to be clarified.
8.2.4.3 CYP2C8. CYP2C8 is the most inducible gene in the CYP2C family, with a
role in the metabolism of drugs such as rosiglitazone, paclitaxel, cerivastatin, and
chloroquine, in addition to endogenous compounds, such as arachidonic acid [9].
The regulation of this protein remains poorly characterized, although DR4 binding
at –8.8 kb is needed for CAR and PXR-mediated CYP2C8 induction [9]. Both CAR
and PXR can bind to this element in response to ligands. However, Ferguson et al . [9]
found that this response is not apparent when the reporter gene assay is performed in
the HepG2 cell line but is seen when using metabolically competent primary human
hepatocytes, demonstrating the limitations of HepG2 cells for drug induction studies.
As with CYP2B6, basal expression of CYP2C8 involves HNF4α binding to a DR1
motif in the basal promoter region. A second functional HNF4α binding site has also
been identified in the proximal promoter region [127]. Site-directed mutagenesis of the
CYP2C8 promoter has shown that both HNF4α sites are important for RIF-induced
PXR-mediated expression of CYP2C8, with that in the proximal promoter region being
essential. Also, silencing of HNF4α using RNA interference (RNAi) decreased basal
CYP2C8 reporter activity by 48% and abolished RIF-mediated induction. However,
this treatment also repressed expression of CAR and PXR by 60% and 40%, respec-
tively [127]. In light of the current limited information, further studies on the role of
CAR in CYP2C8 control are required.
In addition to the above regulatory pathways, the GR also appears to be involved
in the induction of members of the CYP2C gene family, with a functional GRE being
located in the proximal promoter region in many CYP2C genes [9,54]. Ferguson et al .
[9] demonstrated that CYP2C8 induction by the prototypical GR activator, dexametha-
sone, occurs by direct interaction with the GRE located in the promoter region of the
gene, and not by interaction with PXR or CAR. A recent study in HepG2 cells identi-
fied retinoic-acid-receptor-related orphan receptor (ROR) response elements (ROREs)
in the promoter of CYP2C8, which are activated by RORα1, RORα4, and RORγ1
isoforms [128]. The importance of RORs in the control of CYP2C8 was further sup-
ported by the finding that knockdown of the three isoforms resulted in a 50% decrease
in CYP2C8 mRNA. Since natural agonists of these receptors include cholesterol and
its metabolites, CYP2C8 expression is likely to be influenced by normal physiological
processes. These receptors are also linked to the control of circadian rhythm and there-
fore could be associated with circadian expression of the CYP2C genes. In summary,
the regulatory control of CYP2C8 is still poorly understood, although certain key fac-
tors have been identified. More research is therefore required to integrate these signals
into an understandable network and to more fully characterize regulation by CAR and
PXR.
8.2.4.4 CYP2C9. CYP2C9 is the most highly expressed of the CYP2C family [129],
with identified substrates including tolbutamide, diclofenac, and S-warfarin [130]. In
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human hepatocytes, CYP2C9 could be regulated with prototypical PXR, CAR, and GR
activators (RIF, PB, and dexamethasone, respectively), indicating that all three recep-
tors have a role in the regulation of this enzyme [131]. Subsequent studies suggested
that CAR plays a role in the basal expression of CYP2C9, with constitutive expres-
sion in HepG2 cells increasing with stable transfection of mouse or hCAR [131,132].
Two DR5 response elements, in a configuration similar to that of the PBREM and
XREM modules, are located in the proximal promoter at –2899 bp and preferentially
bind CAR over PXR [132]. A DR4 CAR/PXR binding motif at –1839 bp has also
been identified [131]. Mutagenesis of these binding sites provided evidence that both
are sensitive to CAR activation [132]. The induction of CYP2C9 by treatment with
RIF, hyperforin, and PB has been shown to be mediated by hPXR binding to the DR4
response element [10,133]. The proximal DR4 binding site is therefore essential for
activation, with the distal site acting in a cooperative capacity.
HNF4α plays an essential central role in the regulation of CYP2C9, with HNF4α
binding sites located at –211, –185, and –152 bp. The site at –185 bp plays a central
role in HNF4α-induced CYP2C9 expression and CAR/PXR synergism [127,134]. The
HNF4α binding sites cooperate with the CAR/PXR responsive DR4 motif for maximal
gene expression [127]. The underlying mechanism appears to be as a result of recruit-
ment of a number of coactivators to the promoter, including cAMP response element
binding protein (CBP), PGC-1α, PRIP-interacting protein with interacting methyltrans-
ferase (PIMT) domain, and nuclear receptor coactivator 6 (NCOA6) [135]. Current
evidence suggests that NCOA6 forms a bridge between CAR and HNF4α bound to
their respective response elements by direct interaction with the LXXLL motifs of each.
NCOA6 therefore acts as a mediator promoting synergistic cross talk between CAR
and HNF4α. It is not yet clear whether the same mechanism applies to hPXR-mediated
control.
Other pathways that do not appear to directly interact with CAR/PXR-induced
CYP2C9 expression have also been detailed. An imperfect GRE sequence at –1675 bp
allows direct activation of the promoter by the GR, which appears to act synergisti-
cally with CAR/PXR [132]. HNF3γ, also known as FOXA3, has been implicated in
the regulation of CYP2C genes, being found to bind to HNF3γ response elements in
the promoter region, although a mechanism has yet to be elucidated [136]. A study
by Drocourt et al . [137] suggested that the VDR can also regulate CYP2C9 expres-
sion. However, they point out that the concentrations of 1α,25-dihydroxyvitamin D3
required for this interaction are above the levels seen physiologically, and therefore,
the relevance of this interaction is questionable. A recent study has also shown the tran-
scription factors GATA-2, -4, and -6 induce CYP2C9 through direct interaction with
response elements in the promoter [138]. Again, any potential cross talk with other
motifs has yet to be investigated, but the tissue-specific nature of GATA transcription
factors could make this an interesting pathway when considering gene expression in
extrahepatic tissues.
The regulation of CYP2C9 appears unusual in comparison to the other commonly
inducible P450s. Although, HNF4α is again central to promoter activation, regulation
by CAR and PXR is such that constitutive expression appears to be mediated through
a CAR-mediated pathway, whereas ligand induction occurs through a PXR-mediated
pathway, showing a more physiologically cooperative cross talk between these recep-
tors than is often seen. Cross talk mediated through cofactors is also apparent in the
mechanism underlying cooperation of CAR and HNF4α through mediation by NCOA6.
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8.2.4.5 CYP3A4. CYP3A4 is the major P450 expressed in human liver and is
responsible for the metabolism of approximately 60% of current drugs. The variation
in CYP3A4 expression due to enzyme induction is therefore a major determinant of
drug–drug interactions [39]. The key regulator of CYP3A4 expression is PXR, with the
hPXR/RXRα heterodimer binding to an ER6 PXRE motif located at –172 bp relative to
the transcription start site in the proximal promoter region [139–141]. Mutation of this
element led to a 50% reduction in RIF-mediated response, indicating that this motif acts
cooperatively with other regulatory elements [140]. A distal XREM enhancer has been
identified at approximately −7800 bp, consisting of three nuclear-receptor-binding sites,
dNR1-3. Disruption of the PXRE in the proximal promoter and the dNR1 imperfect
DR3 binding motif in the distal XREM represses xenobiotic response by approxi-
mately 85%, indicating that both elements are essential for CYP3A4 expression. The
dNR3 site is also required for maximal gene expression [140]. A further polymor-
phic enhancer module, known as the constitutive liver enhancer module of CYP3A4
(CLEM4), has been identified at –11.4 kbp [142]. This is also required for maximal
gene expression. This module contains multiple cis-acting elements, including binding
sites for HNF-1, USF-1, AP-1, and HNF4α, as well as a perfect ER6 PXR binding
motif. This enhancer region acts synergistically with the distal XREM and proximal
promoter in PXR-mediated CYP3A4 induction [143]. This region also appears to be
involved in constitutive CYP3A4 expression [142]. However, the motif located in this
region has been found to be significantly less competitive for PXR/RXRα binding rel-
ative to motifs found in the distal XREM and proximal promoter, instead the motif has
a higher affinity for a PXR homodimer in vitro [143]. This homodimer has yet to be
described in vivo, but potentially, this could result in a previously uncharted regulatory
mechanism associated with CYP3A4 control.
All PXR binding motifs described above have also been shown to bind hCAR,
although binding to the proximal promoter region alone is insufficient for CAR-induced
expression. Therefore, evidence suggests that CYP3A4 is coordinately regulated by
hCAR and hPXR [144,145]. Although PXR/CAR cooperation appears to be the main
regulatory pathway connected to ligand-induced control of CYP3A4, neither are essen-
tial for constitutive expression, with individual disruption of these genes in vivo having
no influence on basal CYP3A4 expression [142]. Istrate et al . [146] have used gel
shift and LS174T-based reporter gene assays to show that a number of transcription
factors can bind the ER6 and DR3 motifs, thus decreasing PXR-mediated gene induc-
tion through competition. For instance, the thyroid receptor (TR) α1 can bind to the
response elements to repress CYP3A4 basal and ligand-induced expression. The ratio
of PXR:TRα1 was moreover found to be correlated to basal expression level, sug-
gesting a role in endogenous control. The VDR has also been found to compete with
PXR for ER6, DR3, and DR4 binding sites to induce CYP3A4 expression in rat and
human liver and intestinal slices, all with lower activity than PXR [137,147]. However,
a recent study has shown that VDR and PXR can act synergistically in intestinal cell
lines, apparently through VDR binding to the PXRE located in CLEM4 [148].
HNF4α also has a significant role in controlling CYP3A4 expression. Tirona et al .
have identified a DR1, HNF4α binding site immediately upstream of the dNR1 and
dNR2 binding sites in the XREM (–7783 bp). This was shown to be essential for ligand-
induced promoter activity. In vitro reporter transactivation assays in HepG2, Caco-2
and HeLa cell lines indicated that basal and induced promoter activities are medi-
ated through PXR/CAR, with the activity increasing synergistically in the presence of
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HNF4α [149]. In contrast, the PXRE located in CLEM4 is flanked by two downstream
HNF4α binding motifs [143], which suppress rather than facilitate PXR/CAR-induced
gene expression as a consequence of HNF4α interference with PXR DNA binding.
Liu et al . also reported that while disruption of the ER6 motif in the CLEM4 domain
has no effect on basal expression, disruption of the DR3 motif in the XREM results
in a decrease in basal activity. Other regulators of CYP3A4 expression have also
been suggested. These include STAT1, HNF1, HNF3β (FOXA2), HNF3γ (FOXA3),
and C/EBPα [150]. A systematic in vitro analysis in HepG2 and HuH7 cell lines has
been performed by Bombail et al ., in which putative binding sites were disrupted to
identify functional interactions [151]. This study identified C/EBPα as a regulator of
CYP3A4 expression, with mutation of the C/EBPα binding site at –132 bp causing a
60% decrease in basal expression and a decrease in Imax associated with RIF-, PB-,
and metyrapone-mediated activation. In a previous work, two distal C/EBPα sites
(located at –1402 and –1668 bp) were identified in the activation of CYP3A4 expres-
sion. HNF3γ is also a putative regulator, with a binding site located at –1730 bp.
However, this receptor does not activate CYP3A4, but rather synergizes with C/EBPα,
promoting gene expression by chromatin remodeling [151,152]. In addition to these
findings, Bombail et al . reported that disruption of a putative Sp1 site at –104 to –97 bp
resulted in a 50% decrease in promoter activity following PB treatment. Despite the
presence of a putative GRE in the proximal promoter region, it is likely that GR
agonists influence CYP3A4 expression by inducing PXR expression rather than inter-
acting directly with the promoter [147,153]. CYP3A4 expression is also influenced
by various physiological processes, as demonstrated by its regulation by FOXA2 and
FOXA3, which have numerous endogenous roles, including embryonic development,
organogenesis, and glucose homeostasis [154]. Other endogenous modulators include
the HIF-1α transcription factor, which is upregulated in response to oxidative stress,
and interacts to downregulate drug-metabolizing enzymes, including CYP3A4, in order
to prevent the production of reactive oxygen species [155]. This seems to act through
an indirect mechanism, such as downregulation of PXR and CAR, rather than through
direct promoter binding. It is also important to remember that these transcription fac-
tors are subject to control by endogenous signaling molecules. This is highlighted by
a recent report linking CYP3A4 expression to the cell cycle via phosphorylation of
PXR by cyclin-dependent kinase 2 [156].
As this section has shown, although each of the enzymes discussed is preferentially
controlled by a given transcription factor or nuclear receptor, a large variety of signaling
pathways and coregulating molecules interact to control gene expression. The redun-
dancy inherent in this system could be explained by the need to adapt to a wide range
of environmental demands and endogenous stimuli. Our understanding of the interac-
tions underlying transcriptional control is rapidly increasing. However, the networks
we have currently identified are simplistic, omitting key endogenous signaling infor-
mation that can have dramatic consequences for drug metabolism. While this section
has aimed to give a broad overview of interaction at the level of P450 promoter regu-
lation, it has of necessity excluded another level of functional cross talk, which exists
between different nuclear receptors and transcription factors. Several reviews are now
available, which discuss functional cross talk between nuclear receptors and certain
transcription factors [15,16,114]. This interaction can significantly affect downstream
regulation of target genes and thus the overall P450 expression profile.
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8.3 OTHER CONSIDERATIONS FOR TRANSCRIPTIONAL REGULATION
OF CYTOCHROME P450s
8.3.1 Methodological Challenges
Understanding P450 regulation is a vital step toward understanding drug interactions.
Although the mechanisms underlying P450 transcriptional regulation are becoming
clearer, methodological difficulties have introduced other issues that must be considered
when analyzing current evidence.
Although in vitro methods, such as reporter gene assays, have been used to identify
P450-inducing agents and mechanisms of transcriptional control, cell-based systems
are unable to fully model transcriptional activation. Traditional overexpression sys-
tems have limitations because PXR and CAR will spontaneously translocate to the
nucleus, probably because the members of the cytoplasmic retention complex become
saturated [28,157]. This removes one of the key mechanisms underlying transcriptional
regulation. A further problem is that with the exception of primary hepatocytes and a
handful of immortalized cell lines, such as the HepaRG model [158–160], the majority
of cell lines do not express physiologically relevant levels of both the P450-related tran-
scription factors or P450s themselves. Cells also have the disadvantage that they cannot
model systemic interactions, a significant problem when transcriptional regulators are
influenced by systemic cues, such as hormonal signaling and energy state.
The use of conventional animal models to study ligand induction of P450s is there-
fore common, being able to model induction in a more physiologically relevant manner.
However, because of the divergence of the metabolic system between species, models
do not accurately predict P450 induction in humans [161]. The consequences of this
can be profound. For instance, from a pharmaceutical perspective, failing to consider
potential differences in drug metabolism could result in drugs reaching clinical trials
that are therapeutically ineffective or, much more importantly, toxic to humans [162].
Species specificity is therefore a major issue to be addressed when considering results
from animal models.
8.3.2 Species Specificity
The mechanisms underlying species specificity in drug induction are complex. How-
ever, species differences in P450 induction can often be ascribed to differences in the
amino acid sequence of the LBD of the transcription factor involved [7,163–168].
Changes in the activity of NLS sequences have also been associated with alterations
in nuclear localization, resulting in aberrant gene transcription [92,105,106,169,170].
Lichti-Kaiser et al . [37] have also identified species specificity in the response of hPXR
and mPXR (mouse pregnane X receptor) to the cAMP nucleotide signaling pathway.
CYP3A4 expression was found to be synergistically increased on treatment with RIF
and the PKA inhibitor H89, whereas it decreased following treatment with H89 and
pregnenolone-16α-carbonitrile (PCN). However, the study compared data from HepG2
cells transduced with an adenoviral expression vector containing hPXR with that from
primary mouse hepatocytes, which may influence the findings. In the case of AHR,
species-specific differences in receptor protein stability (hAHR< mAHR) and his-
tone deacetylase complex recruitment have been implicated in differential response
[170]. Improved understanding of species differences in nucleocytoplasmic shuttling,
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TABLE 8.4 Examples of Species-Specific Ligands for PXR and CAR
Drug Interacts
with
Species
Mouse Human
EC50 (nM) Action EC50 (nM) Action
PCN PXR 200–700 + >10,000 N/A
Rifampicin Weak 200–3000 +
SR12813 4100 + 120–200 +
Hyperforin NR 23 +
5β-Cholestan-3α,7α, 12α-triol 2500 + 5000 +
TCPOBOP CAR 20–100 + Weak N/A
CITCO Weak 25–304 +
5α-Androstan-3α-ol 250–1500 – 1000–>10,000 –
Meclizine 25 + 500–1000 –
5β-Pregnane-3,20-dione 670–3000 + >10,000
10,000
Weak+
−
2,3,7,8-Tetrachlorodibenzo-
p-dioxin
AHR 0.6 + 0.4–9 +
Includes EC50 (nM) where data is available.
NR, not reported; +, agonist; –, antagonist (inverse agonist, CAR only).
PXR and CAR data adapted from Refs 15 and 16. AHR data adapted from [177] (mouse), [178] (human),
and [179].
cell signaling pathways and subsequent activation mechanisms is therefore of central
importance. The availability of mouse models humanized for both the receptors which
mediate drug induction as well as the P450’s involved can help circumvent many of
these problems.
Although the precise mechanisms have yet to be fully elucidated, numerous P450
inducers have been identified which interact with transcription factors in a species-
dependent manner. A selection of these ligands has been detailed in Table 8.4. These
include numerous drugs, endogenous compounds, environmental contaminants and cer-
tain herbal medicines. Most of this data has been generated using in vitro reporter gene
assays, which are a useful model for identifying species-dependent ligand effects on
transactivation activity of transcription factors. However, there are certain ligands that
have proved of particular importance in the study of receptor activation. The macrolide
antibiotic RIF and PCN have been shown to be species-specific activators of PXR,
with RIF activating hPXR and PCN activating mPXR [15,171–173]. In the same
way, 6-(4-chlorophenyl)imidazo-[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichloro-
benzyl)oxime (CITCO) and 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP)
are species-specific activators of CAR, with CITCO preferentially activating hCAR
and TCPOBOP activating mCAR [15,171,174]. All four compounds are high affin-
ity ligands for their preferred receptor, showing significantly lower or no affinity for
the other species receptor. They are therefore commonly used as prototypical induc-
ers of CYP3A4 (hPXR), Cyp3a11 (mPXR), CYP2B6 (hCAR), and cyp2b10 (mCAR),
respectively, to validate models of P450 transactivation. With regard to AHR, a study
by Westerink et al . identified differential CYP1A inducers between rat and human cell
lines [175], while Boutros et al . also suggested that TCDD, although not affecting
core AHR genes such as the CYP1 family, does exert species-specific effects, having
a binding affinity for hAHR 10-fold less than that of mAHR, which could significantly
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affect downstream regulation of target genes [176]. In view of the marked differences
that can exist between ligand-induced regulation of drug metabolism, understanding
how emerging drugs interact with human receptors before clinical testing is vital.
In order to address this issue, a number of new animal models have been created,
which are humanized for the metabolic enzymes and transcription factors involved in
drug metabolism [174,180,181]. Several approaches have been used in the construction
of such models. Katoh et al . [181] created chimeric mice in which the innate hepa-
tocytes of an immunocompromised mouse (uPA+/+/SCID) were replaced with >90%
human hepatocytes in vivo, resulting in an artificially humanized liver. However, the
drawback of this model is that because these models must be produced as required, it
requires a ready supply of human hepatocytes, which are both costly and hard to source
as well as having the innate interindividual variability seen in the human population.
The technique may also be restricted under legislation regulating the use of animals in
experiments in some countries. A more common approach is to introduce the human
gene into the mouse genome, either under the control of its own promoter by random
integration or by replacing the endogenous mouse gene [174,180,182]. This has the
advantage that the mouse lines can be continuously bred as well as potentially crossed
to other mouse lines carrying linked genes of interest. This potentially expands the
number of criteria that can be studied in a single model and helps overcomei potential
ethical and sourcing issues encountered with the chimeric models.
Many humanized models are now available, including a range of humanized P450
models, such as CYP2D6 and CYP3A4, to enable drug metabolism to be characterized.
However, the key models from the perspective of P450 transcriptional regulation are
those in which the transcription factors are humanized. Some of these models are
reviewed by Stanley et al . [16] and Gonzalez and Shah [180]. A battery of PXR
and CAR models have now been developed to allow PXR- and CAR-mediated P450
induction to be dissected [174,183,184]. These include a model in which both PXR and
CAR have been replaced with the human genes under the control of the corresponding
endogenous promoters, as well as models in which one receptor is humanized while
the other is deleted. Together with more traditional single humanized and knockout
models, these models have the potential to allow species specificity and the role of
receptor cross talk in P450 induction to be fully analyzed. A further advantage of
these models is that their design allows expression of PXR and CAR splice variants at
physiologically relevant levels, allowing interindividual variability to be studied [183]
(Section 8.8.3). These models therefore provide a powerful tool for use in the analysis
of mechanisms underlying species-specific regulation of P450s. Although not perfect,
with receptors still under the influence of the mouse physiological environment, the
data that can be gained from these humanized models is more relevant to humans than
traditional animal models, especially since the majority of species-specific activity is
thought to depend on the sequence of the LBD. As these models become more complex,
with multiple genes being humanized in one model, data quality is likely to improve.
8.3.3 Splice Variants
Alternative splicing of mRNA is ubiquitous in eukaryotes, and many human genes are
subject to the process, with 86% having a minor isoform frequency of 15% or greater,
resulting in the production of different mRNAs, thus potentially generating multiple
proteins from a single gene and greatly increasing genomic diversity [185]. There are
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a number of different mechanisms involved in alternative splicing of mRNA, including
exon skipping, intron retention, and the use of alternative splice donor and acceptor
sites [186,187].
Alternative splicing of human P450 mRNAs was first described in the 1980s [188].
However, the identification of splice variants of hCAR and hPXR was more recent.
Different-sized hPXR mRNAs were first identified in the late 1990s [189,190], with
Fukuen et al . describing a total of 9 hPXR SVs whose expression levels varied signif-
icantly across a panel of 15 liver samples [191]. Further work to define the expression
of hPXR SVs found the most common variants to be PXR.2 (lacking 111 nt) and
PXR.3 (lacking 123 nt), representing approximately 6.7% and 0.32%, respectively, of
hPXR mRNA in human liver and also found in a number of other tissues, including
brain, heart, colon, and bone marrow [3]. PXR.2 was subsequently reported not to
function in a transactivation assay because of the failure of ligands to bind to the LBD
in a productive manner, probably as a result of a change in protein structure and the
continued binding of corepressors [192].
Choi et al . in describing murine CAR, also reported the existence of a variant
mRNA (mCAR2), which lacked exon 8 and was unable to function in a transactiva-
tion assay [45]. The first SVs of the hCAR gene were reported in 2003 when Savkur
et al . described an mRNA for hCAR with a 4-amino-acid insert between exons 6 and
7 and a 5-amino-acid insert between exons 7 and 8 resulting from the use of alternative
splice acceptor sites, and another with a complete deletion of exon 7 and loss of 39
amino acids [193]. In addition to these variants, Auerbach et al . [194] reported further
hCAR SVs with one or other of the insertions between exons 6/7 and 7/8 and con-
firmed that such variants had compromised function. The range of hCAR SVs was
extended dramatically when Lamba et al . reported 22 unique mRNAs from a panel of
human liver and other tissues [195]. Several of these SVs had premature termination
codons and failed to produce protein, but many had significant deletions or insertions,
yielding proteins significantly different in size from the wild-type, or reference, form
and which had altered N- and/or C-terminal amino acids. The hCAR SVs were differ-
entially expressed, with only the hCAR reference form found in the intestine, whereas
spleen, heart, and prostate expressed only the SVs, and were nonfunctional in transac-
tivation assays, although the authors speculated that such SVs might possess biological
function(s) yet to be identified [195]. A biological function was demonstrated for the
hCAR SV with a 5-amino-acid insertion between exons 7 and 8, termed CAR3 by
Auerbach et al ., who found activity in a transactivation assay with an optimized 3×
DR4 reporter using CITCO, thus defining CAR3 as a ligand-activated receptor in con-
trast to the reference form (CAR1) [196]. The same group further demonstrated that
CAR2, with a 4-amino-acid insertion between exons 6 and 7, displayed a regulatory
response distinct from that of CAR1, speculating that the ligand-binding pocket may
be modified by the additional residues found in CAR2 [197]. Subsequently, CAR2
was also shown to be a ligand-activated receptor present in approximately 30% of
total CAR transcripts in human hepatocytes and uniquely responsive to the plasticizer
di(2-ethylhexyl) phthalate (DEHP) [198]. These latter findings—that a nuclear receptor
present at significant levels in human liver (but absent in other animal models) is highly
responsive to a chemical agent commonly found in a wide range of everyday materials,
including medical devices—have potentially significant implications for safety testing
in general and predictive human toxicity in particular.
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To address these concerns, a unique panel of transgenic mice humanized for CAR
and/or PXR have been generated, which are nulled for murine CAR and PXR and
express the reference forms and two major SVs of hCAR (CAR2 and CAR3) and
hPXR (PXR2 and PXR3) under the control of the endogenous mouse promotor [174].
Expression levels of the CAR and PXR SVs in these mouse models were comparable
to that found in a panel of human livers, with the exception of hPXR2 in which
the expression was approximately fourfold higher in the transgenic mouse [183].
The expression profile of the PXR SVs in the hPXR mouse found that PXR1 was
expressed in a range of tissues at varying levels—liver > small intestine > kidney >
lung > gonads > brain—while PXR2 was expressed, as a % of total PXR mRNA, at
approximately the same level in all tissues, and PXR3 at highest levels in the kidney,
gonads, and brain (Bower, CCM, unpublished observations). These mouse models
provide a useful tool to investigate the role of CAR and PXR in drug metabolism,
disposition, and efficacy in humans.
8.3.4 Genetic Polymorphisms
Interindividual variation in human drug metabolism is a significant cause of variability
in drug response [199]; a main contributor is genetic polymorphism [200]. P450s are a
highly polymorphic group of enzymes, with more than 350 different functional alleles
so far identified in the genes, accounting for 40–50% of P450-dependent metabolism
in humans [201,202]. Most of the characterized polymorphisms are variations in the
coding sequence, such as SNPs, deletions, or gene amplifications [203,204]. They
can, however, also be in gene promoters or intronic regions, which interfere with
transcription factor binding or cause alternative or aberrant mRNA splicing [202,204].
Many of these polymorphisms manifest themselves as enzymes possessing altered
activity [201]. One example of this is seen in the CYP2B6*6 polymorphic isoform,
which possesses two SNPs, 516Gly > Thr and 785Ala > Gly [59]. These substitutions
result in alternative gene splicing, yielding a product with a deletion of exons 4–6 and
that displays a significant reduction in catalytic activity and protein expression relative
to the reference CYP2B6*1 . Presence of these polymorphic variants can therefore
significantly affect downstream drug metabolism.
Another source of interindividual variability in P450 expression is the polymor-
phisms in their regulators. One such polymorphic regulator is PXR, with 373 SNPs
having been identified, and many of these proving to be functional [205,206]. As an
example of the effect of PXR polymorphism on downstream gene expression, a study
by Wang et al . [205] has examined the effect of two haplotypes of PXR commonly
found in the Han Chinese population, H1 (TCAGGGGCCACC) and H2 (CCGAAAAC-
TAAT), on P450 expression, using CYP3A4 activity as a marker. They found that those
with the haplotype pair H1/H1 had much higher inducible CYP3A4 metabolic activity
than those subjects with the H1/H2 and H2/H2 pairings following treatment with St
Johns’ Wort, as indicated by the significant differences in AUC0−t and AUC0−∞ for
the CYP3A4 probe drug nifedipine and its metabolite, dehydronifedipine. This phe-
nomenon has been further confirmed by identification of functional polymorphisms
in the FOXA2 transcription factor, which affect CYP3A4 transcription and are also
linked to diseases, such as type II diabetes [207]. Polymorphisms in P450s and the
transcription factors, which control their expression, can therefore play a significant
role in interindividual variation in xenobiotic metabolism. Understanding the genetic
differences in P450 regulation remains an important subject for future study.
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8.4 CONCLUSION
The adaptive response system that has been evolved by organisms to protect the cell
from the many forms of toxic insult plays a central role in the metabolism and dispo-
sition of drugs. The importance of this system is underlined by its robust nature and
built-in functional redundancy that allows at least a partial response in the absence or
failure of a component part. The species differences observed in the regulation of P450
expression underline the importance of developing relevant models to test for human
drug safety and efficacy, and in which factors such as gender, circadian rhythm, diet
may also be taken into account. It is thus clear that an understanding of how drug
metabolism is regulated, and the multitude of variable factors involved, is crucial to
the optimal application of drug treatments and minimization of unwanted side effects
and drug–drug interactions.
ABBREVIATIONS
AF-2 Activation Function 2
AHR Aryl Hydrocarbon Receptor
AP-1 Activator Protein 1
ARNT Aryl Hydrocarbon Receptor Nuclear Translocator
bHLH Basic Helix-Loop-Helix
bp Base Pair
cAMP cyclic AMP
CAR Constitutive Androstane Receptor
CCRP Cytoplasmic CAR Retention Protein
Cdk2 Cyclin-Dependent Kinase 2
C/EBPα CCAAT/Enhancer Binding Protein α
ChIP Chromatin Immunoprecipitation
CHIP C-terminal of HSP70 interacting protein
CITCO 6-(4-Chlorophenyl)imidazo[2,1-b]thiazole-5-carbaldehyde O-(3,
4-dichlorobenzyl)oxime
CLEM4 Constitutive Liver Enhancer Module of CYP3A4
CREB cAMP Response Element Binding Protein
CYP Cytochrome P450
DBP Albumin D-Box Binding Protein
DEHP Di(2-ethylhexyl) Phthalate
DR Direct Repeat
EGR1 Early Growth Response 1
GR Glucocorticoid Receptor
GRE Glucocorticoid Response Elements
HIF1α Hypoxia Inducible Factor 1α
HLF Hepatic Leukemia Factor
HNF1 Hepatic Nuclear Factor 1
HNF3β Hepatic Nuclear Factor 3β
HNF3γ Hepatic Nuclear Factor 3γ
HNF4α Hepatic Nuclear Factor 4α
LBD Ligand-Binding Domain
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LBP Ligand-Binding Pocket
NCOA6 Nuclear Receptor Coactivator 6
NCoR Nuclear Receptor Corepressor
NF1 Nuclear Factor 1
NLS Nuclear Localization Signal
nt Nucleotide
OAREKI Okadaic Acid Response Element
P450 Cytochrome P450
PAS PER-ARNT-Sim
PB Phenobarbital
PBREM Phenobarbital-Responsive Enhancer Module
PCN Pregnenolone-16α-carbonitrile
PDE4A5 Phosphodiesterase 4A5
PGC1α Peroxisome-Proliferator-Activated Receptor Gamma Coactivator
1-Alpha
PIMT PRIP-Interacting Protein with Interacting Methyltransferase Domain
PKA Protein Kinase A
PP2A Protein Phosphatase 2A
PRIP Peroxisome-Proliferator-Activated Receptor (PPAR)-Interacting
Protein
PXR Pregnane X Receptor
PXRE PXR-Response Element
RIF Rifampicin
ROR Retinoic-Acid-Receptor-Related Orphan Receptor
RT-PCR Reverse Transcription Polymerase Chain Reaction
RXR Retinoid X Receptor
SMRT Silencing Mediator of Retinoid and Thyroid Hormone Receptor
SNP Single Nucleotide Polymorphism
Sp1 Specificity Protein 1
SRC Steroid Receptor Coactivator
STAT1 Signal Transducers and Activators of Transcription 1
SV Splice Variant
TAD Transcription Activation Domain
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin
TCPOBOP 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene
TEF Thyrotroph Embryonic Factor
TR Thyroid Receptor
USF-1 Upstream Stimulatory Factor 1
VDR Vitamin D Receptor
XAP2 X-Associated Protein 2
XRE Xenobiotic Response Element
XREM Xenobiotic Responsive Enhancer Module
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